var title_f12_2_12320="LV and aortic pressure - high fidelity";
var content_f12_2_12320=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63573&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63573&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    LV and aortic pressure - high fidelity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 419px; height: 312px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    LV and aortic pressures from dual high fidelity transducer catheter during pullback across aortic valve. Note the matching of aortic pressures between central locations.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_2_12320=[""].join("\n");
var outline_f12_2_12320=null;
var title_f12_2_12321="Longitudinal fracture of the phalanx";
var content_f12_2_12321=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Longitudinal fracture of the distal phalanx",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) The oblique examination of the distal phalanx of the right index finger reveals a longitudinal fracture through the base of the distal phalanx. Note the fracture traverses the distal interphalangeal joint space, and in this view the bony components are anatomically aligned.",
"    <br>",
"     (B) The fracture is magnified and highlighted.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_2_12321=[""].join("\n");
var outline_f12_2_12321=null;
var title_f12_2_12322="Patient information: Bartholin’s gland cyst (The Basics)";
var content_f12_2_12322=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/85719\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/10/160\">",
"         Adult female external genitalia",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?22/52/23362\">",
"         Patient information: Chlamydia and gonorrhea (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/60/43970\">",
"         Patient information: Dyspareunia (painful sex) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/17/11538\">",
"         Patient information: Sex problems in women (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/14/24802\">",
"         Patient information: Chlamydia (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/44/1730\">",
"         Patient information: Gonorrhea (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/4/12357\">",
"         Patient information: Sexual problems in women (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Bartholin&rsquo;s gland cyst (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/bartholins-gland-cyst-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H70180498\">",
"      <span class=\"h1\">",
"       What is a Bartholin&rsquo;s gland cyst?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A Bartholin&rsquo;s gland cyst is a small sac of fluid that forms when the opening of a Bartholin&rsquo;s gland is blocked. All women and girls have 2 Bartholin&rsquo;s glands just below the opening of the vagina (",
"      <a class=\"graphic graphic_figure graphicRef53704 \" href=\"UTD.htm?0/10/160\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      The Bartholin&rsquo;s glands make small amounts of fluid. The fluid helps keep the vulva moist. (The vulva is the area around the opening of the vagina.) If something blocks the opening of a Bartholin&rsquo;s gland, fluid can build up and form a cyst. This usually happens in just 1 gland, not both at once.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H70180513\">",
"      <span class=\"h1\">",
"       What are the symptoms of a Bartholin&rsquo;s gland cyst?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most women notice a lump in the vulva, but Bartholin&rsquo;s gland cysts often do not cause any other symptoms. If they do, the main symptoms are pain or discomfort when a woman walks, sits, or has sex.",
"     </p>",
"     <p>",
"      If a Bartholin&rsquo;s gland cyst gets infected, it can form an abscess. An abscess is an infected lump. Symptoms of an abscess include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Severe pain &ndash; A woman might not be able to walk, sit, or have sex.",
"       </li>",
"       <li>",
"        Swelling",
"       </li>",
"       <li>",
"        Redness",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H70180528\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        You see or feel a lump in the vulva.",
"       </li>",
"       <li>",
"        It is painful to walk, sit, or have sex.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H70180543\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. If you have an abscess, the doctor or nurse will send a small sample of the pus to a lab for testing. This can show what type of germ caused the infection. You might need antibiotics for an infection caused by certain germs.",
"     </p>",
"     <p>",
"      If you are older than 40, the doctor or nurse will do a test called a &ldquo;biopsy&rdquo; to check for cancer. (Cancer in a Bartholin gland is rare, but it can happen.) In this test, the doctor takes a small sample of tissue from the area. Then he or she sends the tissue to a lab. Another doctor looks at it under a microscope to check for cancer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H70180558\">",
"      <span class=\"h1\">",
"       How is a Bartholin&rsquo;s gland cyst treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on your age and whether the cyst is causing symptoms. If you do not have symptoms, you might not need any treatment. Otherwise, treatments can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Antibiotics &ndash; Doctors give these medicines if an abscess is caused by certain types of infection.",
"       </li>",
"       <li>",
"        Draining the cyst or abscess &ndash; In this procedure, the doctor cuts a small hole to let fluid or pus out. Then he or she puts a tiny balloon in the hole to keep it from closing completely. The balloon is connected to a tiny tube called a &ldquo;catheter&rdquo; that helps fluid drain from the Bartholin&rsquo;s gland. The doctor takes the balloon out in about 1 month. It leaves a small opening where fluid can drain. This procedure is often done in a doctor&rsquo;s office. But if you have a large or deep abscess, you might need treatment in the hospital.",
"       </li>",
"       <li>",
"        Surgery &ndash; Doctors can do this if draining fluid and putting in a balloon does not work well. A doctor can make a new opening to help the Bartholin&rsquo;s gland drain fluid. Or he or she can remove the gland and any cyst or abscess. But surgery has a higher risk of side effects than other treatments, so doctors don&rsquo;t do it as often.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H70180573\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/52/23362?source=see_link\">",
"       Patient information: Chlamydia and gonorrhea (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/60/43970?source=see_link\">",
"       Patient information: Dyspareunia (painful sex) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/17/11538?source=see_link\">",
"       Patient information: Sex problems in women (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/14/24802?source=see_link\">",
"       Patient information: Chlamydia (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/44/1730?source=see_link\">",
"       Patient information: Gonorrhea (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/4/12357?source=see_link\">",
"       Patient information: Sexual problems in women (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?12/2/12322?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 85719 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-190.92.87.104-FFAD13B8AB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_2_12322=[""].join("\n");
var outline_f12_2_12322=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H70180498\">",
"      What is a Bartholin&rsquo;s gland cyst?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H70180513\">",
"      What are the symptoms of a Bartholin&rsquo;s gland cyst?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H70180528\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H70180543\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H70180558\">",
"      How is a Bartholin&rsquo;s gland cyst treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H70180573\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/85719\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/10/160\">",
"      Adult female external genitalia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/14/24802?source=related_link\">",
"      Patient information: Chlamydia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/52/23362?source=related_link\">",
"      Patient information: Chlamydia and gonorrhea (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/60/43970?source=related_link\">",
"      Patient information: Dyspareunia (painful sex) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/44/1730?source=related_link\">",
"      Patient information: Gonorrhea (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/17/11538?source=related_link\">",
"      Patient information: Sex problems in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/4/12357?source=related_link\">",
"      Patient information: Sexual problems in women (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_2_12323="Removal of killed insect from the ear";
var content_f12_2_12323=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86353&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86353&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    Removal of killed insect from the external auditory canal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 344px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Once the insect is killed by instilling mineral oil, 95 percent ethanol, or 1 percent lidocaine, it is removed under direct visualization using alligator forceps.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from illustration by Glenn Isaacson MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_2_12323=[""].join("\n");
var outline_f12_2_12323=null;
var title_f12_2_12324="Adapalene and benzoyl peroxide: Patient drug information";
var content_f12_2_12324=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Adapalene and benzoyl peroxide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9507?source=see_link\">",
"     see \"Adapalene and benzoyl peroxide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6865472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Epiduo&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F12931923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Tactuo&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat pimples (acne).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to adapalene, benzoyl peroxide, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697664",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may stain fabric, flooring, painted surfaces, marble, granite, vinyl, and enamel.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697666",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may stain fingernails, hair, and skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697599",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin may look worse before it looks better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697762",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use of other skin products may cause more irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698029",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from heat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12094 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-190.92.87.115-02329B04FB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_2_12324=[""].join("\n");
var outline_f12_2_12324=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6865472\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12931923\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011969\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011968\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011973\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011974\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011976\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011971\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011972\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011977\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011978\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9507?source=related_link\">",
"      Adapalene and benzoyl peroxide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_2_12325="Pancreas anatomy";
var content_f12_2_12325=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F53979&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F53979&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 566px\">",
"   <div class=\"ttl\">",
"    Pancreas anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 546px; height: 571px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The pancreas is a combination exocrine and endocrine organ. Exocrine tubuloacinar glands are responsible for secreting the digestive juices into the pancreatic ducts and subsequently the gastrointestinal tract. Approximately&nbsp;one million islets of Langerhans responsible for the endocrine function of the pancreas are distributed throughout the exocrine pancreas. Beta and alpha cells of the endocrine islets are respectively responsible for secreting insulin and glycogen, while delta cells secrete somatostatin and PP cells secrete pancreatic polypeptide.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_2_12325=[""].join("\n");
var outline_f12_2_12325=null;
var title_f12_2_12326="Overview of invasive cardiac electrophysiology studies";
var content_f12_2_12326=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of invasive cardiac electrophysiology studies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/2/12326/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/2/12326/contributors\">",
"     Philip J Podrid, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/2/12326/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/2/12326/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/2/12326/contributors\">",
"     Bradley P Knight, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/2/12326/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/2/12326/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/2/12326/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive cardiac electrophysiology has evolved rapidly from a research tool to an established clinical technique for the investigation and treatment of cardiac rhythm disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12326/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This technique permits a detailed analysis of the mechanism underlying the cardiac arrhythmia, and precise location of the site of origin. Thus, electrophysiology (EP) studies can accomplish the following goals (",
"    <a class=\"graphic graphic_table graphicRef52417 \" href=\"UTD.htm?41/15/42235\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Make a completely accurate diagnosis of an arrhythmia (supraventricular or ventricular tachyarrhythmias or a bradyarrhythmia)",
"     </li>",
"     <li>",
"      Establish the etiology for syncope (bradyarrhythmia or tachyarrhythmia) especially in patients with structural heart disease",
"     </li>",
"     <li>",
"      Evaluate prognosis",
"     </li>",
"     <li>",
"      Stratification for risk of sudden cardiac death",
"     </li>",
"     <li>",
"      Acquire data regarding indications for therapy (eg, permanent pacemaker or defibrillator implantation)",
"     </li>",
"     <li>",
"      Guide antiarrhythmic drug therapy",
"     </li>",
"     <li>",
"      Evaluate the feasibility or outcome of nonpharmacologic therapy (eg, transcatheter radiofrequency ablation, antiarrhythmic surgery, or implantable",
"      <span class=\"nowrap\">",
"       cardioverter/defibrillator",
"      </span>",
"      therapy)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In 2000, an",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    task force on clinical competency published recommendations for technical and cognitive skills needed to perform electrophysiologic study",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    catheter ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12326/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of invasive cardiac electrophysiologic studies (EPS) will be presented here. Issues related to its use in the evaluation of specific arrhythmias are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22328?source=see_link\">",
"     \"Invasive cardiac electrophysiology studies: Bradyarrhythmias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/1/3097?source=see_link\">",
"     \"Invasive cardiac electrophysiology studies: Tachyarrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     METHODS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive EP studies are typically performed in a dedicated electrophysiology laboratory. Intravenous conscious sedation is used to ensure patient comfort. Standard ECG leads are applied to the patient, as well as \"hands-off\" defibrillation pads. In addition to the electrophysiologist, several other staff members are required. At least one nurse serves as a circulator. A second nurse, nurse anesthetist, or anesthesiologist administers the sedation. Either the electrophysiologist, another clinician, or a technician operates the stimulator. Arterial pressure may be monitored invasively or noninvasively, depending upon the complexity of the procedure. Oxygen saturation, as well as in some cases end-tidal CO2, is monitored.",
"   </p>",
"   <p>",
"    One of the staff continuously monitors the heart rhythm, and is available to defibrillate the patient if necessary. A biphasic external defibrillator should be used, since this technology has been shown to be more effective in terminating ventricular fibrillation than the older, monophasic waveforms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12326/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=see_link&amp;anchor=H11#H11\">",
"     \"Basic principles and technique of cardioversion and defibrillation\", section on 'Monophasic versus biphasic waveforms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Vascular access",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Seldinger technique is employed to place multiple venous accesses. The femoral approach is most common, but the subclavian, internal jugular, or brachial approach may be used, most often for placement of a catheter in the coronary sinus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Electrode catheter placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multipolar electrode catheters are positioned in the heart. Typical positions include the right atrium (high right atrium) and right ventricle (right ventricular apex); a catheter is also positioned across the tricuspid annulus to record a potential from the bundle of His (His). A catheter may be placed in the coronary sinus to record left atrial activation, particularly in studies of patients with supraventricular tachycardia (SVT).",
"   </p>",
"   <p>",
"    When mapping and ablation are performed, electrodes may be placed in the left heart. Left heart access may be obtained via either a transseptal or retrograde aortic approach. Intracardiac recordings and programmed electrical stimulation (PES) are performed via the electrode catheters.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Baseline recordings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Baseline recordings obtained during a typical electrophysiologic study include several surface electrocardiograms to time events from the body's surface, and several intracardiac electrograms, all of which are recorded simultaneously. The intracardiac electrograms are generally displayed in the order of normal cardiac activation (",
"    <a class=\"graphic graphic_figure graphicRef64875 \" href=\"UTD.htm?21/4/21574\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first intracardiac tracing is a recording from the high right atrium (HRA) close to the sinus node. Pacing at this position allows evaluation of sinoatrial node function and atrioventricular conduction; the addition of premature stimulation may result in the induction of atrial arrhythmias. Recordings from this site also help determine the direction of atrial activation (eg, high-low versus low-high, and right-left versus left-right).",
"     </li>",
"     <li>",
"      The next intracardiac tracing is the His bundle recording, obtained from a catheter positioned at the bundle of His (in the area of the tricuspid annulus). This tracing shows low septal right atrial, His bundle, and high septal right ventricular depolarization.",
"     </li>",
"     <li>",
"      One to three recordings may be obtained from the coronary sinus in patients with supraventricular tachyarrhythmias or preexcitation. Since the coronary sinus runs in the mitral annulus, these recordings reflect left atrial activation.",
"     </li>",
"     <li>",
"      This is followed by a recording from the right ventricular apex electrode catheter. The stability and reproducibility of the right ventricle apex position (during a given study as well as from one study to the next) makes it a useful site for adding premature stimuli during programmed ventricular stimulation.",
"     </li>",
"     <li>",
"      Depending upon the particular study, other required recordings may include right bundle branch recording, left ventricular recording, transseptal left-atrial recording, and atrial and ventricular mapping catheter tracings for electrophysiologic mapping and ablation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/23/39289?source=see_link\">",
"       \"Electrophysiologic cardiac mapping: Techniques\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     PA interval",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrophysiologic analysis begins with measurement of the basic intervals that reflect the integrity of the conduction system under resting conditions. The PA interval is measured from the onset of the earliest registered surface P wave, or intracardiac atrial activation, to the onset of the atrial deflection on the His bundle catheter recording. The latter represents late atrial activation from the inferoposterior interatrial septum (the lowest part of the right atrium). The reported normal range is 20 to 60 msec [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12326/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This interval has been felt to represent total atrial conduction, although it is more correctly a reflection of internodal (sinoatrial to atrioventricular node) conduction. Nonetheless, prolonged PA times do suggest abnormal atrial conduction and can be a clue to the presence of biatrial disease or disease confined to the right atrium. Rarely, diseased atrial conduction may underlie first degree atrioventricular (AV) block [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12326/abstract/7\">",
"     7",
"    </a>",
"    ]. In the presence of short PA times, an ectopic atrial focus should be excluded by more detailed atrial activation mapping.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     AH interval",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AH interval is measured on the His bundle electrogram and represents the interval from the earliest rapid deflection of the atrial recording (activation of the lowest part of the right atrium) to the earliest onset of the His bundle deflection. This interval is taken to represent AV nodal conduction. More precisely, however, it is the sum of conduction through the low right atrial inputs into the atrioventricular node, the atrioventricular node proper, and the proximal His bundle.",
"   </p>",
"   <p>",
"    The AH interval has a wide range in normal subjects (50 to 120) msec and is markedly influenced by the autonomic nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12326/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Short AH intervals may be seen in the following circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12326/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased sympathetic tone.",
"     </li>",
"     <li>",
"      Enhanced AV nodal conduction, which may be due in some patients to steroid use or pregnancy.",
"     </li>",
"     <li>",
"      Preferential left atrial input into the atrioventricular node.",
"     </li>",
"     <li>",
"      Unusual forms of preexcitation. In the past, the SVT in patients with the Lown-Ganong-Levine syndrome (LGL) was thought to be due to an unusual type of accessory pathway. However, careful study has suggested that most of these patients have enhanced AV nodal conduction and standard mechanisms of SVT. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11272?source=see_link\">",
"       \"Lown-Ganong-Levine syndrome and enhanced atrioventricular nodal conduction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Long AH intervals are most commonly due to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Negative dromotropic drugs such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      , beta blockers, calcium channel blockers, and antiarrhythmic drugs, particularly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"     </li>",
"     <li>",
"      Enhanced vagal tone",
"     </li>",
"     <li>",
"      Intrinsic disease of the atrioventricular node.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Artifactually prolonged AH intervals may result from an improperly positioned catheter and the incorrect identification of a right bundle branch potential as a His bundle potential. This situation needs to be distinguished from true AH prolongation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     His bundle electrogram duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The His bundle electrogram duration reflects conduction through the short length of compact His bundle that penetrates the fibrous septum. This interval is normally short, 15 to 25 msec [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12326/abstract/5,9\">",
"     5,9",
"    </a>",
"    ]. Fractionation and prolongation, or even splitting of the His bundle potential, is seen with disturbances of His bundle conduction (",
"    <a class=\"graphic graphic_waveform graphicRef80538 \" href=\"UTD.htm?38/51/39729\">",
"     waveform 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12326/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     HV interval",
"    </span>",
"    &nbsp;&mdash;&nbsp;The HV interval is measured from the earliest onset of the His bundle deflection to the earliest registered surface or intracardiac ventricular activation anywhere. This measurement reflects conduction time through the distal His-Purkinje tissue. Unlike the AV node, the His-Purkinje system is far less influenced by the autonomic nervous system, and the range in normal subjects is narrow, 35 to 55 msec [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12326/abstract/12\">",
"     12",
"    </a>",
"    ]. A prolonged HV interval is consistent with diseased distal conduction in all fascicles [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12326/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A validated short HV interval suggests ventricular preexcitation via an AV bypass tract. The only other explanation for a short HV interval is a ventricular origin for the beats, such as PVCs or an accelerated idioventricular rhythm that is isorhythmic with the sinus rhythm. A spurious explanation for a short HV interval is the inadvertent recording of a RBBB potential rather than a His potential.",
"   </p>",
"   <p>",
"    In the case of true ventricular preexcitation, His bundle pacing at cycle lengths shorter than the sinus cycle length should eliminate the preexcitation. In contrast, atrial premature extrastimuli, which retard AV nodal conduction, may exaggerate preexcitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PROGRAMMED ELECTRICAL STIMULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;After baseline measurements are recorded, pacing is performed via the intracardiac electrode catheters. Burst pacing at various fixed cycle lengths as well as programmed electrical stimulation (PES) is administered. With PES, a number of stimuli at a fixed cycle length are delivered (eg, eight beats at a rate of 100",
"    <span class=\"nowrap\">",
"     beats/min),",
"    </span>",
"    followed by a premature beat. The premature beat is moved more and more premature, until the refractory period tissue is reached. Multiple premature stimuli can be introduced.",
"   </p>",
"   <p>",
"    The technique of PES is used to assess the AV conducting system and to induce supraventricular and ventricular arrhythmias. Premature beats can be introduced during a tachyarrhythmia to probe the mechanism of the tachycardia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MAPPING AND ABLATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many cases, catheter ablation immediately follows the diagnostic electrophysiologic study. Mapping refers to careful movement of a mapping or ablation catheter in the area of interest, probing for the site at which radiofrequency ablation will be successful at curing the arrhythmia. Multiple techniques for mapping have been developed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19866?source=see_link\">",
"     \"Catheter ablation of cardiac arrhythmias: Overview and technical aspects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     COMPLICATIONS OF INVASIVE CARDIAC ELECTROPHYSIOLOGY STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of invasive cardiac electrophysiology studies are rare, provided that high-risk patients such as those with critical aortic stenosis, severe hypertrophic obstructive cardiomyopathy, or left main or severe three-vessel coronary artery disease are excluded from testing. In addition, patients with clinically unstable myocardial ischemia or uncompensated clinical congestive heart failure should be excluded or rigorously treated prior to undergoing study.",
"   </p>",
"   <p>",
"    Serious complications of these procedures are generally related to the catheterization process itself, including vascular injury, tricuspid valve damage, pulmonary embolism, hemorrhage requiring transfusion therapy, cardiac chamber perforation resulting in pericardial tamponade, sepsis from catheterization site abscess, myocardial infarction, stroke, and death (",
"    <a class=\"graphic graphic_table graphicRef63157 \" href=\"UTD.htm?20/2/20524\">",
"     table 2",
"    </a>",
"    ). The complication rate is approximately 2 percent, with no mortality in several series [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12326/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The induction of serious ventricular tachyarrhythmias occurs frequently during diagnostic electrophysiologic testing. Such arrhythmias can usually be promptly terminated, either by overdrive pacing or external countershock. However, if the arrhythmia is difficult to revert and is of long duration, there may be complications related to the prolonged hypotension and rarely sudden death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Radiofrequency ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dramatic increase in the use of intracardiac mapping and transcatheter radiofrequency (RF) ablation has resulted in much longer studies with more radiation exposure, administration of higher doses of sedative and analgesic agents, more frequent catheterization of the left heart, and more frequent change of catheters.",
"   </p>",
"   <p>",
"    The duration of some of the RF ablation procedures may raise morbidity from vascular complications, thromboembolic complications, cardiac chamber rupture, or radiation exposure including skin injuries and a possible increased risk for malignancy (",
"    <a class=\"graphic graphic_table graphicRef63157 \" href=\"UTD.htm?20/2/20524\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19866?source=see_link&amp;anchor=H22#H22\">",
"     \"Catheter ablation of cardiac arrhythmias: Overview and technical aspects\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PRESTUDY ANGIOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An electrophysiology study can be undertaken with exceedingly low risk in young patients with documented supraventricular or ventricular tachycardia, and with no evidence of structural heart disease by noninvasive studies including echocardiography. Settings in which coronary angiography is recommended prior to electrophysiology study include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the clinical presentation is prehospital cardiac arrest or ventricular tachycardia causing hemodynamic collapse, coronary angiography and contrast right and left ventriculography should usually be obtained prior to invasive electrophysiologic studies with programmed cardiac stimulation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two exceptions to this requirement are Wolff-Parkinson-White syndrome with documented atrial fibrillation preceding ventricular fibrillation, and congenital prolonged QT syndrome; in these circumstances, ventricular fibrillation has a reasonably straightforward electrophysiologic explanation and prestudy angiography is not necessary.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An assessment for ischemia should be considered in patients with known coronary artery disease or left ventricular dysfunction prior to implantation of a prophylactic defibrillator. Coronary angiography is not necessary in clinically stable patients without symptoms of ischemia or heart failure.",
"     </li>",
"     <li>",
"      Coronary angiography is not generally required before the implantation of a cardiac resynchronization (ie, biventricular) device for the management of heart failure, unless active ischemia is felt to be present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"       \"Cardiac resynchronization therapy in heart failure: Indications\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H431969\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Invasive cardiac electrophysiology (EP) study permits a detailed analysis of the mechanism underlying the cardiac arrhythmia, and precise location of the site of origin. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Invasive EP studies are typically performed in a dedicated electrophysiology laboratory. Intravenous conscious sedation is used to ensure patient comfort. Standard ECG leads are applied to the patient, as well as \"hands-off\" defibrillation pads. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Methods'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multipolar electrode catheters are positioned in the heart. Typical positions include the right atrium (high right atrium) and right ventricle (right ventricular apex); a catheter is also positioned across the tricuspid annulus to record a potential from the bundle of His (His). A catheter may be placed in the coronary sinus to record left atrial activation, particularly in studies of patients with supraventricular tachycardia (SVT). These electrodes allow for the measurement of several intervals with diagnostic implications. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Electrode catheter placement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After baseline measurements are recorded, pacing is performed via the intracardiac electrode catheters. Burst pacing at various fixed cycle lengths as well as programmed electrical stimulation (PES) is administered. The technique of PES is used to assess the AV conducting system and to induce supraventricular and ventricular arrhythmias. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Programmed electrical stimulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications of invasive cardiac electrophysiology studies are rare. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Complications of invasive cardiac electrophysiology studies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12326/abstract/1\">",
"      Rahimtoola SH, Zipes DP, Akhtar M, et al. Consensus statement of the Conference on the State of the Art of Electrophysiologic Testing in the Diagnosis and Treatment of Patients with Cardiac Arrhythmias. Circulation 1987; 75:III3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12326/abstract/2\">",
"      Guidelines for Clinical Intracardiac Electrophysiologic Studies. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee to Assess Clinical Intracardiac Electrophysiologic Studies). Circulation 1989; 80:1925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12326/abstract/3\">",
"      Tracy CM, Akhtar M, DiMarco JP, et al. American College of Cardiology/American Heart Association Clinical Competence Statement on invasive electrophysiology studies, catheter ablation, and cardioversion: A report of the American College of Cardiology/American Heart Association/American College of Physicians-American Society of Internal Medicine Task Force on Clinical Competence. Circulation 2000; 102:2309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12326/abstract/4\">",
"      Schneider T, Martens PR, Paschen H, et al. Multicenter, randomized, controlled trial of 150-J biphasic shocks compared with 200- to 360-J monophasic shocks in the resuscitation of out-of-hospital cardiac arrest victims. Optimized Response to Cardiac Arrest (ORCA) Investigators. Circulation 2000; 102:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12326/abstract/5\">",
"      Narula OS, Cohen LS, Samet P, et al. Localization of A-V conduction defects in man by recording of the His bundle electrogram. Am J Cardiol 1970; 25:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12326/abstract/6\">",
"      Castellanos A Jr, Castillo CA, Agha AS. Symposium on Electophysiologic Correlates of Clinical Arrhythmias. 3. Contribution of His bundle recordings to the understanding of clinical arrhythmias. Am J Cardiol 1971; 28:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12326/abstract/7\">",
"      Sherron P, Torres-Arraut E, Tamer D, et al. Site of conduction delay and electrophysiologic significance of first-degree atrioventricular block in children with heart disease. Am J Cardiol 1985; 55:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12326/abstract/8\">",
"      Benditt DG, Klein GJ, Kriett JM, et al. Enhanced atrioventricular nodal conduction in man: electrophysiologic effects of pharmacologic autonomic blockade. Circulation 1984; 69:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12326/abstract/9\">",
"      Damato AN, Lau SH. Clinical value of the electrogram of the conduction system. Prog Cardiovasc Dis 1970; 13:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12326/abstract/10\">",
"      Amat-y-Leon F, Dhingra R, Denes P, et al. The clinical spectrum of chronic His bundle block. Chest 1976; 70:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12326/abstract/11\">",
"      Bharati S, Lev M, Wu D, et al. Pathophysiologic correlations in two cases of split His bundle potentials. Circulation 1974; 49:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12326/abstract/12\">",
"      Kupersmith J, Krongrad E, Waldo AL. Conduction intervals and conduction velocity in the human cardiac conduction system. Studies during open-heart surgery. Circulation 1973; 47:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12326/abstract/13\">",
"      Dhingra RC, Palileo E, Strasberg B, et al. Significance of the HV interval in 517 patients with chronic bifascicular block. Circulation 1981; 64:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12326/abstract/14\">",
"      Dimarco JP, Garan H, Ruskin JN. Complications in patients undergoing cardiac electrophysiologic procedures. Ann Intern Med 1982; 97:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12326/abstract/15\">",
"      Horowitz LN. Safety of electrophysiologic studies. Circulation 1986; 73:II28.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 980 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-189.2.19.178-DF24B1B659-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_2_12326=[""].join("\n");
var outline_f12_2_12326=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H431969\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      METHODS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Vascular access",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Electrode catheter placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Baseline recordings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PA interval",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      AH interval",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      His bundle electrogram duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      HV interval",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PROGRAMMED ELECTRICAL STIMULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MAPPING AND ABLATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      COMPLICATIONS OF INVASIVE CARDIAC ELECTROPHYSIOLOGY STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Radiofrequency ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PRESTUDY ANGIOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H431969\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/980\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/980|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/4/21574\" title=\"figure 1\">",
"      Normal intracardiac electrograms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/980|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/15/42235\" title=\"table 1\">",
"      Indications electrophys study",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/2/20524\" title=\"table 2\">",
"      Complications EP study",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/980|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?38/51/39729\" title=\"waveform 1\">",
"      Electrograms intra Hisian block",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=related_link\">",
"      Basic principles and technique of cardioversion and defibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19866?source=related_link\">",
"      Catheter ablation of cardiac arrhythmias: Overview and technical aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/23/39289?source=related_link\">",
"      Electrophysiologic cardiac mapping: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22328?source=related_link\">",
"      Invasive cardiac electrophysiology studies: Bradyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/1/3097?source=related_link\">",
"      Invasive cardiac electrophysiology studies: Tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11272?source=related_link\">",
"      Lown-Ganong-Levine syndrome and enhanced atrioventricular nodal conduction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_2_12327="Rounded atelectasis PA";
var content_f12_2_12327=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F82006%7EPULM%2F78745&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F82006%7EPULM%2F78745&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rounded atelectasis in the right lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 320px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFAAYkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UpwR2+6rH6ChBudVHUnFenaD4LmurSGRoXXcucleKAPMxBKekUh/4CaeLS4PS3mP/ADXsKeBpFdd2F56kVsQ+BJiAUeI/jQB4KbacHBglz/uGnLZXTfdtpj9IzXub+BrlrjztluDHwCx+97V0Wm+CrJ7YO5gAYdB1zQB82Lp1633bO5P0ib/AAp40nUT0sLs/wDbFv8ACvrHT/hzoDQLuuJQ+Oi9K1ofh1o21fKmfd3JoA+Ojo2qAZOm3oHr5Df4VGdOvQcGzuQf+uTf4V9op8PoF5jujt7ZFJP8KYboCRZYgx9VoA+Lv7Ovf+fO5/79N/hThpd+eljdH/ti3+FfXN/8HLpjmERN/unFUZfhHqlvH5hgIUdADkmgD5V/srUc4+wXefTyW/wqaPQdYkP7vStQf/dtnP8ASvpwfDO/kuVCRyJ6llrp7DwHeWcYWNQW6dOTQB8hp4V8QucJoOrMfQWch/pVmHwL4tnz5PhbXpMf3NPmP8lr7j8P+DpoFM12o3dhXXWFmLOBgoAz7UAfnjJ4A8Yxruk8J+IEX1bTZgP/AEGmjwJ4vIBHhXXyCMj/AIl03T/vmvu/W2nnuAC7BFPA9KgCTqQyyOT0FAHwsPAvi4nA8La8T7adN/8AE0//AIQHxjx/xSfiDnp/xLZv/ia+6ZpZQ6RlNx7leDW1CxECgZJI6HqKAPz+Hw98aHp4Q8RH6aZN/wDE07/hXXjbGf8AhDvEeP8AsGT/APxNfovZMrJgH6irfAQ7vu4oA/M258KeIrVit1oOrQt6SWcin9RUA0DWCcDSdQJ/69n/AMK+2vHqot++wIOd3IzWL4Xso9T1BvPlSGFASzBcYoA+RovCniKUgRaDqzk/3bOQ/wBKvL8PPGjKCvhDxEwPII0yY5/8dr61jWWz15rYSFucow6MOxr1qxkZbJELZcKBQB+eB+HvjQdfCHiIfXTJv/iaQ/D/AMZjr4R8Q4/7Bs3/AMTX6HXEEhjVlmaJ8+mcjuMf1qG/lk+zD7OqcHkucCgD89D4D8X5/wCRV1//AMF03/xNRP4N8TxgmTw3rSgdS1jKMf8Ajtfa3iXxFb2TNEjeY54O096891PVrm4RzK5WMn5QehFAHzEfDeuA4Ojaln0+yv8A4VYh8G+J5k3w+HNakX1SxlI/9Br3Oa+twCBnd65rW8I6+1lqBRZW8px93dkGgD55HgjxWTgeGNcJ9tPl/wDiaU+B/FiglvC+ugDqTp8v/wATX2fpXiK0klxNwPVRXTD7PdIr2c6OSMFTwTQB8Av4W8QIcPoWqqfe0kH9Kjfw9rSLufR9RVR3Ns4/pX2xrmjFZnAiK7uRxwa5K905oyRs9iDQB8mtpGpKMtp94B7wt/hUL2V0n37adfrGRX0nrWhKVL26nH8S+lcdqOiqyHcmfbFAHjPkS5I8p8jr8p4pDFIOsb/ka9Eu9BKlvKU8nNZkujXK/ehbHrigDjSjjqrflSYPoa6i40xlB4warHTJSQBGxPsKAOforXfSJi5AifPsKgk0m8U8QSH8KAM+irZ068HW2l/75qJraZfvROPqKAIaKUqR1BFJQApGDg8Gkqa8UpdzoequwP51DQBPY/8AH7b/APXRf519qeEwv9gachiR2ES5OK+K7D/j+t/+ui/zr7R8HW8zeH7LyjsYxDHvxQB0TaPBclWKxL7MMCpZvDVjJHtJhhY/xq1UYLOYEmZmkGepJ4q79k3ON2SB+VAFF/A1uW3xX0L/APAsVLZ+EIrcs0dxE2Tnbuq89sqnhlUnoMYrPu7V5FbYxSQdCDQBd/sZw42uqjsM1dttLuI48zSRBvQGuJfVNR09isrZGeCadDrriQtMjMpHLBv6UAdzCjxOMke/Nbdo42qMZz6V5nZa1vlHlCRsdOa7DS9XLCMNC+48YAoA7O1jwOatHkgVFbFVhBbg4yc9qdFIkuSjAjOOKAH9TgdKRgqgnaM06RliXLHH1rKurwO+0MCPY9aAL00kagb+Se1R+dblcs22su6nZ14Y4HWse6uhGM7yfagDfFtYzSFhKGYnoTU0lmqqDEifiOtcJLfrazmcBmBPTOK0bXxe6kBoBs9c0AdGtgrybmj2t6imT2ro4wMj2q3pup297GCrbXP8Jq5ICAWxnA6DvQBQgX5lbpVx5NkL5xgjgd80u0GNTsPIB21NLEjRYIx7+lAHkfjiImVpCuWNcxoOoJAt1by/JJNwrEcD616d4h0SSd22ONjdCfWvNr3wrqJunSMoTu4agDVtJ2ubmzixukiO3eOmK9Qt4DHCu772Oua8+8NeFL+2uES5nG0MCcDk16lHagBRngCgCrJGxjUknC+vNcT4y1hhGbe19ME13t5kQMEXoK8912zEbM79X70AeZzRH7Z5l02WByF9az9fkeW3Dx7AF4wew9q19X8kTMWJGOnPJrn7wJcxlcOo7DPWgDkLmeKM5kkJI7Cn6TeJ/aEbxxNtXknNba6LbNGzeTk98nNaum6VFb2y7YU3HnpzQBYs9UjMg2RTD3FdRpM083yoxjJ5G7isK3TyQN7BV9wAas3F+VX5HwBQB6Tot1f5WC+iM0R4Dda6K48O2V/GDJEVfHUV5d4T1DUDeIFmkK9cZ4r1jTtbVwqz4z0ytAHOz+BIyx2tIffisfUPhtDJ88cLse6k4r1yNlkQMhBBHUGl25zQB4z/AMKzDLuSGGL/AHuahk+GMEn/AB8Shx/dXAFev3UGzJAODWfPbh+vT64oA8ZvPh5otjJ89sHbsWbNQyeFNLEZ22ygD+7xXp2oadaeYXmuUUDs3NQDTLPyt6TI49RQB43d6JZ2pby7IN9azrm0hAwtuiY9q9mvE0aMbbiZA57KuTWHqP8AwjsUXyxyyH0xigDxi+sXcODGcD+7XM3uhrIp3KwP1r2LUb3TFdhDYS4PvXPXmpaYuQ1hJx/tf/WoA8V1XRTGCVQ4rmrm2eJvu8dK9x1CXTb3McVpOkp6bRu/Ssa5+HeqaiY3jhjhhLA7pTtOM+lAHlmuLs1rUE/u3Eg/8eNUa2vG0BtfGevW5IJi1C4jJHQ4kYVi0AWtMGdStB6zJ/6EK+9PCFoToemgrjZCOfXivg3R/wDkL2P/AF3T/wBCFfoz4VsQPDmnEkk+QufyoAh+yLsOFGaSygJuPKK5B61uC1jdSDkVNa2sUALgEt70AV20uFU5QE/SszUNJilhLQrtkUdB3rpN25ehqJ4UCM5+UYoA8v1GwW5jaCQYfsTXJ3dk9pKY5gQ35A16leac80wMWG5yatx2MKoBcQxykdiucfjQB5noNldXV0qWsBIxksB8o/GvSdJtotPjXLLJcd2xwv0qC7uIYDsQhB02RjA/Gp9Ot2nwc/e70AbImM0TIvPvTpJY7C1aaUgYGcVPBbrDFx0xya5fxjcxRWJlmlK7TwB1P0oA5/WfF13JcN5UmEHY1lyeMPKZfNG4jqQa5LXNVS5Z9i+WueAOv41yV/dk8MzAHoAaAPWX8WJdvhZvLA6gmo/7aiJIWbzCTyRzXkJ1V7dlVgDEwwfUVpaTLLMxMCsvpz1oA9YE0F2gCuQcdGqOCMSHHB2nOf61xFubyEhjcsQeMKM1tWOoSWri4MTSKPvEmgDt7a58jawJ3dTiuy0a+a6jG7p/Dz/OuJ0LWbHVgQSEnXGI8dRXXadB5bboidvpQB0acgGklwV2k4zSQNujHGBSSoWzzxQBhasskUBWMl3ZuDjhRVbS4DcSgMVwDkg9a1mtwVcOxOe1NsFWKXCov170AWRbgzhxVwDA5pqYVQM5NO4NAFS+cRxsMdq5K8t11AOH5ZRwB6V1U0PlxvudmUksWPJHsBWd9kVZHlTGNhAx1oA8j1jw0890TGCcniq0WhR2cW6+AyO2Oa7O/umt7sqpUMT0J5rG1a3kvVYOxEmM+1AHPoumPOFSPavfJxV91sQf3SDGOMGsmCzjgkJu2VVHcmmT6/o9m5WNixHJwM0AFzbQyTZaKVgOhzUVzYK+FDFIxz06mob3x9piwONkkbAf3f61y83jaCVgI23nPRuKAOzs5prVxsJORt+U4xW5aarLbjlzjocmvMZPE0ki5hjVB6g5py6veTYzKfLI5FAH0R4b8T2pth5t2kZXjDEV1lprFld48mVWPt0NfMWlhZkUTBgnXcDyTXYaBf3OmKCG8y2z0PVaAPdZJd8bAjAPFebeJ5NT0y8w87GBzlGA4+ldD4e10XkS+a4OeFPTI9D71tX1jDqNq1vOoaNhxnqtAHjOpaldPuxLnPXIrHiuroMT9olx9eK6XxHoU+n3TxMOP4W9RXPrG0JO5D9MUAWrYPcnr83r3qdtOdhnGSfWl0qIs4ZMAV6NoGiLLbJNKu4n7qnpQB52NHVuAmW9BzV6z8ArdgSXirGvXbjkivUG0W3gBkiiBl/lVUud7I2OO1AHGDwtpunRYs7WMS93xk1y/ifTXjAYuSCRx0716lPCDlmPA9qyJNF/tKQvP8lurDLHkmgD4V+IYx4/8TA9Rqdz/wCjWrnq6f4oqqfEzxcifdXV7sD6ec9cxQBc0b/kMWP/AF3j/wDQhX6Q+DH3eHrBSc4hX+Vfm/on/IZsP+viP/0IV+kXhFQNE09gMfuVyPwoA2DF3HFPjBwKRmO7jpTowe54oAlCqOcVj+INQEAWJQCT1zU17qgiJSBd57nsK5+7tp72UyOfm7cdKAKkmoqjguxYf3VouNVuWULDHlD1Herllo8SSB5FLtW5BZRAAqgB9hQBhafpL3QEmCAecNXUWNiltGFHNS26ojbcgNjO2ppXEUZY9qAMjxBqgsLUhBmRhwDXknia/kubeZpCS7ZIOa6zxReNPNJgksO3pXC3ce6NhM5GecCgDg57jex38MeDxWHqCTF93RexNddq1qsch+yR/vO+eaxHtdrF5s5HOO1AGRFCpyTlj79K6jwzPGI3VyNy8KPWsK9niteJFGSOewrPfVijBoHCbTxt/rQB6RHdrHuDYBznJOOK2bLVdPSArITKHGGVRivOdF1G31CbFzKElHT3ro7eAK+7adn8PpQB0+l2sct75ljvCqcjB5+ler6Mky2uX4kwD9a8i0qRYgqxEhzya73S9QljCKshLqOM0Ad5asPLCscmrR+7x2rlLLWJTeoko+VupxxXSJco0m3IyaACSNWzxgmolgUuNpwwq2wXbnpVVUaVgQSsf6mgCxEmPmzUuKAMACmtx9KAIbpiFIHSsDV3dLeQxHBKkcVs3sgGPTvXCeK9aSE+SJNvqRQByGpzPBc+Ze/Nzz61Q1bxV/oMzQQ7WUYRD1b8atXN8LlvLXEjkEqSOtclrDyWrv8AaXCM3RR1oAw/Pvr68kurssISMZzwPoKytRiEAJiIfd+lXyLiWNnZgFzgAms9rS6ZizcJ3BNAGLqCyyadI8q42nArmHyBg/ersNSDurbE3RqODkda5S5jZXJ2nrQAtrPNAwZJGUj3rtfDuoyTFVuIw69yODiuCjY78MDyfSu20MLFZhk5PvQB6FYXVpcYiglVH/uPwa3LJygaF1O0V5HHdBLpyzjrkY610OmeJp7FQCwkjPVXoA9Y0C4WK6EYJ8pj8wz0PrXqumGSSyAkJLp0b1HavBtA1K3vXjEMnlTNzsY9foa9p8GXEjweVL1Ud/SgC3qMMN9bFZ4g7AfiK4rVPDHnBpLE+ZH3QnDA16RLbAksvBrKu7R0l3oMZ5yvrQB5/o/h29FwMr5cYbndXq9rAtvbRovRQBmsWAq8oEi7W9R3rfTDIBntQBE/OaoTwxE7pgBjoR1NacihEJHWsmWNnlJbJPoKAK8lqLhwASB2FT3luI7ZIYiBjHarcEYXB/iqaS38zmgD83/iqMfFDxgD21i8/wDR71y1dV8WOPin4y/7DN5/6PeuVoAvaH/yG9P/AOviP/0IV+knhsgaFp+RgGJQPyr83NB/5Dmnf9fMf/oQr9JfD5/4klhkAHyV4/CgDVUZbiq2oXAQCFWALHHXr7CranZETWdJaxy3CTSLmRM7G9M0AV/KHpVqGA4BqwIhxTloAYI1AqzEvGKYBUyDigBwRSwYqCw6HFZ2uOTAUVto6k1pjgVha1IGRhnmgDhdTuMsyIuMcH3rlNSnVWYblAXqSelaXii/js5HI+aXH3AePxrzu9u5byR3mIC9lB4oAvXmqWySMsOXkbox6ZrltUvg7kykmQenSpLiWLJjCnHr6VnXtjN5ZY52sPvGgDBvriSaZnlcnNQRJIVJVTg+tbIsE24VWZu5NVpIWSQhhgZ4AoANMtWd2YvgrzxXc+HNajsrWRbpDPFkYDHkfSuPgRVYHeI1781Zae3iQ/OW5znNAHsOm6jpt1FG8aBc9M9q7HSIY5/3tu5wo6GvA/DWtQR3IWcHyTxjNez6DJ9nt1ktpfMhcDBFAHYW7mRVIjGQeQanm8z7ZEyll9RUmnBZY0wN2ehq/PDtkVhg0AaGd6Ig7jJPtUq/f4qOIr5SkowzxhRmpwMdKAFqOXpUlNZdwxQBlX6gxEZOcV5f4mtFM/mS5254HrXr0luuMkZrlPFWjNcQtJEgJ9KAPLLZ47a63P8A6sDgVja3JBO7ygbn6gt60viSdrO6aOQ4wcYFcZrWpsobEvljHRetADLu6RmbfLt284rI1PUJpkKwEiPp7tVG5uW2blxg55PU1jvdTE8sVHtQBp4mWPyeQGOTzVe5t3Zdg6DkZqj50zMW84jsDU0N1cZCu5Iz+dAD4IMSjP4VqGR1QIpwR/dqs135HLRqWPAOKW2uI5JBuOwnjJ6UAWobdlberAlueTUEk8i3DeYnA4HpV14plhDQQmfLgcHoO5q3BChdl2kr2zQBraJcs0KHcFK4INe7/DLW22RxXD+YuOGPUV4HZ2UZOYmKHuD0r0bwXJPaWwfvnAxQB9GKQ6gjkHoailXjNYnhbUXuLVVmK5HH1rflKqjFyAvcmgDMuNoPyoAfWqbXUsXzK54NaUqK4yDlexHeqE0IycdaALVtfmUbJxtz3FWUiEQAjGV9epNYzIykHtV+xuNq7ZOV/lQBdQjd05p88qxxlmJAX0ppwGyOhqlqRLW7pnBPegD86viswb4o+MGHQ6zeH/yO9crXT/FEY+Jni4Hr/a93/wCjnrmKANDw/wD8h7Tf+vmL/wBCFfpP4fUjR7PPH7peB9K/Njw9n+39MwcH7VF/6GK/SfQif7Hs9xyREvT6UAacnKYqNRiljKvEjLnaRkZ60o60AIAA2MkluQDT8UdKU8jmgAAO4elWEHFQoM4xU46UAMlOBXDeM9UNuGjg4yOZP6Cuo1O625VTgdzXAeIP9OlaFAD6n0oA831x2kk3qd2Tzz1rAuLKYxllGN/HNd3d6aLZsbd4POfSuf1Vwh+VcEdPagDmVs3tpvKkiKv13v0/Cr88MIhXzW3cY46Cqt9c5JaaRmPpWHNduOdxKg/dFAFm+uo8GOH5QOAawbudxnJHtitGd0eIyPwew9awXkDMSCM5oAsJGsu0ucNnirl5aCKFQpDSMOcVQgLSMvGQPStMW88kkZjjZlNAGTCWWQLivT/hvrtxBcpZSPlP4QTXKJo0rYLRHJPAzWvo+m3EWqWzCMrtPJ6UAfR2gXh2os4UkjPy10c+0hSDg9q5Lw5ACYXZw3yjGDXVSKXEe0cZ5oAv2/MY6Z71JUcI2jjipKACiiigAIyKq3ADIRjORVqoZBk4oA+ePjjoVxDK15akqnV1Xqa8KupHZNgYkn1r7E+I2mG+01kVQSRg5HavlfV9Hax1C4hlXARj0FAHNSMZEUg/MowarLGXk2k4966F3tF/dRQgSEZ+YZqKIAEfuwD9OlAGX9hkEJl2sQvfFVApZ12E7s11er3GYYIk+UY5X1rNZoUCrjLeuOlAFK6iO5d7DgfrUcTwo43hmAOTk1euWSSYfKrHHGKbBpaylmOQByT6UAXLHUijFAfLQntWvBfRTDY2FBOC6jBFc+LGQy5jIK9Bmr0UMkQB8vaWOM44zQB2WmWpODCQ6t/EOeK77w4VjCKwIUcZ9a8y0iWWwXzoWyx+9z1ruNB11LiNUmAhnYcAfdP+FAHqvh6Qrc5iOAOcdjXfRMJYVPtXl3hR384gscj1r0PSZy6srdaALci5U+1UJV+Y1pMDzVWRcNQBUaM9/wAaRVAbpUrk5qMqS4bcenSgC3D5jNtyPKx+OagusPwSNw9amtm2kEjFRX0YOWHBoA/Of4qDHxP8Xj/qMXn/AKPeuXrqPinn/hZ3i/PX+2Lz/wBHPXL0AaPhwZ8QaWD3uov/AEMV+k+hDGlWnGP3S8fhX5s+GufEelZ/5+4v/QxX6UaMcaZaj/pkv8qANBjwO9Jjml6pSE0AONN/ClJ4pqgls549MUAWIulLK+yJmoUYFR3hHkkGgDnNQVpWd2OExXH30rGfYg2jNdPq0zIjEAlTxXFalewW8jOJC0hBATPT3NAFfU2aFGaSUKB39fpXAazcm4ZmgBAHb+9Wvqd3LLITcOX9h0FUXt/tO0QBY+/zUAckwaSUx4IfvUB0+Vlbso7V11vp0UN05nUyOB24xUAtFk81pTsjQ9PWgDkriwkjtm3MSM8YqgNOTrt56810uo3CQOZI/wDV9AprGluLeT968oQZ5A60AUC7QEIqkAHjArX027dZFjYEqec+lFre2rNzbsyZ4Y/4VeuLRbqIXNmyR7eq96ALpfD71cjB/E12vh+M3a+aCNqgZJ6mvKV1Bob0BixXpzXpGhahC9quxhG5HSgD2zwtbo2nRkLgiumSMheea5jwNL5ulJk5I4NdZHwKABDkZxTqKKACiiigBqsxdwy4UYwc9aUgYNLRQBi62B9mclQeK+ZfH0SNrc+DjPPNfRfi++jtLCfzZFQEcE18y+L9UtbnU3MRbzem5ulAHHXRWMSEjLZ+lUrXVgl8nmBCgNO1FmYbi5ODz6VhmI+cXxxQBu67r8M12WSJduMDA6VijV0YHemctWXNueVsZJp4g2hNwyx60AbyX1uSm0Mrn2rdjMbwbFlHPUd65GZ/JZSoGMVcgu28pTjk9z1oA6e2ijy24npxWnZXSKdjR5TsDzzXKpdOkQ2OeeRmtLS9VSBt06bvpQB2UVnBPC0gHlkddp61USG4tWLo2+PPUdqn0+6hmiJgk4IyR3qOaQtIqp3PIFAHfeAfELpMEnbfH2PcV7XpMgdVkRgysMgivnrQwhmRQu2UdCOhr2HwjeSQ+XG+SCOR2oA7z7wz3qvOKlibcoK8g02ccZoApsBSKNvXmlfg9jTYxsA+UfgaAJYxyD3zRecLQhOaS+Py0AfnL8U+fid4v/7DF5/6OeuXrqPil/yU3xd/2GLz/wBHPXL0AafhnnxJpX/X3F/6GK/SfSFxp1rj/nkv8q/Njwx/yMuk/wDX3D/6GK/SnSiDp1sAc4jUH8qALkTh1O09CQe1K2R0GaVc/WhhQAdqE689KWnKORQBKBVe85BGM8VZHtWfqrstu6xf6w8fSgDiPF175MDxQkFyOW/u15RNFO97n5tpOSzGvTNQjxKfM57Y61z9zYCcSE4LfwqKAObliQzBUBdiOp/pVxNNEWHf7x6Z7VdWzFrCzSrkL1boB+NYmp6wsMBS3YSljgu3b8KAEv5oLdiC5Zu9YF3rsbMY41V16bRWff3DzTkSyYUjk561lyRoATCCz46+lAEep281xKQXVQ3YHGKow6Y8auCN+OcinPKfmWTcX6Zq9pRdEmLOPu9zmgCgfMVNpBA9utS2YmtZA6P9/wDhJq/EhkZAyBiTjirNzZpFOAIXcgdAOlAFvVdHSOwimQKZD8xI7VV0O4eO6jUgkFq2bKCSeFI2im56qBnFaGj6BKl6paFvXLDigD1z4cyTwl4sYjYAjJzXoUbuY22BfM7A9K4nwRC6nMnUDgV2lsrCXnpjrQBaXOBuxnviloooAKKKKACo2kHllhUlR3H+qNAHk/xPdplkG7AUdK+b9Xhkl1R2QFsHtX0p46DyvcI4XaRwK8L1GzZLuZ4wM7uAD1oA5CVT80TIc9cVVl0+TyXZI3/Kuhup2WcO0aqc88c1tW8LXGmmQnco5AoA82t9PnRvmhZmPTtirdh4dv726jt44iWbnI5xXZT23lwmVVJkPtV/Q5jp7iQHy5wM5PegDzjWdEu7K8aKaNsrximL+7jBeF96juOtd14jdr24kvIgZCOuO1Yqusq/6Txxxgc0AYNpNJJMCyADpitLzIlkBC5A64qy1skpJA2x9sDk1nNHhmWIlEPUEdaANT+0LVABEXVu5Q4re03Uo5lTJAHaQdfxrhvsssZ3gZX2NamnuY03Y+VuMUAepaMkguEkiZXX1WvV/C9zsVTLkjpz2r520PUp7G4Q27lsn5kPQ19AaIYr3TreS2OJMAunegD0jS5hInByDVuUda5rw/OySBG4HTFdNKMqKAKMgw30poPGM1LcJkhh1FQBST0xQA+PqMdKLzlaci4YUlyMigD85fil/wAlN8Xf9hi8/wDRz1y9dR8U+Pid4vH/AFGLz/0c9cvQBp+Gf+Rk0n/r7i/9DFfpNo5/4l9qP+ma/wAq/Nnwx/yMuk/9fcP/AKGK/STRz/oFt3/dr/KgDTWnEU1adQA1kDOrEcr09qmQY5pg5qUDgCgBf4TWZesACCa0nOENZtyu9WYnAA60AcrdIokeRIhIc9DWFqeq6fp6SeYgMx/gXoPrWnq2qxxu0VquSeC+a4zV9Na9uFMCnLctk9aAMLWtVmvwQrDYegHQVzF2kiI/lxc+rV29xopiYII8NjpVDULOSCRSmxnxySM4FAHGf2dLK6PKhUEZq3b6cojYuMAnAxW2xym5fnOeW/pXK6lqtxc3M1jpjmNUO24usZEP+yvq/wCg7+lACvo9urF5d+CeMmtixs9MitSTAHOMkk5rm7dYLaNYV3CKL7uWJPXPOeueuauxXVsqHF024jlFHSgDZhmggKrBagKTkkDtSy6gu9wse0kcGs+HVoLaNi0bHjrQJ47iISWyghckg8mgDT0nUhHdxEy8Mdrc17T4e08XGkeawBZuVLCvneDVFubuJRaKxDAYU459TX1B4YaN9EtlVdjBBkH6UAW9CsxDN6HHSuiVdorPsIBGS4+bPb0rRFABRRRQAUUUUAFMlXchAp9FAHnPjmJbYPK6fKwI5rwO6mIvrpTj5m4OelfTfju0ju9EnUqTIFO3HrXyN4nt72LUpchsDqBQBr3FrZuhN1dxK+OCD+lXbdzZaTulg2wsMo45DfjXCRwGaEhyeTXXQXFw/hz7GzlolOVB7fSgDNvvEa26HavJ6cVmnWTc3SbkJ4yTVDWIlWZVl4wM4PFY094EBCMSR6UAdz/wkMFmG8yFVQccd6i07XdM1GR4ri3KMfuuo6Vwskss4QsT9DVi3hCp5hYrg9qAOkv4iLkGCUNGB/CahEO4bnYfN+tc7JcMT8rvu3dc1ux6g0Eccdztboc45/OgDWsrSPKgvtHcMMZrX/sy3cgBRuI4xTdJW2vmQxSI7YHDnBFdNpmlskwaMFvrzQBmaboTW0yzOpZP7wH3a9H8OyyiGJ0JQqcDFU7K3ClVAOQeQeldbpelrLbM0YCsDnHrQB1WiSJdoCcCYdfeulRspg9a5HSswy7SCrLXWW7h0yKAGzLwargc1dcZFVmGDzQAKOajuCAfftUyVWuOv0oA/Oj4qf8AJT/F/wD2GLz/ANHvXLV1HxT/AOSneL8/9Bi8/wDRz1y9AGh4fO3XtNPpcxn/AMeFfoj4UvDNplqc5/dr/Kvzp0lgmq2bE4AmQ/8Ajwr7w+Hd6JdJiIkJ+UYHoMUAemRHIqSqVhKX4PpVw545+tADx1qYVEnUVLQA2Xp1rB1e5IhdYzheh963Lj7mKyJ7Lc27+KgDlobItMZHCrH7jJNTSvHG22O3UsOhIrZlV8NiPAA7DNYs8TrLvkVs/wAIIxQBz+pmS4lLzny4842rXM6gPkljhKqjDgtycVpeMfEMNjFJLJJEIokZnPYADJNfL9p4+1XU/EUsd5c3X9nX0+DDDy8SE4xHjkccHHuRzzQB6VfarJeSz6fpEpihRilzepyQe6R/7Xq38P16ZTzCygFvZxiOBRjb/X3PvXR/ZbeztVggiEIj+VUC4AFYV6v7wcruz0oAz5FSQZkdi5PFMRVEuAMtjj2rahsftMbCSMDA4x1+tJY6DPPerHbygsepI6UAY4Mzfeztz3roNMkK2gt0i2iXq+OlbNl4TuLm6MYUE56gcGu70f4dTSSL9pKxrwQuaAOK8CeFn/tZTIjnccg44NfROnWvkwImMYGMVFpuiWNi0C+WvmKMA+lbCIN7YoAsWqBcAdqnJ96ihGCc1IRk0AOoGcnPSgdKKACkBBOO9LRQAUUUUAUdTgE1u6kdRXzx8StMEF9vhABOc4HWvpR1DKQa8p8e6GJXb5c4bP4UAeB2lu8hKC2VyGyR0zVy6snhiAwVPXaOgruotGhsrgylfkrlvF0rRKxtgzKeM46UAcXrNup+f/Wt0+asa40ZsJOkJRP4gfSte4MsdqzNkqw5zVdZpns2VvmDfdJoAwJliE5CFvL7VoSwxpZAZOOp4qmbdyzN0OaWTzygVn3J6UAJG8EZ/wBTuz0IqxHHHcSZALHsM1WitJim5Oewq1Yx7HYShlb1FAG9pcccYVm+V8YwD0rs9E1W7tCoBDwjuTyPpXGWUkTqMggjv611+iCB1JznA70AehaLsvgJInHbOeua7HSRIp2sAP615np9ysOGQeWwPr1r0PwtqK3hjW5+WUdPQ0AdbZwiQ7mPzdjWrbZj4NVbddjYxV1RnHNAEzVXlXuKsdV+lQk8kGgCNSSuaqX0ywxs57VZLYHJrnfE135duw9s0AfAXxLfzfiP4rk/vatdt+cz1zVb3j1t3jnxE3rqVyf/ACK1YNAElscXER/2h/Ovqv4HeJGnjNjcPiSNBtJ/iFfKkH+uj/3h/OvZvAlzJZ3UEsRKyDH40AfZekMHCkHPHWtYcmuR+H+pLqOmRycBwuGUdjXWrQBKg4zUg45qPIA/nT+q/WgBshG0HrVcFSTmrDKAAAMDtVC7l8hSUGWP6UATlowQCRnsKpahHDcIY5QCp6iqiuZJNxHzdSakCs7cgbfegDyz4mfDUazpMsNnqDwWsrgzqgBZ0ByVBPTnHODxxjmuE03wtpHhpFh0/T0hl6Gdvmkb/gR5/DpX0Tc28QRiclccj0rifEemupkmMCTIF+UqP6UAeWX9ukjA7nMnqaz7zShbhsCNpuCuTXTXltDMQ43xsP4SCKZBbQTuAXVGFAGDaCSCTckIGeMYrsYYILiwje2Vo7kjDFR1qNraCGFmiKtJjqx5H4VJpt5b6ZZNczOZXbjbnAoA2tGlhsFQ3W15E4Vc9TWxqeoavKFuLMNEq4JAHGK83u9ekvZ8xxKin7p7ita3utZa2WGK8cqOuDQB2eg6tq9zfLHPHkE53dxXo0cZKckgnqR1ryvwtcXMepJvOV4DN6161atvQHoDQBNEm1AMk/WnMDtODg9jS02TcUbYQGxwT60AEQdY1EjBnHUgYzTqgsRcLaxi9ZHuAPmZBgGpgwPTNAC0UUUAFFFFABWTr1qksO4oCemTWtUV3Cs9u8bDIYUAeTa7pywk7po0jY9+1cLd/ZoXkWZllVjgj0969A8ToS0kUy4SPjmvLPEFm88h8oMhzgKaAOd1Gxbc4jCPGTnaRWOFil3xfKn+znjNbF9NcacsccqkhskhjUF5d2N/YAG2jFwO6jBNAGXBpwPHlFz0yvNMls4VcCSPbzjinw38tmzKgEYHQg0p1mRW3XEcbA9CV6igBGUxIFiiCp6VJbRQyttnARm4BA60q3FrdMXcMjfw88Vfi2xWm2YImTkPjNAD7XTRJujMLBv4SO9a2nWMiqwPBXj3FU7a7eHrKdjdDj+Va1hK24ySs2M8MD1oAvWNlIzhjulx/D6V2ugy+Wqgg8HqT0rE0p0aYNEWHrXZWdgs8Zk4VvYdaAO10W88+NFY544NbWOmK5nR4JIYxvBA7Y6V0VvJvXBILUAWDwBULcPUp+6Kil4waAKtw2047VxPjiQxWcrluAM12l2TjcTx2ryL4zasNO0qVEJM0q7VH9aAPjXxfIJfFmtSA5D3s7A/WRqyKtaqSdUvC3JMzk/99GqtAEttzcxf74/nXtfhiAbrfKnOBzXitp/x9w/76/zr3fwyp8lCeBgYoA9w+FlybbVDDk7JF24zx9a9cXnFeHfDyY/bUYtkqQM17Xbyb1BoAtnJIwKkzyBTVHend80AMmbaOOtZ8kfmZOTVu4Y9e1UTcglgBgigBgjw+D19aefvc4/CoTcN5mCQVHapA8bfPkAGgBzIM5Bz6iue8R2bSQsyyCMDnANbM1x8rBVIxXO6sWmjYSM2D2FAHnN9rSwySRSw5wdoYjrWC943mM0ZTbnkgciruv2Ux1B1KsV67AOcVgvo1+zkDEEBGfmNAF5tRjMMku7aQdvXrWTczTPIrEkxAfdHepGtLSPy7eed5DnBRBwT9akmuY5WEEUWI4vlHqaAHaYzGNpNgUAY5r0PwxbD+zlmLEnOABxWD4Q0dL2R1njClx8vP3frXeWlkunxLDbgtzgkigC1pVoI59xdT83C4rv7IZjXntXC6fBK+oKT1z2r0C2TbCueuOaAJKUUUUAFFFFABRRRQAUUUUAFFFFAHFeOtEa4IvIWwBxIoHX3riruxEsJkijDBOuRzXsk0ImRkcAqRg1wuraFNYSyyQYaCQ4x/doA8Y8c2iy2ShYwzqeGFebNasJTljuHIHTBr2nxYiopDgD3rzjVtMkmeOe0OGJwx7mgChawJdwMZsbgMAAc5qjd6Yd+1yVXt7VBeG4069CS5B3cgU9b+XdmVt0PoaAKU0bW7bC3HYjvVhNVYYgK7h2V6SWN5MuMmMche9MB8so6gc889jQB0dhP5nlpJDmPHY8iunsbSN0ZYd0i9xu5U1wtvOjOGk3qR3T1rq9EunREkxlifvjrQB2WjKIm2ncNoxkjpXd6M77AZQSmOD71zWktG9uJAwzj5z3/AArYtLwIwCsY+4B6EUAdvZzNJEQat2+YzlelZGkXKTtgEbsdfWtqFgny9qANFWDR5/yKa/K4pIcbT79qZNNGksUTNiR87R60AU7w/uDyDg14B8Z2a7mkYDKxjaK981fAgcr6V4X8RoC0E7Adc5oA+RdV/wCQpef9dn/9CNVat6qMapeD/ps//oRqpQBNaDN1CP8AbX+de5aIWjsU5ydowK8OsRm9tx/00X+de86Wmy0gxjJFAHqHw5Uny5cEc9favatOKmIHPHXrXknw/jaOBI2X5SM789/TFeo6NkFFPIPWgDew2wEP+GOtOG843Bce1KoB6DgUp5oAo3b7ZQD0NYWpSiDc24L6k1oa7dLaI0shwAK851nxTBLn7TGxhXqo4NAGw+uRvNsiY5HBerun3svnlJMyKfTpXEJrGnTKFsh+9c8KBk1rwa7aaHHvv5A0x6Qocn8aAPQoIZLhBvVUX1HWorixtLX95K5cn+EVx8fjh7viNBDCRwO9blhB9vt8+eWJ5x3oA5DxtrC27Omn2yRyEH5wBuP415dLe3dxMWOS/TnnFexa9oDFSQoYjq2K4oaTHHcHzcAl+/agDmYtNupJFZcMzc/KORXTWvhxTCjwlTOwwQOx9aNRv44JBHYhSRxkdSa7nwXoUn2NZrlczscn2FAE/hjRItPiUugMr9XIrpZrNTF8oGFPYdar32ISoUcDoK1tMffB8ykH3oAj02wWNw4HatkcCoomHQCpaACmSSrGVDZ+Y4GBThnnOPbFLQAUUUd6ACiiigAoOe1FFABRRRQAVHPEs8RRgCDTmIyAQTmgAA5A5oA80+IXhgvotxJAoyoyuF5rwm0lubW7CTwEx54bHFfW+pRrNZzKwyCpBFfNvizT3065ndSz28jnAH8NAGbrWgWmuwpJCyRuB8x71yc3he6tSYfNTHUM/pW9DbEvugmkC44O7+lXhLB9nkjvGaWUHAI7CgDiYreeyd0n2yJ6oc5p39nNLaiW0QM+eUP3gK6tNHikYSWe1VAySefxq1pmk+TcJOtyhLHk4/SgDjLfT5pQfLX5s8rnGK6/w7p/kDfcNgdMAV0kWmWss7SQRo7jg7fWt2306CBd9yijI4zyaAMD+0djKiYTb6cYrRe8M9upjfLDqBWNq8AF47iMkZ4PYVnO08TmSKQ7F+8EoA9E8Lav5U6oW3IDgr3/AAr0aGVHCspBB6V8++G9XeS6cSKd4PBAr1rRL5h5MjHEZGCKAO6tG3Zz2FOngjaeOYj94ikKfQGm2DJIgaPlSOtTvyh9qAM3Vxm0Y+leQ+OI1a3m385B4r2G+UPaup7ivKfGKbraQYGen0oA+JteXZrmoqO1zIP/AB41QrU8Urt8TauvpeTD/wAfNZdAE9icXtuf+mi/zr3fw9m4kgA4VcEYrwiy5vIP+ui/zr6M8A2e+JHI6ACgD1bwgjiFdqnAHQ+temaKCdrYxheRXE+GoAsKr3rv9IjCgigDTjxil+tInU+lHVs0Acp4xgeWBnGSF6ivHdWtZZZXDMFTP3j2r6Av/L2ncgf1Fec+IdLtvMeVAQCfqBQB5rZmSzLrp6lZDwZWHzfgO1Mh0ya4uPNYtI27nccmuq/s4FiUZSPypIYCsymMYPQkdKAKS20lthWGcnqe1db4fvpbV02z7kyDhuv0rHmtJERtzA919Kz7m6ESbVJ3Act6UAetyTQ3kYkhlVJP4kPOa5Pxfb28caOqIGfhjnGD615MvxUtrPW7bTdOP9ranPIIUht2+XcTgbpOQB64zj0r2ua70+W0j8zEjMcOp5xQBxPh7Q4ZrwXBj3Kh5bPSvZoVih0+MQp8oXiuMiXT7eQJYSKnmH5lJro7QuuJUn3oVCGI/dXHce9AFKOBnuWkmLO5OFx0FbtjZ+XblSzEt1JqOzjVm8zPJ4wK00GAB6UAJFGIxgU+iigAooooAKKKKACiiigAooooAKKBwPWgdPSgAoHFFJQAhUH61w3jTQxc20m2NCSdwO3GK7sVFcRLKhDgEe9AHyxqWmYmmjmje3dc7XU8Vzv2aQzLMJCEBw3P3q+lPFvhqG9s5gsagsOGA5FeC634XvrWR/Kk863ZuGTmgCKzvPshJDL5T8FAc4rptNWymti/m7Ywc7sdT7Vzelxw2e7MRfcMETcc1taNcW5mSEWjN83QcigDpSEKIsKgb8YaPr+NbkWmSmONZDuTHfqKu6LpM0pWRIFRSOARXTjT4oUHnSLnGdooA5A+GzdRmOEAxk/NnqKzrrwrbpH5czAA9SnLH611eoX3kN5UThF/uL3+ppYiksOUjGTyc0AcTb6AtmpFrEPL6lxy2K39Hg8uIkknngGtCaIrwhHPOB2qfTLEupdgwbOcHvQBu+H3KZVjw3OK2e5FYdioSYBeK3Mg8jrigCjdEKQvduleZ+L48ySqB3r0285jyDg1wHi+EDJz1/WgD4U8YDHi3Wx6X04/8iNWRWz40/5HHXf+v+f/ANGNWNQBPYDN9bj/AKaL/OvqP4ew7tNjPPQV8uWXF5Af+mi/zr6s+HQMmn25+6QBQB61oKBETn867bTV2wZPUmuM0PPGevSu4g+UKvoKALK8L2zQOlNJywFLK2xCaAMXWHYAgcCuOvnKSFMkxt1rr74rcK2M5HUVympToqMAPnHYDrQBzWoxGI71fZ+NN07zJ3KICzn8jW0mmrqcOJ9qH+EisvUpl0aRVg+dlIyF5IoA0VtfLyk5y3dD1FcF8bNL0+78Nf2Wk0o1K8YC1jhOC7jn5h/cAzuJ4A564rsJbw3LRzS5/efxjsfeuW8RxW0GuT3ryNNdyxrDuZtwjUfwqOwJ5Pcn6DAB5b8FvB91oPiS+1PXrfyJ7VDDabuQ7sOXUjqNvGf9o9xXqlxqV7FcFYo+AQ2F5yahtI5ZYgETLKcgnmu88PaWskCz38aBgM5I6fWgDnbSwvZrhbq482KFuTkc13uiLdySLDbZEKgBi/eqk1q19cIkFwGgHBC13Glwx21sscYBIHJoAs2sAhjUDt+tTAfNSbsDnrSKT+FADXh+cyRnEnv0NSrkgZGD6UtFABRSYbeeRtx096WgAooooAKKKKACiiigAooooAKKayKzKxHK9KdQAYoNFFAFaeISKyuMgjFeeeK/Ctw58yycptJKqo4/KvSyPSoZ13LjHbrQB48vhdLi32ahCDI3UgYNaen+HtI0sBpnHHIUNzWp4p8yFXMBkaXBwTwK8c1DVNSjuWe4aUqZMc/0oA9ri1piPJgijihXoxNUtR1Hy3BEmcDJ7mvJ5NXYXqAvLjAyrHGT6iuhs5woy5ypGWLGgDoZ2jYGckvIeiMcCnWupyIyrM6x/wCyOQK5+/uRcRebHJtRTxVSw1KC0Yu85Yt2YdPegD0czWzshRg7ex4rVtJjgF9v0Fec6HqSzK7qxHPygjg11eiXgmfZvU59aAOriCuQ0Z5q/GcKM1mW5CADIzV+3AZWagBsi7iwJ4I6Vwvi1Rt2/wAXSu8n6BugrjvGMI8xTkYIz0oA+BPG3/I56/n/AKCFx/6MasWtzx0MeN/EI/6iNx/6NasOgCexAN7bg9DIv86+qvh2SbGAYIAA696+VrD/AI/rf/rov8xX1h4DZUsbYY7DJoA9f8MRAzRrjIPNdfbtulP51znhWMeUZO22ujsxjc3agCeOMiVnLk5GNvYUzUG2W7H0FTLWVrUx2GNehHNAHKPqzLqaxLnY2QWPeuZ1a/ZbhjbnkEhgT1rTm+SaSTG548gL3rnL6FHlJV/nbsOeaANyG+kitFJQkt79M9xUd/aG/sXkgA86MdcckVGZVaKCBMlwOcVs2sZtQHkYcjG30+tAGb4eUSW/kTpgg/MSOKreI9PsWkVVVBIpzu9a7KLTFNg8sIAaQ9BXMaxCrOLZ0+YHGcdKAKGjIDcRI7IM/wB3rW1rdwpT7NEfkxliD19q5+RPsJWKE5Zgdz+2O1ZscxjiMxaQt0UUAdp4cJSVVGVOcA+1ehacuI9xYNnvXAeClnaNJbgfIRhTiu/iZIYgCcAdM9zQBPO+1gKkRcjJqurCQ55JHtVlBgUAOooooAKKKKACiiigApCM45xilooAKKKKACiiigAooooAKKO1ID2oAWmPzwKd1qOX5SMZ5oAwNfsmnik9cV59qPh9Zp0KTr8hztxyK9bcCQbXXOfWud1Xw8krNLbv5bnuKAPI/EVhDFd5ZF+1DH7ztWZBNvcRNG0kZ+9IeAtesSeEUnjYX0gUEY9z9K4/VNDitLgQFmFuOij+L60Acpq0qG3KWTvsHU+3tTNMsTLENx5xjdIetal4lvEf3agKP4KWCB7hCzgRr6njAoAfcILK1SGGTgHPFXtFu5IJImwcA9SazpUt1nSMTiQ4xnPH40JJmTy0YHbzkHtQB6t4fvhfFg5AkHX3FdTZ8RsPWvJfDt60dzHs3DHGfWvVtOmE0SsByByKAHuuUYHtzXMeLYw1mkg6oeceldXIOawtXj86CaPHIHFAH53+PP8AkePEX/YRuP8A0a1YVb3j4Y8d+Ix6alcj/wAitWDQBZ03/kI2v/XVP5ivrDwUn+j22DwQK+TtOONQtj6Sr/MV9VfD+TfawDncBwaAPdPDGTZuMDsBXRxLtiArnPCSE2Z3jvXRxnAJPagCf+HFc7qsmJvm6dK22k2xszGua1OQSZJ+8vJNAHJ670IgXJzub3rBgtvMTc7hWLce1dNIitK0YUfP0PvWFKkljORN9xDyQaALAYJefuzu8tRzitOAvezqIxhjjIrGmuFlkRoY2KtyQOmK6fwvagzCVkyVyw5/KgDqQVhtViTqg6+9ZbaXHezvK3DOOo7VZkZ9jLt/eE81LBuE0Yj4z1xQBzM3hOZppniZWXadoNYtr4Wv57plkhKxxnK+5r1nZ8hGOTxUJiEaEIMGgDnPDul3cdwwuEKrGu1K6iWEiLaPwzS2ivvJbjNWJOR60AVreMxR4LZzVxelV+c1PH0oAdRSAYz780tABRRRQAUhOOxP0paKACiiqeqWj3tv5CXM1sCcmSFtrY9AaALlFQ2duLW2jhWSWQIMb5XLsfqTyamoAKKKKACiikbpQAhpm4A0jnmomII60AWWYAZxx7VG5BHWmK+ahkl2mgCGaUq/yt07VXur9YbdnkzlR271U1FsSB05x1FcD461+ex084A3M3LdwKAF8SeJ5nkLROyBTjGetNXWkl0+Nr5cy5wGJ5rxbxB4inkKTxSll3fMaqzeJ5Z3jRZCCcZAPSgD1q/Ns7SPMo8xz8ijoDWDqltqEs2IJG2EZxXL2/iCSOdBM5mQEZz1rcm12KWZIm+WMjgehoAEWQMqTHYqD5sHJJpv20LOREcEnAqcwFkcM6lWGQw7Vz6q8eoINny54f1oA9Q8JXfmQZcKoRsBu7GvSNDu/LkXcThuteTaNfrHCEhxwOSB3rsdC1TJXcRu7UAemv8Ae46GsK7J891IxnjmteGUSWqMDyBzWHrzeW0cwzgnBIoA/Pb4iDHxA8TD01S6H/kVq56uh+Ipz8QfE59dUuj/AORWrnqALGnf8hC2/wCuq/zFfVXw9VltocfONo5r5VsP+P63/wCui/zr62+HJX7FAVwTtHNAHuPhgbdL39SxrYY4UL61m6ViGwhj6fKCavowabGR6AUAFxH5lq65xkVyWtTFUyoORwcV180ijcueQKwbtVZmQryR1oA5qFdzRl8896y9ftZJ32qf3fXPvXTXdhefJ5KZB64FOj8PXdywZhsA7N0NAHPadpxRImfk4xXYaLbeTbEuux2OePQVp22hRRoiyHO0dq00tYlBwCQegPagDBS1ka8E3O3pxWhaWxWUMegrSWFFAwOlHljtwKAI5CVTKqSfrVVhcmQFPK2+jZzV9kGBjtSKmDmgBsCyL9/Z/wABqUgEUtFADdo54p1FFABQSB1OKKCAetABRRRQAUUUUAFFFFABRRRQAUUUUAFHaimk7enFAEci1TdXEqsGIQfeXHWrjHNV5SApJ7igChe3LwncvAqk2pL949utLriN9m3Ln8K5a4vUJKbiJB29aANm8vIpyywvhzzzXlXxfldLGBXyGZscd639RuyJw0MgDDgr71h+KZPt2nK8+HaM8E85NAHjetW81jbMswBeUZXHb61yVvK8d0jbuVaui8QT3QvpGlU4Y4Hpj0rEugWYSKNqfToaALN3rRjv02qQFHzc9TXWW91DJpMV1ExkmPBXvXm10S7kgDJ75q1puqz2sYCt8o7GgD1TRNYaciOUksD908EV1P7ia0k2IBLjoe1eaeE9TW6keWRMFR1Hc118F9FCPMaXcW4K96ALuj3NxZ3JimOUPIPY12ml3ex1lDY9OK5ezSO/twnIJOQw6itmPNtCqSHBPyjPcetAHsnhW+W8tuCTx0qxrEXmWsiY5HzCuX+Hc58yWPdxsBFdhfc8YzkdaAPzj+IP/I++Jf8AsJ3P/o1q5+uh+Iq7fiD4nX01S6H/AJFaueoAms/+PuD/AH1/nX1X8JyXit4j9zAr5UtOLuH/AH1/nX0z8NLkRfZRuzyOlAH0nZyZnVV+6fWtGzjK7iTnJPWsTTzuvYwD2roosUAU7hG85uCd1UmhdpuVPtxW24HpQoHXFAFa1hcKAwwc1eVdowKRBzT+cjGMUALiiiigAooooAKKKKACiiigAooooAKKKKAM/TrW6hurqW6uWlEj/u0/hRa0KTJ3YxxjrS0AFFFFABRRRQAUUUUAFFFFAAajc8Zp56VDJIqKd5UAdyaAIWJV2Jbgjp6VCzqyhScn1qrqmrWdrEXkmXB9Oa59fEVqswKEuD1oA29XH+jhOQCK4G/tJkumyOO+a3JfFdvdySxYC7ehNUYtUtryUI5xnv2NAHEa5b3BnDxbl759ayfKmu1eLDbXHc969U1XSAyRsi7kPTAri9UEGlXe6VMMOg7UAeT67oszO25WBU85FZbaG62kiyRlmbkbRXt8A07WnKwxMHIy2fWtu38CG7jV4VVUYbcjk0AfHutWb20pEoKtniqsFu90gCArt6n1r6I8V/CS9Jbyl3kE43DNecar4T1PRIl+1Wbx8/fUcGgDn9KzBMsaEqAvI7mtqC585iZGYAcjFRyW6w20bqm1j/e6mmafCWuzGIztfquelAHfeGb4boYy23Izk8V2Erm9iaWMAtEOPcV5tYyvawNEw/eA4A9q9F8E209yikIxxwTjtQB3fw7R9guT0b5dprvb7CIp9Otc9pWnHTLWIAcMwf6Vuau4WzDHoe/pQB+dXxIO74ieKSO+q3R/8jNXOV0PxEx/wsDxPg5H9qXXP/bVq56gCa0/4+of99f519GfDZS2zaMhcGvm2igD9LdCTcIpiBygrcjYA4PWvy2ooA/U4DcMUqpivywooA/VMUtflXRQB+qlND5kK4bgZzjivytooA/VSivyrooA/VSivyrooA/VSivyrooA/VSivyrooA/VSivyrooA/VSivyrooA/VSivyrooA/VSivyrooA/VSivyrooA/VSivyrooA/Um/uvs6cd+/pXKa5L5kJYzHd2ANfnDRQB923d1Llo2jZ07tjpWVcSx2qNIZPm7Ka+J6KAPr211SK2uyXO/ceR6Vvw3Nu0yPajIOCVr4jooA/S7RsXekpsHIGea8j8eRytqLwwxtLKx5O3O2vi2igD7V8MeGdYlCtIJIYiOrLgkV7B4ZtHtLdEdz8oxg1+ZVFAH6pOiOPmAIqhf6TYajA0F5axSxHqGHWvy8ooA/RDXPhT4fvlXyImttvQKeK5Kf4TJb3DvbyKw7Z618OUUAfcifDZnvElcKsagV3ehaRa6b8kCYJHOa/OCigD9MbrMqbVBBByKi1t2NhGD3xmvzTooA6D4hgDx/4mA6f2nc/+jWrn6KKAP//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest frontal radiograph shows a nodular mass in the right mid-lung (long arrow). A tail-like connection is seen between the mass and the hilum (short arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT scan of rounded atelectasis in the right lower lobe",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 290px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEiAUQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5p2ClCD0p1KBmgBNo9KNgz0rc0Twvq+tRNJp1qZI16sTtFbUXw18TSBcWcYzxzIKAOK2D0o2D0r0GH4TeKZXVVt4Mnj/WCtZPgT4zkAMUVo4PHEtAHlOwelLsHpXs0X7Ofjlwpb+zkzxzN0p6fs5eNWcq02mIBxkzHmgDxbYKNg9K9yH7NfjAgZv9IB9PMb/Cl/4Zs8Wd9S0jP++3+FAHhoQelOCD0r3D/hm/xSM51LS+OvzH/CoV/Z91/eobVdOyTjgk4oA8V8selHlj0r3uD9m3XJM7tc09fTAJp8v7NmsoRjXtPx3ypFAHgXlj0o8sele3T/s/6rASJNatC3QBUJz+NWB+z7ciLL+Irff/AHVhJoA8J8selGwele92/wCz95jES+JFXHpbE5qyP2d4sAv4mwvtbE0AfPewelJsHpX0RD+zvas4DeJ2wf8Ap2q6P2b9PyQfE83HX/R+lAHzUUHpSeWPSvpCP9nCzeRlXxO5A6f6PVtP2Z7Mj5vEs31EFAHzGUFJsHpX09J+zLZYXy/Ek55+bMPb2ok/Zs0pTx4hu8Y6eUOtAHzBsHpSbBX0qf2eNKQ7W1q9c+ojAFNH7PejlsHWL4D/AHBQB817R6Um0elfTn/DPegKCX1bUCPoKil+Afh1RldQ1I+nIoA+Z9o9KQoPSvo6L4EaAxAbU9R3d8ACmXfwF0iP5oNQvnUcnOKAPnTYPQUbBXuUvwe0uJj5l1eY7c4/Oo4PhPpGWMs90yjphgKAPENo9KNo9K7/AMceAzoqG400vNaj7245YVwRFADNo9KNoz0p1FADdo9KNo9KU0tADdo9KNq+lLRQAm0elFLRQBIK3fB2itrurpag7Yx87n0UVhV6L8EoBN4juAeghNAHruhadFaWsdvbRiOKMYAx1966axgJXaI8k+lLptiXYKorstG0yNFBYd+poAb4d0hdodlAyc59K62zihhURx9e5NY95fR2y+XEQqDvXI+I/H+meHoGkvrtUbHCA8n8KAPTp5Y42iDMByTj14qNr23U7mxivljxN8e55JWXRbQ+gllP9K861b4m+K9SLeZqksSN/DHwKAPuW51azUHNzCgHq4qmfEGnKx/0uAn/AHxXwHPreqTkmbULlz15kNRLqF4DkXU3/fZoA+9bnxJaKrETRfgwqrb6xa3CNtcbj/EuM18X6Hr99DcIGuJWUkcE5r6O8E7rzTopkV9rDJZl/lQB6KmsBdwQlgBwSMGqs2qyOwU55GQT0qmLZcjJOMdlqlMjtKqRrxnrigDSgkNwSSxIHXI6Va8kEeuPaqVrYsvBJVj12g1sQQyx24AjDHOAB/8AXoArJA3XAVfcVJsUJjePw5q9HYTSD5kPPYGrNvphU4a1YL04delAGMuwSjZHk4xuOalxKWyRgeua6eLT4lAwvH0qY2sIxlRk0AcrGkiybiKnW9kjyCOD61vtZRnoKryachPA9xQBj/2plsAg54GDTHvS/wB0CtVNLhQELGipzkAU5LCFkDRgYPfFAGB5sjBthB49O9R7ZGXjrXSrp0SfdAH0FVL3SvNi2RO0JyDuQc9aAMJkdSM80wTRp/rcA1uS2oxhh+IrmdfsnWJmjJHf2/GgCpc3do052SqrU+HUYd20sCPXNfPnxJvtT0m9doZXVSc8Eiq3hD4qy20kdvq8fmQHgvnkUAfQl7HDcRvtAJPoa59olQFT27Vf8PX9lqlpFcWEweN+cA5xVvU9OLAvGcH2oA4rUYEkVkkjBR+Cprw34heFZNIumu7ZCbOQ9v4TX0Pf2UygsQcDoa5fWbNb2ze2uIy0Ugx06e9AHzWaStzxVocuiak8LgmJjlGx1FYlACd6KKKADtSUtIaACilFFAElep/s+R+b4qukxnMBrywV7N+y7a/a/HF0pBwtsScduaAPpbSrFIY145PWrV1OluhIbHGOtab2oVTt4z+leJ/HXxt/wjtl9hs5P9OmGBg/dHrQBj/Fb4nppbSWOlyCW8PBIOQlfPmpajdandPcXs7yyMcksarzzSXEzyzOXkc5LE9aZQAtLikpaAFpyikFSIKANjw5Ym71GJApILDtX1/4WsY9P0K3iVADsGRtr5u+EmlG/wBfts427gcYr6vECRRoNvyqMCgCh5IIyRjPTirFhab2yq4Xu2DVuC2M7AtjHpWxaWoGAowBQBVt7E78gfL9K1re0Uc1PFEBgAcVOBxQA1UCjpT8UUybf5beVt3443dKAH0EA/hSLnaN2N2OcUtAB3pGHfFIzAOBS9fpQBGRxxTSaJQTIqbW2/eLf0p5Ucc5oAhbduXaBjvmgDJ5HFSY6j0oxQBWmj3EHnA6j1rMv7RZVb5elbLrk5zjHb1qtMvX0oA+cvjnoedLkmROUySa+ZXGGIr7k+Kmmi58NXxCk4jJwO9fEWoR+Vdyp6NQB0/w/wDGt34Y1KNt7PaE4dM9q+r/AAprll4i05LiylWRGHI7g+9fEFdn8N/HN54Q1SN0YvZsR5kftQB9dahZ/Jjbx9K4fVbRoJnwCVc9COB9K9C8M6xZeI9FgvbNg8Uozx2NZviPTQULIAwFAHjHjTQE1rSpIig+0IN0bAd68DuYJLa4khmUrIhwQa+pbuPEpUptbrjFeRfFXw4Ef+1bSPg8SgD9aAPMqQ0tBoAQ0lO7UlABRSYooAkr6B/ZESP/AISHXZW++lsoB9ia+f690/ZRkC+KNXQ/ea1GPzoA+oNb1W30vR7u/vGVIoIy7HPoOlfCHjrxHP4p8S3epTk7XciNT/CvaveP2m/Fv2XTLfw/aS4ln+ecA/w9hXzPQAtLSUtACinj2pgpwoAcKlXio1qVR0oA9i/Z+ty+u+Z1Cqe1fTaRidcdu5rwP9m7TZZpLmcJhEUDcRX0XaWxXkYFADrOA8AqFP1rUjj2jjimQxbQDVkDtQAfhS00gllIYgDqPWnEZFABQRSEhVySABS0AFFFFADcYkz2IxTqKB+tABSYFLQaAGkdabzjPWnGkHpQAxxg9aqyng8+9WnHeq8vQ0AYmvW63FhPG4yGQjFfBvjq1Fn4nv4VGAsh4r781AAwPk8Yr4V+KwX/AITbUin3fMNAHG0UrDFJQB6t8CPHz+Gdfj0++lP9mXTbDk8I3Y19YOsd2AvBVxlSO4PSvz5UlSCDgjvX1z8A/GI8SeFUtLuUHUtPwhyeXXsaANbxDpZildtvzCuM1HT0uopIZkDJICGBNeza9bLPZCUD5gOfevPNTtkUkggfQ0AfLfjHQpdC1aSBlPkscxt6isE19D+PvD8OtaQ6Af6VEN0Z/pXz7cwvBO8UoKuhwQaAIqSndqb0oAKKKKAH169+ztqlvomp6/qd2wVLaxLcnqc15DVyzvpba2uoInKpcKFfHcCgDR8W65P4h1+71K6YlpnJUE/dXsKx6TOKBQA4UtNFOoAcKcKYKeKAJVFWrGPzLmND3NVErW8OxmXVrdAMksKAPrH4Fac1n4cPybBIc9+a9Yto8Dk5Ncx4AtRb6DaooH3BmuvUbFLHgYoAkAOBjGKUHPrTY2yMNw2MkelOHSgBaKKKAAjI5pqqQ7kuSDjCnGF+lOoIyMGgApCMjBoVQoAXgDoKWgAooxiigApCQM0tIwyMYGPegBpPI5+tHajoPemjJUEjB9KAGv8AWq8uMc84ORU71WmGc7hx60AZOsyCOzlbphSa+GPiO4k8SXkn96Qn9a+2/Ejq1ncRlvmVOeOma+IviKI08R3CRfdDHt70AcqTSUppKACuz+EfiZ/C/jWyuy2LeRvKlBPG0964unKdrAg8g54oA/Q+3miubQNGQ0ciZUj0NcHr0CxM4AHU81lfBLxaus+EbaKSUtcWw8ts9SB0rp9VVbh5ABxQBwV1Gd+MD868f+Knhzypv7StU4J/eAD9a90vbRhubZjFYGqWKXdtJBMm5H4PFAHy+elNroPGOhyaFq0kDj92x3IfUVgGgBKKXNFADqUUlKKAFpR1puaWgB2adTBTyCDg0AOFPFRinigCVB3rc8Kll1e3MYO7cMGsFa3/AAncrb6tAWOMsOfxoA+7PBabdBtNwG7ywTz7V0QHHP61g+D5Fl0OzZTnMY5H0rfHSgBaKO/tTIpUlXdGcjJGaAH0UUUAJtG7d3xiloooAKKOaQjJGaAFzRRQfegCKd2jVTujXLAfOcZ+nvT8Zbqfpmh0VwA6hgDkAjPNDDgkcH1xQAHmmdvemSRK8sbyE7k+7zgZ+lSEUARSVCwHI61M5wOmarztt4BoA4D4r60ukeHbiTIDbSBkV8T6zdG91KadzncxNe7/ALS3ijzLyPSbZxhBulI9fSvnpjzQAxutNIqQ9aY/WgBtFFFAHpfwM11tL8UC3dyILgbSM96+l8Esx3kg9B2r408KXRtNfs5h/DIK+v8ARJxc2Uc7ZO5QeO/FAFq+C+SUKDkda5q8sigLfpXT3Mby4yoBx0rKvonVSMcH2oA8I+OEaqunuQN+SM+1eT17D8dk2wad0HzNXj1ACGilooAWlFJSigBaXNJSjFACindDTeKevzLjuKAJoUieKUvMElUZRCpw/rz2NMFMFOFAEq1Yt5DHIrqcEHNVlqRT0oA+3PgVrg1bwXaZfdJCNjAHJFenjpXyd+zJ4nNrrEmkTPhJvmQE96+r4zkc+lAD6KTIAzniloAKKKKADvRSA5GQQRSMwUjOeTgYFADqKBxRQAUdetFJk49aAFpCaPxpG5xQA1+R0BpDyevFAAUYAwB2poPOKAI5fl47e9c14v1iHRNHubuVyNqnaPU1vXs6xKWcgKO5r5++OXiETQiAPhc8D2oA8D8dai+pavPcSsWllcuSa5ZiMc1a1Ccz3LyHpniqRNAC55pCc0lFABRRRQBLbP5dxG/owNfXnwuuhf8Aha0kDZYLivj4V9Sfs5ytf+Hmiz/q2xQB6b5eFH8RPeq97BvixtGMelbDweU7KQNo6VFNEPLIPSgD5q/aCi2R6d/vNXixr3j9pOILbaXIvKs7cjpXg5oASiiigBRThTRTloAKWiigAFPXOaTae1HagCSlpi06gB609e1RrT1oA7H4X3sll430mWI4PnKD9M196WEolhVs9Rmvg/4ZR2ieIre5vpliihO7k45r7H8J+IrO8tovJuonBHZhQB2TKHUr2NKBjjtTI5UcAhhzUmaACkPC+tJkL3o3rnGeaABTn2/CnUCigBFUKMClpAMdKCcdaAFopMgkYNIWw4XB570AAUB2YAZPWmqGy24gjPGB2oEqmYxjO4DJ44pXJ7UAIwqCVgh5OKdLJheaw9Rvo1jMEb9ODk5NAHKeO/EIhLxxZIUc8da+UfiT4gfUtWkRG+UHBxXqHxp8VpZI9raOjTNkEr1FfPUsjSOzucsTkmgBh6VEakamAZNADacFPfir1vAkcRmk+YDtVKV97E+vagBvQ0hoFB60AFfSn7JtyjxapasRuXDCvmuvYf2ZdXGn+OTbOfkuoymPegD62vYxtyBWdcbUXLEBfU1sXI325rHlOFJPT86APn39p/jT9KUcDzGr55r6G/ajx9k0jacguxr55NACUUZooAcOasQRbreaTuhFVxWvplu0ui6nKBkRbM+2TQBl9KKDRigABI6GlBpMYPNKKAHAU4UuAE4602gBwNOHFNFOHSgCWN2HQn8DWvpOvalpkoeyu5Y2ByMNWMnJqUMcYIFAHtvg347atpxSLWF+1Q9N38VewaJ8afDd/Cubo28pH3XGMV8Zg04MexoA+77bxhYXyboL6FgeR8wrZs9QWQAnp2I5zXwJZapd2bBoJmXHvXpvgj4qX+nSxx3rmaIcHPXFAH2DFcocfMMdKtqwI615x4V8Xabr9oHt5PnxypGCK7G2uMhdpPpzQBr5prNhST2qCCYSM20ZwcE+9TAqTz196AIfNBUeYoDHrikMigYVmH45qZ41Iqjcps5U8UASmcgHJDc/ShrtAPmBFZN9qcFpGXuJFQL6mvO/GHxG06ztJfLuVMg4AUjrQB1fjfxhY6Lp0kkky78YUA8mvmvxV8Vb+R5lsJCu48t3rl/HXimfXp97ylvQZ6CuNEMp2rtPzGgC5f3Fzqkct3cOWfOST3rIwcE4reuPD2qQWqyG3k8huS2OKoX5hSJY4l+bHzHHegDNamZp7Ak1t+GPD1zq92AkTeWOScUAZ0zGO1VCcbuao1veKLCazvjC8bIqccisE0AFJSkjsMUnegBa6L4faodH8X6ZeA4CSjP0rnKfC5jlR16qc0Afova3C3VhHKv3ZEDD8RWTIu5ju6Dt61zHws8RDVPBtjIxy6xhG/AV0quXJYnjPAoA8F/alUfYNGb/AG3FfOxr6G/amL/ZtH+bMZZsLjofrXzxQAUUUUAOFek/DDSTqvhLxoqruaO1R19iDXm9e8/sv2wuoPFkLAFXt0U5+tAHhbDBIPUcU3vWz4r05tL8QX1owx5crAfTNZOKAGHrQKXHNFACjpS00VNaW8l1dQ28IDSyuI0BYKCxOByeB9TQAwVKjhQQVzT9RsbrTb6eyv4JLe7gcxyxSLtZGHUEVCAetADhTwSODTBx1Fa1hBHqUscC4ifu56UAZwNOBJrotA0O2u9ZW2vboRW4bDSVv/EfwXZeH7S2vdMvoriCbjYHBYUAcByAKfE+1gfSozSigDqNJ8WXmlyq1o5jI7ivUvh78Wry61e2sdVxIjuPLOMYb+teDVNaTvb3MU0Zw8bBgR7UAfoPaTmWNW5ywzVtS6k9CT1Nch8MtbXXvB+nXqnLmMK4HYiuzTBXIoAqSXRTIOQfbvVS6unMTFCGIGcdK0BZeYxL96jeyCxn+8c0AfJ/xX+JN1e6rcafaqY4oWKtg4JIryS6vZbtyZ5WyexNe4fGH4Ral/al5rGjr58chMjxjqPpXg88M0LlJkKsvBVh3oA2tI0JNRhnla8hj8pNwDMBn2rF+1vDKwB3Y4GahDgcZZAeMqc0wxk/cIce3X8qAO/0b4jSwaBLpd9brOuwrG5HIrz+V/Nld1GMnpTQdpPHPoaYCVYkUAKjYcEjNdpYa/qGn6Rusk8tB1YCuHJOc1dOp3H2L7MD+7oAm1XW7vUyTdPuJ71kmlPNJQAUYoozQAUd6KUUAfT/AMCLrd4QjUMSVYrXrloUFvxwBxXjf7OMTTeGZh2Ele0QQtGWUigDwT9qbAtNF/3nr54NfRP7VUZW20Rj/ecV87HrQAUUUUASCvoP9k3/AF/iMescf86+fBX0P+ySD9o8QsOfkj/nQBlftG+GBZ6nDq9un7uf5ZCP71eKYr7j+IXhmPxJ4au7N0y7KWjPo3avinU7GXT9QntJ1KywuUII9KAKOBSEVIwxTDQA0U/bxmkFKcmgDvdLvLXxvYwaRrlxHb6/Agi07U5ThZ1H3bedv0SQ9Oh4wV4zULK60u/nsr+CS3u7dzHJFIuGRh1BFVh+td5p17beNrGDSNcnjt9fgQRadqcpws6jhbedv0SQ9Oh4wVAOHVz3rR0mcLdxgrjc2M0240XUbW5vre4sLpJ7En7UhiOYMHGX/ujJAyfUVDaMI51kP8PNAHWeKNOTTWhkgukk3ruIXjFc9ulvZ1hMzNk4AZsioLy6e5k3Ox/Oo7WQxTpIOqnNAF7VtKk02REmYEsM1QxV7V71764EjsScY5qmmc0AC4zzSgZNOBHfrQBzQB9H/sta4Wt77SJG4Q+Yg/nX0VF84BFfIX7N+9fGbsDhREd1fXdq3yJtAI7+woAtDgU04PPWnZ4z2poGe4P0oAhmgSQfMAc18o/tF+DBpesLqVnEFt7r7ygYAavrJgSwwRt7jHWvNfjtp8d74Ju3ZQXhHmKfQigD4lmtWCFh1HUVT6H0q9cTMJX5PNU25NACPuJyxyfWmg889K9R+F3gq08V6Td75ALmM4VfWrUvwc1R76a3iX7oyrZ4NAHkeATTHGODXUeIfBureH7po7+Dbg8Ed6TSvDd1rsiw2cTefjp60ActRXZ6v8OPEOlWrXF1ZOsQ7jmuPlieNirqQR60AMo60YooAMUDrRS0AfUH7KzLLouoR5+64OK90vIgoVsV89/slSEvq0f8IVTivoy8ObfPpQB82/tXN/omiL/tPzXzka+kv2rlH9maKSOfMavmygAooooAlFfSP7H8QeXxGefuxjH4183gV9LfseABvER9o/50AfSEFsGDJjP1r5y/aQ+HUiXa6/pUG5GGLgIOh9a+mIuJfrVPxNYpqGi3VvIgYPGRgj2oA/OW4Qo5UjBqHFbfiu1+yeIL2DGPLlZcfjWRjrQA3FLtOOlPQZNa0EEb2TrKNr9VNAGOoyRTwMc8U/yiDj0qW3haRgqgmgD7U+GOp+CvE/gldB03Uo9QllshbXiXOEu5QE2ksDycDgEZAGADxXx94w8P3PhXxTqWi3pzNZzGPdjG9eqsPYqQfxqhJHNZXEckMjxzIQysjFWU+oNWdd1vU9fuobjWruS8uYolhWWUAuVBONzYyx5PJye2eKAKYt2aMyLyB3pPLOM44rs/AGjRa0Lm1Y4l27lHrWn4e+Ht3q19cWtrsdkJBBYZBoA87IyMmrWmvFHKTOm4Y6V3mvfCbxDpaljaPIg7pzXHzaLfWkmJ7WVP95cUAZ1yweVmjAVT2pi5qzcWzR8kYHpUMUbPIqAHJOBQB7j+zpp7Bry+IwBhQa+l9JuN8AGNzCvLvhF4am0nwlbr5f7yYeY2c969GtYpYHBXgelAG/1HB5o55yKitpA+ePmHU1N096AIJmZZYgqk7jgkdF471x3xKRL7wrqVumSTE3briutvZgEMYzk8VzurR/aIJo5FIDKUC46DFAHwJdrtuplPG1iKrBTmtnxVaGy8RajAy7SkzAA+maxjxQB3Xwiur+28UW/2F5FQthwucEe9fUupXc2maR/aqETLGpZwB1Hevm34ReJrLw1DfXFzaLPLt+U8cV0+tfGS91nQ7izt7NIlYFWPXigDlvi147j8R36yWQZYwMbT2Ncz4H8WT6Bq0dz99R1BPaue1AhpmwMAnOKpg4oA9o8V/GefUbE21pbhARgk815VqOqG7be0agk5PFZZ606Mbjt9aAJ2nideYgD6iq7Y7UhGCQaM0AJSjrQcUlAH0J+yZNjV9Uj9Ywf1r6Xuzi1fHODXy5+yrkeIb9s4HlCvp6/b/QWNAHz1+1OFfRNJkY/OJSAM9sV81mvor9qOVv7P0iLHBdjmvnU0AFFFFAE4r6T/AGQTt/4SI+0f86+bhX0d+yPIsa+Id3RvLH60AfT0LDg9asuNyEeorLt5hjg/hWjA4ZfegD4R+NelPpXxC1SJhgO5kX6GuCIr6T/aw8O/6RZa3BHnI8uUgflXzeRQBJZIrXMYY8E81sauFjnCgYjxxisVPlOe9Wp7hpokD8kUAQglnO0E5rf8Mw+VdJNPEWQNypHUVc+HOlLqerbWRXCqTtNXvE+LG5kjhXbsbBxQBVljtNX8YxwQosFs7AYP8NUfGOnQ6brslrCwZEOAR3qpp7Mdbhc9S46V2HxM0R7S8srwKfLnQcgd6AL3wxu7LS9WhuJ1YliFJHavoKz8GW02twa7os7W7sAXCn5XH0rgfg14KttQ0l7u4jyT93Ir3zQ7BbGxSIdAMCgCdLVJEQyqCyj8DVW68P6ZcgiWzgbPcoDWrjFFAHj/AMUPhJY6xp01xpFvHb3kall2DG/2xXi/wu+G+oax4rAvrWSKztHzKXXGSO1fZBAJ5FRJBFGT5caIWOTtGM0AVdLsxbW6x7VVFG1QB2q0IFzmpaAMDigBAoAwBihVC9KRk3FTuYYOeO9OoAjmhSVSHXORiqQsY4YRGAfLQYHOeK0aRiACWIA96APir9ovRF07xzLcwLthuVDfj3ryYjFfZX7SHg5NY8Iy6lax/wCk2fznHde9fG0gINAFi3laK1lAON3BqOzuGilA3YQnmm8i3PuahQZYCgD1nw/8NV8XaBNe2c6pPGpKr6n0rybUbOWwu5bacYkjYqw9xXX+HPGWp+F2/wCJfOQjrhl6g1zuvXTajey3jfelO5vrQBkmgcUGigCTAkXOfmqI8UoODmnPg8igBg4pRSUvegD3z9mKLy59QuWzjAWvofV7rZpq46ntXinwBsGtvC4lwMzyZr1nWXJjjT0oA8H/AGl5zLZ6QD2ZjXgVe5ftHAiLSs56tXhtABRRRQBZHvX0X+yagkXxCp9I/wCdfOor6N/ZIIz4gHfCH9aAPfVDRS8kirtpcsk2ScgfrUc8W/rwT096rqpQ4brQBU+JWhR+JvCt1ZunMiEpkchu1fC+r6fNpmo3FncoVlhYqQa/QGKUyQGNuSK8F+P/AMPPtkba7pMObhP9eij7w9aAPm0Dil609lKkqwII6g00D8qANjwxrU+hapFdW55U/MPUV7F4s8N2viLwh/bulHMrLvkUYznvXhAPzcV6V8MPG0mkXgsr07tPk4dG6CgDkfD0SjWrUXK/KsgDcds19Q6p4dstd0eJXhVljUGMkdOK878aeDLa4aLWfDaiS1YhnVDnHuK9y8HLBdaDZMUG7ygpJHOcUAVvhfbNa2DW/l7FRsAY7V6CBgYFc7oluLO4lB4Vm4GK6FSGGR0oAWij6UUAFNByxx2p1RpnOSACelAElGecUUUAB6Ug5A9/WlpFG0YzQAtIQCMEAg9jS0UAZXiqJZ/DuoxOu4PCwx+Ffnlq0Jg1C4iIwUkYY/Gv0X1RBJZSoRkEV8JfFrSG0nxnfR7Nscjl149aAOIJ+TFMU7TTmBBJz+FN75oACxOc0kbDayt3pD60xhxkUANbjg02nE5pvegBKWl4zz0pCBng0AJVrTrZ7u9ht4hlpGAAqtXpHwT8PNqniIXciE29v8xJHGaAPovwJpi6XoljbAYMcYLY9a3bna7MWPPalsoxFbEnAGOp4FMaNpLjA6UAeEftKIRZ6QxHBZq8FNfQv7UY22mioMY3NXz1QAlFLRQBZFfQf7J8qx3uuBsfMic/jXz4K9x/Zll8u81f3Rf50AfVUbKQOc02aLf8wxgdqyrK6yAHPHrWqj5HB57UAQIwRsdKfNbpKGDqGRhgg9DSTjJ3Y+YVPayByFbrQB4J8X/g8lxHPrPhuMLKPmlt1HDepFfOk0LwStHKpWRTgqRgiv0OeHapIUle4xXhvxt+FkWq2sut6DCI7xF3ywqMbx/jQB8wDrU8b7HVgcfSmSxPFIySKVdTgqeoNIORigD2v4PeOF0uePTtSIexlPDMfumvpzRobVrdZLRlMLjcNvSvgXT7t7ZwRyB2r3X4S/FL+zlWy1B2eDopJ5X2oA+mPs6ZBxyKXzBGPnIrF0bxNYapbiW3mUg+h6VqqkNw2/O6gCwjhxleR607vTUXbwAAPanUAFMlHFPJpk33aAFRsjnrTqjhPBBqSgAooooAKiV5PtDoYz5YAIfPU+mKkyKMjGe1ADZVDowPevmv9pjwwk1lBqtmu54mKSlR2r6PllAUqR1rl/FOmwarp81pcoGilUqRigD4BkHNRmuz+Ing698Ma7JbyRsYHbMTgcEVyNzBLbyGOdCjjsaAIPamZwfan45pjDPSgBD3pmKkIz9aaRxQA00UoqSCB5pVjiUs7HAAHWgCfStPuNTv4bS0jLzSttAHNfWnw88LJ4Z0G3tEiMk7YaZl65Nc38F/h2dHtY9SvYt2oTD5AR/qx/jXtSWi2sGX+93NAGfK4gTaF4FLbqcGQ9Wp0kfmyfMPlXoKe7JCmSMAdOKAPAv2pB+70bJ5y3FfPp617x+01cGZtKH+8RXg5oASiiigCyK9p/ZuuIU1PUoJJFSWRB5ak/exXiqmtLSNRuNLuobqzkMc0b7gQaAPt+1mZWIfaB2wa2LOcrg5yDXlXw08d23iywWOV1i1OEfOn9/3FehwTMMdR6igDpl2yLuziomjKP5iHgc1m293s5yB9a1LedZAASM0AadnKJUBOAw6ikntdwbGDn+HFVo/kYMp5rRikDr7+lAHgHxe+D6au0uq+H4xFe8tJABgP9Pevm7UtJvtMuHgvraWGRDghlIr9D5ohIOgz61ga14a0zVIympWME4PUsgz+dAHwKo5qe3keOQFGIr6+1L4MeEr1SYrNrdj3QmsB/2ftEL5S+uAv0FAHiHh/wAU6tp7YtLhx7A9a92+E/ibxPqcrRXNs8lv/wA9WGMVs+Fvg1oOi3qXTNLdMhyqygYH+Nemw20cKqsKBAv8KjANAEttv8sGUjeeuKlpuD9KQou4NzuAwOaAH1BcvxhetTcY4qKQYJwOKAEts7OnfvU9QLJhR2HvUwOQDQAtIRilpH3bTsxntmgCLG5sVIEAAHYUKpBJJp1AFaeFVLyM7YwPlPQVk3gJBwDkVvnGOazbi2O4lGHJoA4zxL4c03xLYta6nEGBGA2OVPqK+a/ib8LdX0WYT2qtd2SDCso5A96+t5rXPtioZYQyFJFVkxggjrQB+fE8EsMhWVGQjsRUPevtrX/hv4e1xDJPp6xSNzlRtNcJd/AXS3GYrl437gLkfhQB8v4pNpJ4HNfUFh8A7Hed1zIVI/uV0eifAfQLOVZLgPNg5w1AHy14c8J6vr9wkenWckgJwW28CvpH4XfBqHRBFe6oizXvUA8qleyaN4f07R4FhsraONF4G1QK0wm3PPf8hQBm2VpHDuVExt43ev0qG8YPuTpzVy6nVF2Iee5rIllWINuOT60AMfbEvPFYmozguxGc4x1qa+uvMIAbHpXG+MfFumeHLZpL2dWlxxGDliaAPK/2ist/ZbH/AGhXiddl8RPGcvi25iJjEcEJOxe9cZQAUUUUATL61Kp+WoRT1NAGjpOpXWlXsd3YTNFPGchlNfR/w4+LVhrUcVnrzraX4AUSnhX/APr18xg05WwQQefUUAfeIIKZGHjYcMDkGrVvMV6n5a+SfAPxT1jwxIkM7m90/oYpDkqPavo3wf4v0nxXZrPpdwomA+e3Y/MpoA7y3uxgDqDV+KXBDIQK5pH59DV+2uNvGRx60AdNFKr8dG9KkIBGDWRFcLJjJw3rVtLllKhhuHQkdqAJmgHO3vTPLYY+WrG7KkoQaFJ2jcAD3FAFbO0gA81Jlhjn3pZ0V025Ks3AZeopSoC4zQAwSHuaC2Tnr7Ug2KMKMU4Ece9ADVYk56D0pzqWHJ4petLx60AQ7O9PZgAv3uOw70/+E0xwD60AN89scAUsFyJG2sMN2qtKpAyM/wCFVS5SQE8Y70AbZOASaqPKzjIOB2qst2ZrcxyLtctjhs8fWpN6xgA9cflQAu915PIqdf3iZHQ1SknVF3MTgnbkDNTxyeWeBxQA25i2jNVCners8wkHsKrZPO7FAEark5NKw2gtgHvjFO4HQ0xm2qeRgetAE8UkYXjA9DUV46SIq+dLFhw+6NtpODnB9j3FZzzlTj+D1x0qGWRiobeOOx6UAbJvF5KiqlxekggkAVkvct3bj9BVO4n2qWdgFHVmPAoAs3V4ACFJrB1K/itojLeTpBEByXbFeffED4saboIkttMK3d90yD8qmvn3xN4u1jxFcNJqN27KTxGpwo/CgD2vxx8WdOsYpLfRHNxcEEeZ2WvA9a1a71e8e4vZWkdjnk9KoE0hoAQ9KTtSnpSUAFFFFAEgpymmUuaAJgaUGowacDQBIDWho+rXuj3qXWn3DwTIcgqcVmA07NAH0V4H+NlrcpHbeJk8mYDAuEHyn6ivWrLxFo93Es1vqlm6EZBMoBFfDgNKDjoWH0JoA+7v+Ej0yID/AImNmSeOJ14qzF4t0ZBh9WsAfeda+Cc/7TfmaPr/ADoA++x4w0ND/wAhrT1P/XwtPHjnw+jYk1/Sx3ybla+AcL3FG1P7q/iKAPvxviB4ZVdx8QaYF7j7QvNNm+IfhGPmTxDpo4zxMDXwNtTP3F/KlATH3F/KgD75b4j+D1Qs3iLTQBzxKM1W/wCFmeDbd5N/iWwIY7wN+ce1fB+Ez9xfyowg/hX8qAPumT4v+Bl6+I7X8A1Rn4yeAwPm8RW+cf3G/wAK+G8j0FGRnoKAPt9vjV4Bx/yMMXH/AEybn9Khf42eAOD/AG+v/fl/8K+Jd1IWoA+1bj45eAlHy60ZP92Fqyrj46+B3yBfXJ9D5Br4/wA00mgD7Ag+O3gSAEyXl5Iw/uQdaoz/ALQvg8ykqmplR0/cj/GvkzdTSaAPrD/hojwipyINWz6eSP8AGnv+0b4QUfLbauxx/wA8V/xr5LzSZoA+rT+0d4WJJ+x6t7fu1/xqOX9pDwwAfL03VXOOMqoz+tfKham5oA+oZP2k9FA/d6JqB9cuBVSb9pPTWYgeH7xkxxmYDNfNBNJQB9Gy/tH2ZY7PDlxtxjH2gf4VUl/aJhKkL4bl56ZuR/hXz7SUAe+v+0Nx+78NnP8AtXGf6VxHjH4t674jRoU/0G2PHlxN1+przmkoAfJI0jFnYsx6k03NJRQAUGikPWgANFGaKACiiigB9LRRQAtOWiigBy0veiigBe1LRRQAtFFFAAKUUUUAFL2oooAKO9FFABSUUUAFJRRQAGmmiigBDSGiigBO9NaiigBG60neiigBKDRRQAlFFFACUlFFAC0neiigBRSGiigA7UlFFABRRRQB/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan shows a subpleural mass in the right lower lobe with tentacle-like extensions towards the hilum (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_2_12327=[""].join("\n");
var outline_f12_2_12327=null;
var title_f12_2_12328="Alteplase: Pediatric drug information";
var content_f12_2_12328=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Alteplase: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"    see \"Alteplase: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/17/6420?source=see_link\">",
"    see \"Alteplase: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F132252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Activase&reg;;",
"     </li>",
"     <li>",
"      Cathflo&reg; Activase&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F132253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Activase&reg; rt-PA;",
"     </li>",
"     <li>",
"      Cathflo&reg; Activase&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1050935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Thrombolytic Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Thrombotic Occlusion (Central Venous Catheter), Treatment Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11431468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Occluded I.V. catheter:",
"     </b>",
"     Intracatheter:",
"     <b>",
"      Dose listed is per lumen; for multilumen catheters, treat one lumen at a time; do not infuse into patient; dose should always be aspirated out of catheter after dwell.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Manufacturer's recommendations (CathFlo&reg; Activase&reg;): Central venous catheter: PNA &ge;14 days: Use a 1 mg/mL concentration; instill a volume equal to 110% of the internal lumen volume of the catheter; do not exceed 2 mg in 2 mL; leave in lumen for up to 2 hours, then aspirate out of catheter; may instill a second dose if catheter remains occluded after 2-hour dwell time",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Chest",
"     </i>",
"     , 2008 dosing recommendations: Central venous catheter: 0.5 mg diluted in NS to a volume equal to the internal volume of the lumen; instill in each lumen over 1-2 minutes; leave in lumen for 1-2 hours, then aspirate out of catheter; flush catheter with NS (Monagle, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alternative dosing: Central venous catheter: 0.25-0.5 mg/mL solution; instill a volume to fill the catheter; leave in lumen for up to 2 hours, then aspirate out of catheter; dosing described in trial of 18 neonates including four patients with GA &le;32 weeks (Soylu, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Systemic thromboses:",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     The optimal dose for various thrombotic conditions is not established; most published papers consist of case reports and series; few prospective neonatal studies have been conducted; dose must be titrated to effect (eg, fibrinogen &gt;100-150 mg/dL). Administration of FFP may be considered prior to dose infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Chest",
"     </i>",
"     , 2008 recommendations: 0.1-0.6 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     for 6 hours (some patients may require longer or shorter duration of therapy). Higher doses (&gt;0.4 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ) may be associated with an increased incidence of serious bleeding (ie, IVH) (Monagle, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alternative dosing: Limited data available; dosage regimens variable (including use of a loading dose):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     No loading dose regimen: Seven neonates (GA: 24-38 weeks) with arterial thrombosis received a continuous I.V. infusion of 0.1 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     initially and infusion rate was titrated to response to maintain fibrinogen levels &gt;100 mg/dL; dosage increases were made in 0.1 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     increments every 6 hours to a maximum of 0.4 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ; no heparin was used in these patients (Weiner, 1998). In case series of three neonates (GA: 26-36 weeks) with infective endocarditis and intracardiac thrombosis, a daily intermittent infusion of 0.2 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     over 6 hours for 5 days was used (Anderson, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Loading dose regimen:",
"     <b>",
"      Note:",
"     </b>",
"     Dosage reported varies widely: One trial of 16 neonates used a loading dose of 0.1 mg/kg over 10 minutes followed by an intermittent infusion of 0.3 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     infusion for 3 hours every 12-24 hours as determined by response and monitoring parameters; a maximum of 4 additional intermittent doses were allowed; heparin was held during alteplase infusion (Farnoux, 1998 ). In another trial, a loading dose of 0.7 mg/kg bolus over 30-60 minutes was used followed by continuous I.V. infusion at an initial rate of 0.2 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     for 1-4 days in 13 neonates (GA: 27-42 weeks) with catheter-related thrombosis (used in conjunction with heparin infusion); reported effective range: 0.1-0.3 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     (Hartmann, 2001).",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1050928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"      see \"Alteplase: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Infants and Children:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Occluded I.V. catheters:",
"     </b>",
"     Intracatheter:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Chest",
"     </i>",
"     , 2008 dosing recommendations (Monagle, 2008):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Central venous catheter:",
"     <b>",
"      Dose listed is per lumen; for multilumen catheters, treat one lumen at a time: Note:",
"     </b>",
"     Some institutions use lower doses (eg, 0.25 mg/0.5 mL) in infants 1 to &lt;3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Patients &le;10 kg: 0.5 mg diluted in NS to a volume equal to the internal volume of the lumen; instill in each lumen over 1-2 minutes; leave in lumen for 1-2 hours, then",
"     <b>",
"      aspirate out of catheter, do not infuse into patient",
"     </b>",
"     ; flush catheter with NS",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Patients &gt;10 kg: 1 mg in 1 mL of NS; use a volume equal to the internal volume of the lumen; maximum: 2 mg in 2 mL per lumen; instill in each lumen over 1-2 minutes; leave in lumen for 1-2 hours; then",
"     <b>",
"      aspirate out of catheter, do not infuse into patient",
"     </b>",
"     ; flush catheter with NS",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     SubQ port:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Patients &le;10 kg: 0.5 mg diluted with NS to 3 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Patients &gt;10 kg: 2 mg diluted with NS to 3 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Manufacturer's recommendations (CathFlo&reg; Activase&reg;): Central venous catheter:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Patients &lt;30 kg: Use a 1 mg/mL concentration; instill a volume equal to 110% of the internal lumen volume of the catheter; do not exceed 2 mg in 2 mL; may instill a second dose if catheter remains occluded after 2-hour dwell time",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Patients &ge;30 kg: 2 mg in 2 mL; may instill second dose if catheter remains occluded after 2-hour dwell time",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Systemic thromboses:",
"     </b>",
"     I.V. (",
"     <b>",
"      Note:",
"     </b>",
"     Dose must be titrated to effect):",
"     <i>",
"      Chest",
"     </i>",
"     , 2008 recommendations: 0.1-0.6 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     for 6 hours (some patients may require longer or shorter duration of therapy) (Monagle, 2008).",
"     <b>",
"      Note:",
"     </b>",
"     The optimal dose for various thrombotic conditions is not established in pediatric patients; most published papers consist of case reports; few prospective pediatric studies have been conducted; several studies have used the following doses (Levy, 1991; Weiner, 1998).",
"     <b>",
"      Note:",
"     </b>",
"     Bleeding complications were associated with doses in the higher range.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Initial: 0.1 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     for 6 hours; monitor patient closely for bleeding, monitor fibrinogen levels; if no response after 6 hours, increase infusion by 0.1 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     at 6-hour intervals to a maximum of 0.5 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ; maintain fibrinogen &gt;100 mg/dL; duration of therapy is based on clinical response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Low-dose (local) infusion for occluded catheters:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     No pediatric studies have compared local to systemic thrombolytic therapy; therefore, there is no evidence to suggest that local infusions are superior. The pediatric patients' small vessel size may increase the chance of local damage to blood vessels and formation of a new thrombus; however, local infusion may be appropriate for catheter related thromboses if the catheter is already in place (",
"     <i>",
"      Chest",
"     </i>",
"     , 2004). Various &ldquo;low-dose&rdquo; regimens have been used; the following dosing recommendations are based on Doyle, 1992 and Anderson, 1991:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Initial: 0.01 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     for 6 hours; if no response after 6 hours, increase infusion by 0.01 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     at 6-hour intervals to a maximum of 0.05 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ; monitor patient closely; systemic fibrinolysis (decreased plasma fibrinogen levels) or bleeding has been reported in some infants receiving 0.05 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ; duration of therapy is based on clinical response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Adults:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Acute MI:",
"     </b>",
"     I.V. (",
"     <b>",
"      Note:",
"     </b>",
"     Alteplase should be administered as soon as possible after symptom onset):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Accelerated infusion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Patients &gt;67 kg: Total dose: 100 mg given in 3 divided doses as follows: Infuse 15 mg I.V. bolus over 1-2 minutes, then infuse 50 mg over the next 30 minutes, then 35 mg over the next 60 minutes. Maximum total dose: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Patients &le;67 kg: Infuse 15 mg I.V. bolus over 1-2 minutes, then infuse 0.75 mg/kg (maximum: 50 mg) over the next 30 minutes, then 0.5 mg/kg (maximum: 35 mg) over the next 60 minutes. Maximum total dose: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Acute ischemic stroke:",
"     </b>",
"     I.V. (",
"     <b>",
"      Note:",
"     </b>",
"     Alteplase therapy should only be started within 3 hours after the onset of symptoms of stroke and after exclusion of intracranial hemorrhage by CT scan or other sensitive diagnostic imaging method): Total dose: 0.9 mg/kg (maximum: 90 mg) given over 1 hour as follows: Infuse 10% of total dose (0.09 mg/kg) I.V. bolus over 1 minute, then infuse the rest of the total dose (0.81 mg/kg) over 60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Pulmonary embolism:",
"     </b>",
"     I.V.: 100 mg infused over 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Occluded central venous catheter:",
"     </b>",
"     Intracatheter: Manufacturer's recommendations (CathFlo&reg; Activase&reg;): Patients &ge;30 kg: 2 mg in 2 mL; may instill second dose if catheter remains occluded after 2-hour dwell time;",
"     <b>",
"      Note:",
"     </b>",
"     A recent study using escalating doses of 0.5 mg, 1 mg, and 2 mg (60 minute dwell time) found that 86.2% of catheters were cleared with the 0.5 mg dose (Davis, 2000).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F132234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [recombinant]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Activase&reg;: 50 mg, 100 mg [contains polysorbate 80; derived from or manufactured using Chinese hamster ovary  cells; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cathflo&reg; Activase&reg;: 2 mg [contains polysorbate 80; derived from or manufactured using Chinese hamster ovary cells]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F132219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1050939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Activase&reg;: Reconstitute vials with supplied diluent (SWI); do not reconstitute with bacteriostatic water for injection; use large bore needle and syringe to reconstitute 50 mg vial (50 mg vial has a vacuum) and accompanying transfer device to reconstitute 100 mg vial (100 mg vial does not contain vacuum); swirl gently, do not shake; final concentration after reconstitution: 1 mg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: May administer at a final concentration of 1 mg/mL or may dilute and administer as 0.5 mg/mL. Prepare bolus dose using one of the following methods: 1) Remove bolus dose from reconstituted vial using syringe and needle; for 50 mg vial: do not prime syringe with air, insert needle into vial stopper; for 100 mg vial, insert needle away from puncture mark created by transfer device; 2) Remove bolus dose from a port on the infusion line after priming; 3) Program an infusion pump to deliver the bolus at the beginning of the infusion. Administer the remaining dose as follows: From 50 mg vial: Use polyvinyl chloride I.V. bag or glass vial and infusion set; from 100 mg vial: Use same puncture site made by transfer device to insert spike end of infusion set and infuse from vial.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     CathFlo&reg; Activase&reg;: Reconstitute vial with 2.2 mL of SWI; do not reconstitute with bacteriostatic water for injection; allow vial to stand undisturbed so large bubbles may dissipate; swirl gently, do not shake; complete dissolution occurs within 3 minutes; final concentration after reconstitution: 1 mg/mL. Discard any unused solution (solution does not contain preservatives).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intracatheter: Instill the appropriate dose into the occluded catheter; leave in lumen; evaluate catheter function (by attempting to aspirate blood) after 30 minutes; if catheter is functional, aspirate 4-5 mL of blood out of catheter in patients &ge;10 kg or 3 mL in patients &lt;10 kg to remove drug and residual clot, then gently flush catheter with NS; if catheter is still occluded, leave alteplase in lumen and evaluate catheter function after 120 minutes of dwell time; if catheter is functional, aspirate 4-5 mL of blood out of catheter in patients &ge;10 kg or 3 mL in patients &lt;10 kg and gently flush with NS; if catheter remains occluded after 120 minutes of dwell time, a second dose may be instilled by repeating the above administration procedure.",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14471278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     0.5 mg/mL",
"     <b>",
"      or",
"     </b>",
"     1 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F132307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS, sterile water for injection;",
"     <b>",
"      incompatible",
"     </b>",
"     with bacteriostatic water, LR;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Eptifibatide, lidocaine, metoprolol, propranolol.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Bivalirudin, dobutamine, heparin, morphine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Dopamine, nitroglycerin.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1050931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Activase&reg;: Store lyophilized product at room temperature [not to exceed 86&deg;F (30&deg;C)] or under refrigeration; protect from excessive light exposure during extended storage. Reconstituted solution (1 mg/mL) must be used within 8 hours (manufacturer's recommendations).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     The 1 mg/mL solution may be diluted further (immediately before use) with an equal volume of NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W to yield a final concentration of 0.5 mg/mL; swirl gently, do not shake to dilute; diluted solutions are stable for 8 hours at room temperature. Dilutions to concentrations &lt;0.5 mg/mL are not recommended for routine clinical use; dilutions &lt;0.5 mg/mL using D",
"     <sub>",
"      5",
"     </sub>",
"     W or SWI will result in a precipitate; an immediate formation of a precipitate following dilution of alteplase with D",
"     <sub>",
"      5",
"     </sub>",
"     W to 0.16 mg/mL has been reported (Frazin, 1990); after reconstitution to 1 mg/mL, alteplase may be further diluted with NS to concentrations as low as 0.2 mg/mL without precipitation (Frazin, 1990); do not dilute &lt;0.2 mg/mL; after reconstitution to 1 mg/mL, further dilution with NS to target concentrations of 0.05 mg/mL, 0.025 mg/mL, and 0.01 mg/mL resulted in &lt;90% recovery of active alteplase (data on file at Genetech).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Solutions of 0.5 mg/mL, 1 mg/mL, and 2 mg/mL in SWI retained &ge;94% of fibrinolytic activity at 48 hours when stored at 2&deg;C in plastic syringes; these solutions retained &ge;90% of fibrinolytic activity when stored in plastic syringes at -25&deg;C or -70&deg;C for 7 or 14 days, thawed at room temperature and then stored at 2&deg;C for 48 hours (Davis, 2000). Solutions of 1 mg/mL in SWI were stable for 22 weeks in plastic syringes when stored at -30&deg;C and for &sim;1 month in glass vials when stored at -20&deg;C; bioactivity remained unchanged for 6 months in propylene containers when stored at -20&deg;C and for 2 weeks in glass vials when stored at -70&deg;C (see review by Generali, 2001).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Do not add other medications to alteplase solutions. Alteplase is incompatible with bacteriostatic water, dobutamine, dopamine, heparin, morphine, and nitroglycerin infusions; physically compatible with lidocaine, metoprolol, and propranolol when administered via Y site.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     CathFlo&reg; Activase&reg;: Store lyophilized product at refrigerated temperature [2&deg;C to 8&deg;C (36&deg;F to 46&deg;C)]; protect from excessive light exposure during extended storage. Reconstituted solution (1 mg/mL) must be used within 8 hours when stored at 2&deg;C to 30&deg;C (36&deg;F to 81&deg;F); do not add other medications to CathFlo&reg; Activase&reg; solutions",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1050938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Activase&reg;: Thrombolytic agent used in treatment of acute MI, acute ischemic stroke, and acute massive pulmonary embolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     CathFlo&reg; Activase&reg;: Treatment of occluded central venous catheters",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F132309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Activase&reg; may be confused with Cathflo&reg; Activase&reg;, TNKase&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Alteplase may be confused with Altace&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       &ldquo;tPA&rdquo; abbreviation should not be used when writing orders for this medication; has been misread as TNKase (tenecteplase)",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (I.V.) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F132306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As with all drugs which may affect hemostasis, bleeding is the major adverse effect associated with alteplase. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables, including the dosage administered, concurrent use of multiple agents which alter hemostasis, and patient predisposition. Rapid lysis of coronary artery thrombi by thrombolytic agents may be associated with reperfusion-related atrial and/or ventricular arrhythmia.",
"     <b>",
"      Note:",
"     </b>",
"     Lowest rate of bleeding complications expected with dose used to restore catheter function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Bruising",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: GI hemorrhage, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: GU hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Bleeding",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Bleeding at catheter puncture site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Angioedema (orolingual), intracranial hemorrhage, retroperitoneal hemorrhage, pericardial hemorrhage, gingival hemorrhage, epistaxis, allergic reaction (anaphylaxis, anaphylactoid reactions, laryngeal edema, rash, and urticaria)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Additional cardiovascular events associated",
"     <b>",
"      with use in STEMI:",
"     </b>",
"     AV block, asystole, bradycardia, cardiac arrest, cardiac tamponade, cardiogenic shock, cholesterol crystal embolization, electromechanical dissociation, heart failure, hemorrhagic bursitis, mitral regurgitation, myocardial rupture, recurrent ischemia/infarction, pericardial effusion, pericarditis, pulmonary edema, ruptured intracranial AV malformation, seizure, thromboembolism, ventricular tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Additional events associated",
"     <b>",
"      with use in pulmonary embolism:",
"     </b>",
"     Pleural effusion, pulmonary re-embolization, pulmonary edema, thromboembolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Additional events associated",
"     <b>",
"      with use in stroke:",
"     </b>",
"     Cerebral edema, cerebral herniation, new ischemic stroke, seizure",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1050942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to alteplase or any component",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Contraindications for use in the treatment of acute MI or pulmonary embolism: Active internal bleeding; known bleeding diathesis; history of CVA; intracranial neoplasm, arteriovenous malformation, or aneurysm; recent intracranial or intraspinal surgery or trauma; severe uncontrolled hypertension",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Contraindications for use in the treatment of acute ischemic stroke: Active internal bleeding; known bleeding diathesis (including but not limited to: Current use of oral anticoagulants or an INR &gt;1.7 or PT &gt;15 seconds, use of heparin within 48 hours before the onset of stroke and an elevated aPTT at presentation, platelet count &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ); evidence of intracranial hemorrhage on pretreatment evaluation; history of intracranial hemorrhage; suspicion of subarachnoid hemorrhage; recent (within 3 months) intracranial or intraspinal surgery, serious head trauma, or previous stroke; intracranial neoplasm, arteriovenous malformation, or aneurysm; seizure at the onset of stroke; uncontrolled hypertension at time of treatment (eg, adults with blood pressures of &gt;185 mm Hg systolic or &gt;110 mm Hg diastolic)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1050927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Activase&reg;: Use with caution if drug is readministered; discontinue immediately if anaphylactoid reaction occurs. For treatment of acute ischemic stroke, frequent monitoring and control of blood pressure during and after alteplase administration is recommended. For systemic use, pretreatment lab studies should include platelet count, PT/PTT, fibrinogen, fibrin degradation products, plasminogen, antithrombin III, protein S, protein C.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     CathFlo&reg; Activase&reg;: Consider other causes of central venous catheter occlusion (eg, mechanical failure, constriction by a suture, catheter malposition, and drug precipitates or lipid deposits within the lumen of the catheter) before use; do not use vigorous suction when determining catheter occlusion (vascular wall damage or collapse of soft-walled catheters may occur); avoid excessive pressure when instilling alteplase into an occluded catheter (catheter may rupture or clot may become dislodged and enter the circulation). The use of CathFlo&reg; Activase&reg; has not been evaluated in patients who are at risk for bleeding; use with caution in patients with active internal bleeding or those who have had any of the following within 48 hours: Surgery, puncture of noncompressible vessels, obstetrical delivery, or percutaneous biopsy of viscera or deep tissues; use with caution in patients with thrombocytopenia, hemostatic defects including ones caused by severe renal or hepatic dysfunction, any condition in which bleeding would be a significant risk or would be especially difficult to manage due to its location, or those who are at a high risk for embolic complications (eg, venous thrombosis in the region of the catheter). Discontinue CathFlo&reg; Activase&reg; and withdraw from catheter if serious bleeding in a critical location occurs. Use with caution in patients with known or suspected catheter infection (use of CathFlo&reg; Activase&reg; in these patients may release a localized infection in the catheter into the systemic circulation). Use of &gt;2 doses of CathFlo&reg; Activase&reg; has not been studied.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1050926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Activase&reg;: May cause bleeding (internal, superficial, or surface bleeding); concurrent use of heparin anticoagulation may increase bleeding; monitor all potential bleeding sites. Avoid I.M. injections and nonessential handling of patient; carefully perform venipunctures and only when necessary. If an arterial puncture is required, use vessel in an upper extremity that can be manually compressed. Stop alteplase (and heparin) if serious bleeding occurs (effects of heparin can be reversed by protamine). Do not exceed recommended doses; do not use doses of 150 mg to treat acute MI as this dose has been associated with an increase in intracranial hemorrhage.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Risks from alteplase may be increased in the following conditions (risks versus benefits should be weighed carefully before use): Recent major surgery (eg, organ biopsy, previous puncture of noncompressible vessels, coronary artery bypass graft, obstetrical delivery), recent trauma, recent GI or GU bleeding, current use of oral anticoagulants, cerebrovascular disease, diabetic hemorrhagic retinopathy or other hemorrhagic ophthalmic conditions, hypertension (eg, adults with systolic BP &ge;175 mm Hg and/or diastolic BP &ge;110 mm Hg), patients with an increased risk of left heart thrombus (eg, mitral stenosis with atrial fibrillation), acute pericarditis, subacute bacterial endocarditis, hemostatic defects including ones caused by severe renal or hepatic dysfunction, significant hepatic dysfunction, pregnancy, septic thrombophlebitis or occluded AV cannula at seriously infected site, advanced age (eg, &gt;75 years old), any other condition in which bleeding would be a significant risk or would be especially difficult to manage due to its location.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Cholesterol embolism may occur (rare). Risk of stroke in acute MI patients who are at low risk for death from cardiac causes and who present with high blood pressure, may be greater than the survival benefit from thrombolytic therapy. Reperfusion arrhythmias may occur following coronary thrombolysis. In patients with pulmonary embolism, alteplase has not been proven to adequately treat underlying DVT; possible re-embolization from DVT may occur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Acute ischemic stroke: Risks of alteplase therapy may be increased in patients with major early signs of infarct on CT and in those with severe neurological deficit at presentation (risks versus benefits should be weighed carefully); treatment of patients &gt;3 hours after onset of symptoms and those with rapidly improving symptoms or minor neurological deficit is not recommended.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Injection contains polysorbate 80 (Tween 80&reg;) which may cause allergic reactions in susceptible individuals. In premature neonates, thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported after receiving parenteral products containing polysorbate 80 (Alade, 1986;",
"     <i>",
"      MMWR",
"     </i>",
"     , 1984). Infusion of polysorbate 80-containing solutions through polyvinyl chloride tubing may cause DEHP to leach into the solution; in immature animals, exposure to DEHP may adversely affect the development of the male reproductive tract.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F132228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.  Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprotinin: May diminish the therapeutic effect of Thrombolytic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Thrombolytic Agents may enhance the anticoagulant effect of Dabigatran Etexilate.  Management: Carefully monitor for bleeding.  Dabigatran Canadian labeling recommends avoiding use with thrombolytic agents. Consider avoiding alteplase treatment of acute ischemic stroke in patients receiving dabigatran (see full drug monograph for details).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Thrombolytic Agents may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: Whenever possible, avoid use of drotrecogin within 3 days of a thrombolytic agent.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Thrombolytic Agents. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroglycerin: May decrease the serum concentration of Alteplase.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F132230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7872251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. There are no adequate and well-controlled studies in pregnant women. The risk of bleeding may be increased in pregnant women. Use during pregnancy is limited; administer to pregnant women only if the potential benefits justify the risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1050934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Systemic use: Blood pressure; temperature; CBC, reticulocyte, platelet count; fibrinogen level, plasminogen, fibrin/fibrinogen degradation products, D-dimer, PT, PTT, antithrombin III, protein C; urinalysis, signs of bleeding",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intracatheter use: Catheter function (by attempting to aspirate blood); temperature, signs of sepsis, GI bleeding, bleeding at injection site, and venous thrombosis",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1050925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A naturally-occurring serine protease (enzyme) that initiates local fibrinolysis by binding to fibrin in a thrombus (clot) and directly activating entrapped plasminogen to plasmin; plasmin degrades fibrin, fibrinogen, and other procoagulant proteins into soluble fragments",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1050941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Initial: Approximates plasma volume; distribution into breast milk is unknown",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial: &lt;5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Terminal: 72 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Clearance: Plasma: Adults: 380-570 mL/minute",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1050943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Activase&reg; and CathFlo&reg; Activase&reg; also contain L-arginine, polysorbate 80, and phosphoric acid (for pH adjustment).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Advantages of alteplase include: Low immunogenicity, short half-life, direct activation of plasminogen, and a strong and specific affinity for fibrin. Failure of thrombolytic agents in newborns/neonates may occur due to the low plasminogen concentrations (&sim;50% to 70% of adult levels); supplementing plasminogen (via administration of fresh frozen plasma) may possibly help. Osmolality of 1 mg/mL solution is &sim;215 mOsm/kg.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Appropriate intracatheter use of alteplase for the treatment of occluded central venous catheters is not expected to cause systemic pharmacologic effects; in adults, if a 2 mg dose is administered I.V. (instead of being instilled into the catheter), the serum concentration of alteplase would be expected to return to normal endogenous levels within 30 minutes.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     An open-label, single-arm trial of CathFlo&reg; Activase&reg; in pediatric patients, 2 weeks to 17 years of age (n = 310), was conducted using the manufacturer's recommended doses; catheter function was restored in 83% of patients (similar to adults); rates of serious adverse events were also similar to adults (CathFlo&reg; Activase&reg; package insert, 2005).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alade SL, Brown RE, and Paquet A Jr, \"Polysorbate 80 and E-Ferol Toxicity,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1986, 77(4):593-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/2/12328/abstract-text/3960626/pubmed\" id=\"3960626\" target=\"_blank\">",
"        3960626",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson BJ, Keeley SR, and Johnson ND, &ldquo;Caval Thrombolysis in Neonates Using Low Doses of Recombinant Human Tissue-Type Plasminogen Activator,&rdquo;",
"      <i>",
"       Anaesth Intensive Care",
"      </i>",
"      , 1991, 19(1):22-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/2/12328/abstract-text/1901463/pubmed\" id=\"1901463\" target=\"_blank\">",
"        1901463",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson B, Urs P, Tudehope D, et al, \"The Use of Recombinant Tissue Plasminogen Activator in the Management of Infective Intracardiac Thrombi in Pre-term Infants With Thrombocytopaenia,\"",
"      <i>",
"       J Paediatr Child Health",
"      </i>",
"      , 2009, 45(10):598-601.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/2/12328/abstract-text/19825023/pubmed\" id=\"19825023\" target=\"_blank\">",
"        19825023",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Andrew M, Brooker L, Leaker M, et al, &ldquo;Fibrin Clot Lysis by Thrombolytic Agents is Impaired in Newborns Due to a Low Plasminogen Concentration,&rdquo;",
"      <i>",
"       Thromb Haemost",
"      </i>",
"      , 1992, 68(3):325-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/2/12328/abstract-text/1440499/pubmed\" id=\"1440499\" target=\"_blank\">",
"        1440499",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cada DJ, Levien T, and Baker DE, &ldquo;Alteplase,&rdquo;",
"      <i>",
"       Hospital Pharmacy",
"      </i>",
"      , 2002, 37(2): 148-54.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control (CDC), \"Unusual Syndrome With Fatalities Among Premature Infants: Association With a New Intravenous Vitamin E Product,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 1984, 33(14):198-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/2/12328/abstract-text/6423951/pubmed\" id=\"6423951\" target=\"_blank\">",
"        6423951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Choi M, Massicotte MP, Marzinotto V, et al, &ldquo;The Use of Alteplase to Restore Patency of Central Venous Lines in Pediatric Patients: A Cohort Study,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2001, 139(1):152-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/2/12328/abstract-text/11445811/pubmed\" id=\"11445811\" target=\"_blank\">",
"        11445811",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davis SN, Vermeulen L, Banton J, et al, &ldquo;Activity and Dosage of Alteplase Dilution for Clearing Occlusions of Venous-Access Devices,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2000, 57(11):1039-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/2/12328/abstract-text/10876745/pubmed\" id=\"10876745\" target=\"_blank\">",
"        10876745",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Doyle E, Britto J, Freeman J, et al, &ldquo;Thrombolysis With Low Dose Tissue Plasminogen Activator,&rdquo;",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1992, 67(12):1483-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/2/12328/abstract-text/1489229/pubmed\" id=\"1489229\" target=\"_blank\">",
"        1489229",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Farnoux C, Camard O, Pinquier D, et al, &ldquo;Recombinant Tissue-Type Plasminogen Activator Therapy of Thrombosis in 16 Neonates,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1998, 133(1):137-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/2/12328/abstract-text/9672527/pubmed\" id=\"9672527\" target=\"_blank\">",
"        9672527",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frazin BS, &ldquo;Maximal Dilution of Activase,&rdquo;",
"      <i>",
"       Am J Hosp Pharm",
"      </i>",
"      , 1990, 47(5):1016.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/2/12328/abstract-text/2110773/pubmed\" id=\"2110773\" target=\"_blank\">",
"        2110773",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Generali J and Cada DJ, &ldquo;Alteplase (t-PA) Bolus: Occluded Catheters,&rdquo;",
"      <i>",
"       Hospital Pharmacy",
"      </i>",
"      , 2001, 36(1):93-103.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hartmann J, Hussein A, Trowitzsch E, et al, \"Treatment of Neonatal Thrombus Formation With Recombinant Tissue Plasminogen Activator: Six Years Experience and Review of the Literature,\"",
"      <i>",
"       Arch Dis Child Fetal Neonatal Ed",
"      </i>",
"      , 2001, 85(1):F18-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/2/12328/abstract-text/11420316/pubmed\" id=\"11420316\" target=\"_blank\">",
"        11420316",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kothari SS, Varma S, and Wasir S, &ldquo;Thrombolytic Therapy in Infants and Children,&rdquo;",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 1994, 127(3):651-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/2/12328/abstract-text/8122615/pubmed\" id=\"8122615\" target=\"_blank\">",
"        8122615",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levy M, Benson LN, Burrows PE, et al, &ldquo;Tissue Plasminogen Activator for the Treatment of Thromboembolism in Infants and Children,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1991, 118(3):467-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/2/12328/abstract-text/1900334 /pubmed\" id=\"1900334 \" target=\"_blank\">",
"        1900334",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Monagle P, Chalmers E, Chan A, et al, \"Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),\"",
"      <i>",
"       Chest",
"      </i>",
"      , 2008, 133(6 Suppl):887S-968S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/2/12328/abstract-text/18574281/pubmed\" id=\"18574281\" target=\"_blank\">",
"        18574281",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Monagle P, Chan A, Massicotte P, et al, \"Antithrombotic Therapy in Children: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy,\"",
"      <i>",
"       Chest",
"      </i>",
"      , 2004, 126(3 Suppl):645S-687S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/2/12328/abstract-text/15383489 /pubmed\" id=\"15383489 \" target=\"_blank\">",
"        15383489",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Monagle P, Michelson AD, Bovill E, et al, &ldquo;Antithrombotic Therapy in Children,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2001, 119(1 Suppl):344S-370S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/2/12328/abstract-text/ 11157659 /pubmed\" id=\" 11157659 \" target=\"_blank\">",
"        11157659",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nowak-Gottl U, Auberger K, Halimeh S, et al, &ldquo;Thrombolysis in Newborns and Infants,&rdquo;",
"      <i>",
"       Thromb Haemost",
"      </i>",
"      , 1999, 82 (Suppl 1):112-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/2/12328/abstract-text/10695499/pubmed\" id=\"10695499\" target=\"_blank\">",
"        10695499",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ponec D, Irwin D, Haire WD, et al, &ldquo;Recombinant Tissue Plasminogen Activator (Alteplase) for Restoration of Flow in Occluded Central Venous Access Devices: A Double-Blind Placebo-Controlled Trial - The Cardiovascular Thrombolytic to Open Occluded Lines (COOL) Efficacy Trial,&rdquo;",
"      <i>",
"       J Vasc Intern Radiol",
"      </i>",
"      , 2001, 12(8):951-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/2/12328/abstract-text/11487675 /pubmed\" id=\"11487675 \" target=\"_blank\">",
"        11487675",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Soylu H, Brand&atilde;o LR, and Lee KS, \"Efficacy of Local Instillation of Recombinant Tissue Plasminogen Activator for Restoring Occluded Central Venous Catheters in Neonates,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2010, 156(2):197-201.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/2/12328/abstract-text/19969306/pubmed\" id=\"19969306\" target=\"_blank\">",
"        19969306",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weiner GM, Castle VP, DiPietro MA, et al, &ldquo;Successful Treatment of Neonatal Arterial Thromboses With Recombinant Tissue Plasminogen Activator,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1998, 133(1):133-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/2/12328/abstract-text/9672526/pubmed\" id=\"9672526\" target=\"_blank\">",
"        9672526",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13363 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.80.101-F770B2E4D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_2_12328=[""].join("\n");
var outline_f12_2_12328=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132252\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132253\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050935\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11431468\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050928\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132234\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132219\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050939\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471278\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132307\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050931\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050938\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132309\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132306\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050942\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050927\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050926\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298716\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132228\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132230\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7872251\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050934\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050925\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050941\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050943\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13363\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13363|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=related_link\">",
"      Alteplase: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/17/6420?source=related_link\">",
"      Alteplase: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_2_12329="Dermoscopy melanoma 1";
var content_f12_2_12329=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F79576%7EDERM%2F60407%7EDERM%2F73202&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F79576%7EDERM%2F60407%7EDERM%2F73202&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Dermoscopy of superficial spreading melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Melanoma 0.98 mm. Atypical network, peripheral streaks (solid arrows), blue white-veil, and off-centered blotch (dashed square) are observed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Dermoscopic image of thin melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 302px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Superficial spreading melanoma 0.5 mm. Atypical globules (solid square) and atypical vessels, including serpentine vessels and dotted vessels (solid arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Dermoscopic image of thick melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 292px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Melanoma 3.8 mm. Atypical network (solid arrow), negative network (solid square) and atypical globules (dashed square) are observed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_2_12329=[""].join("\n");
var outline_f12_2_12329=null;
var title_f12_2_12330="Hospital discharge";
var content_f12_2_12330=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hospital discharge",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/2/12330/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/2/12330/contributors\">",
"     Eric Alper, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/2/12330/contributors\">",
"     Terrence A O'Malley, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/2/12330/contributors\">",
"     Jeffrey Greenwald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/2/12330/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/2/12330/contributors\">",
"     Mark D Aronson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/2/12330/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/2/12330/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/2/12330/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Discharging patients from the hospital is a complex process that is fraught with challenges. Preventing avoidable rehospitalizations has the potential to profoundly improve both the quality-of-life for patients and the financial well-being of healthcare systems.",
"   </p>",
"   <p>",
"    There were over 39 million hospital discharges in the United States in 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/1\">",
"     1",
"    </a>",
"    ]. Among Medicare patients, almost 20 percent who are discharged from a hospital are readmitted within 30 days [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/2\">",
"     2",
"    </a>",
"    ]. Unplanned rehospitalizations, at a cost of $17.4 billion, accounted for 17 percent of total hospital payments from Medicare in 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the exact number of avoidable readmissions is unknown, a systematic review of 34 studies, most based on retrospective chart review, found that between 5 and 79 percent of readmissions were likely to be preventable [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/4\">",
"     4",
"    </a>",
"    ]. Decreasing the rate of hospital readmissions has been targeted as a high priority for US healthcare reform [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/5\">",
"     5",
"    </a>",
"    ]. In 2012, the United States government started to penalize hospitals for excess readmissions, initially involving up to 1 percent of total payments from Medicare [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/6\">",
"     6",
"    </a>",
"    ]. Approximately two-thirds of US hospitals realized some penalty under this program in 2012. These penalties will rapidly rise to up to a maximum of 3 percent of total Medicare reimbursement by 2015. Readmission rates are calculated on a rolling three-year basis; each year, the penalty will be determined based on the previous three years for which data is available (eg, for fiscal year 2013, the data comes from 2009, 2010, and 2011). These penalties, anticipated to yield CMS over $300 million in savings (averaging over $130,000 per penalized hospital), result in even greater scrutiny of the discharge process and methods to prevent readmissions.",
"   </p>",
"   <p>",
"    This topic presents an overview of the discharge process, determination of the appropriate next site of care, and review of interventions that have been developed to reduce the likelihood of unplanned readmissions and adverse events after discharge. Much of the discussion relates to structures for care within the United States; availability of services and types of facilities vary significantly across geographic areas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     APPROPRIATENESS FOR DISCHARGE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Need for ongoing hospitalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical necessity of continued hospitalization is primarily determined by the presence of an acute health condition of sufficient severity that ongoing diagnostic or therapeutic intervention, or careful monitoring, is required.",
"   </p>",
"   <p>",
"    However, patients often appropriately remain in the hospital when these criteria are not met, due to the lack of a suitable alternative setting to provide necessary care or other social factors.",
"   </p>",
"   <p>",
"    Premature discharge or discharge to an environment that is not capable of meeting the patient's medical needs may result in hospital readmission. In addition, early hospital discharge may not lead to overall cost-savings if it results in need for more intense subsequent healthcare utilization, including emergency department or nursing facility visits, as indicated by one observational study comparing patients who received hospital care from a primary care physician with care by a hospitalist [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DETERMINING THE POST-DISCHARGE SITE OF CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;When it has been determined that a patient is medically ready for discharge, the health care team must determine the most appropriate setting for ongoing care. Determinants of the appropriate site of care involve medical, functional, and social aspects of the patient's illness. The patient&rsquo;s acute and chronic medical conditions, potential for rehabilitation, and decision-making capacity must be taken into account [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Input is needed from multiple sources to determine the most suitable discharge plan. Involved parties often will include the patient, family, case manager, nurse, physician, physical and occupational therapist, social worker, and insurer.",
"   </p>",
"   <p>",
"    In order for the patient to be deemed safe and ready for discharge to home or to a non-acute environment (rehabilitative, transitional, or chronic care), a provider must take into account a number of factors beyond the medical determinants. These factors include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patient cognitive status",
"     </li>",
"     <li>",
"      Patient activity level and functional status",
"     </li>",
"     <li>",
"      The nature of the patient's current home and suitability for the patient's conditions (eg, presence of stairways, cleanliness)",
"     </li>",
"     <li>",
"      Availability of family or companion support",
"     </li>",
"     <li>",
"      Ability to obtain medications and services",
"     </li>",
"     <li>",
"      Availability of transportation from hospital to home and for follow-up visits",
"     </li>",
"     <li>",
"      Availability of services in the community to assist the patient with ongoing care",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Discharge home",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately three-quarters of hospitalized patients are able to return to their home environment following discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/9\">",
"     9",
"    </a>",
"    ]. For discharge home, patients, with help from family or other caregivers if available, should be able to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Obtain and self-administer medications",
"     </li>",
"     <li>",
"      Perform self-care activities",
"     </li>",
"     <li>",
"      Eat an appropriate diet or otherwise manage nutritional needs",
"     </li>",
"     <li>",
"      Follow-up with designated providers",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific insurance benefits and availability of services in the community may also influence whether or not the patient may be safely discharged home. Home services, such as visiting nurses or infusion providers to administer intravenous infusions, may allow selected patients, who would otherwise need nonacute residential care, to manage their care needs at home.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Discharge to another care facility",
"    </span>",
"    &nbsp;&mdash;&nbsp;If discharge to the outpatient setting is not appropriate, the team must then arrange transfer to another inpatient facility for ongoing care. Determining the most appropriate inpatient setting of care for ongoing treatment involves determining the patient's needs and matching needs with the capabilities of potential sites of care.",
"   </p>",
"   <p>",
"    One model to help accomplish this involves assessing a set of parameters that describe generic clinical characteristics (medical and surgical issues, mental and emotional status, physical functioning, and environment) that are largely independent of the patient's specific diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/10\">",
"     10",
"    </a>",
"    ]. Components of this model are shown in a table (",
"    <a class=\"graphic graphic_table graphicRef50380 \" href=\"UTD.htm?42/20/43340\">",
"     table 1",
"    </a>",
"    ). These needs are then matched with the services offered at different types of facilities. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Types of care facilities'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Once it is decided that discharge to an alternate facility is necessary, referrals are made to facilities that are felt to be potentially appropriate, and the patient is screened for acceptance. The patient must consent to transfer to an accepting facility; if the patient or family declines, then negotiation ensues to find an acceptable discharge placement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Types of care facilities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity of functional impairments and the need for assistance with activities of daily living (ADLs) often determines whether a patient can be safely managed at home, or requires care at a skilled nursing facility (SNF) or extended care facility (ECF). In making this determination, particular attention is paid to need for supervision in ADLs and safety awareness.",
"   </p>",
"   <p>",
"    Medicare in the United States identifies three categories of health facilities:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute care hospitals",
"     </li>",
"     <li>",
"      Exempt hospitals (inpatient rehabilitation hospitals and long-term acute care hospitals)",
"     </li>",
"     <li>",
"      Nursing facilities (skilled nursing facilities and extended care facilities)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Functional capabilities of each of these facilities are shown in a table (",
"    <a class=\"graphic graphic_table graphicRef66215 \" href=\"UTD.htm?30/10/30893\">",
"     table 2",
"    </a>",
"    ) and outlined briefly here:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inpatient rehabilitation facilities &mdash; To meet certification criteria, inpatient rehabilitation facilities (IRFs) must admit 75 percent of patients for one of 13 specified diagnoses such as stroke or major trauma. Patients must require multidisciplinary therapy (eg, physical therapy, occupational therapy, speech therapy, orthotic or prosthetic services) and be able to participate in intensive treatment. Physician supervision is provided at least three days per week.",
"      <br/>",
"      <br/>",
"      The patient's stay at the IRF may continue as long as there is continued progress and the ability to participate in and to benefit from at least three hours of therapy per day.",
"     </li>",
"     <li>",
"      Long term acute care hospitals &mdash; Long term acute care hospitals (LTACs) must maintain an average length of stay &ge;25 days and patients must require daily monitoring and complex medical interventions. Patients may include those with complex wounds, chest tubes, ventilatory dependency, or multiorgan failure. LTACs are more likely to take complex medical patients than IRFs, and are less widely geographically distributed than IRFs, although the number of LTACs in the United States more than doubled between 1997 and 2006 [",
"      <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Skilled nursing facilities &mdash; Skilled nursing facilities (SNFs), transitional care units (TCUs) and subacute units provide similar services. TCUs are hospital-based and therefore have more ready access to hospital-based services.",
"      <br/>",
"      <br/>",
"      To qualify for Medicare coverage in these facilities, patients must have a \"qualifying event\" that includes a three night hospital stay, and must require skilled nursing or rehabilitation for at least one hour daily five days a week. Medicare SNF benefits last 100 days without a new qualifying event and most SNFs do not accept high cost patients for admission.",
"     </li>",
"     <li>",
"      Extended care facilities &mdash; Extended care facilities (ECFs) provide long term custodial care reimbursed through Medicaid. In order to qualify for Medicaid, a patient must have exhausted his or her assets, require assistance with a least three activities of daily living (ADLs) and require skilled nursing supervision (medication management). Medicaid does not cover therapy services or skilled care, aside from the Medicare copayment.",
"     </li>",
"     <li>",
"      Home-based services &mdash; Availability of home-based services is highly variable. Multiple domains may be addressed by home-based care, including services provided by Medicare-certified home health agencies, private duty nursing services, hospice, infusion services, physician home visit programs, hospital-in-the-home, and telemedicine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ELEMENTS OF THE DISCHARGE PROCESS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Discharge planning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Discharge planning is the development of an individualized discharge plan for the patient prior to leaving the hospital, to ensure that patients are discharged at an appropriate time and with provision of adequate post-discharge services [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/12\">",
"     12",
"    </a>",
"    ]. Such planning is a mandatory part of hospital accreditation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Discharge planning is a complex process that seeks to determine the appropriate level of services required by the patient and then match the patient to an appropriate site of care [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/14\">",
"     14",
"    </a>",
"    ]. This process ideally begins at the start of the hospitalization. The hospital case manager should be involved as soon as it is clear that the patient will require services at home, or will require transfer to an alternative level of care.",
"   </p>",
"   <p>",
"    The impact of discharge planning on outcomes appears to be limited. A 2010 systematic review identified greater patient satisfaction and small decreases in length of stay and readmission rates with discharge planning, while mortality rates were unchanged [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/12\">",
"     12",
"    </a>",
"    ]. A study that examined discharge planning for patients with heart failure measured chart documentation of discharge instructions and patient reports of the discharge planning they had received [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/15\">",
"     15",
"    </a>",
"    ]. No correlation was found between readmission rates and the chart-based measure, and only a small correlation was noted for lower readmission rates with highest versus lowest quintile on the patient-reported measure (22.4 versus 24.7 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Medication reconciliation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medication reconciliation is the process of verifying patient medication lists at a point of care transition, such as hospital discharge, to identify which medications have been added, discontinued, or changed relative to prior medication lists.",
"   </p>",
"   <p>",
"    The ability to generate an accurate discharge medication list requires detailed knowledge of the patient's prior medication history and hospital course, as well as clinical judgment to determine which medications will be continued after hospitalization. The ability to communicate this information effectively to the patient",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    subsequent caregivers is essential to the process.",
"   </p>",
"   <p>",
"    An accurate medication list at hospital discharge is contingent upon the following factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Availability of an accurate pre-admission medication list. This list may have been assembled at the time of admission, and revised during the hospitalization if new information became available, to reflect the pre-hospitalization medications.",
"     </li>",
"     <li>",
"      An accurate and available list of medications being taken at the time of discharge.",
"     </li>",
"     <li>",
"      For changes in medication that occurred during the hospital admission, knowledge of why such changes were made. As examples:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If a proton-pump inhibitor (PPI) was newly prescribed, was this initiated for prophylaxis of stress ulceration and therefore no longer required, or is ongoing PPI therapy necessary for treatment of an ulcer?",
"     </li>",
"     <li>",
"      If a different agent from the same class as one taken prior to admission was substituted during the hospitalization, was there a clinical indication for making that change or does this represent a hospital therapeutic substitution related to formulary preference? If a therapeutic substitution, the medication should revert to the medication that the patient was taking prior to hospitalization.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A prospective cohort study from one institution of patients aged 64 or older who were discharged home after hospitalization for pneumonia, heart failure, or acute coronary syndrome illustrates the extent of patient lack of understanding of medication changes following discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/16\">",
"     16",
"    </a>",
"    ]. At discharge, 22 percent of medications from admission had been stopped or the dosage changed. The majority of patients did not understand the new dosing (70 percent), why medications had been discontinued (82 percent), or why new medications had been started (62 percent). Nurses reviewed all medications with patients at discharge, but there was no formal medication reconciliation process.",
"   </p>",
"   <p>",
"    A systematic review of 26 controlled studies of variable quality, including 10 randomized trials, found that medication reconciliation consistently reduced discrepancies, with most studies indicating a decrease in actual and potential adverse drug events [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/17\">",
"     17",
"    </a>",
"    ]. Interventions were most effective that involved pharmacy staff intensively and that targeted high-risk patients. Evidence was less robust that medication reconciliation reduces postdischarge hospital utilization, although two studies did show some impact.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In Sweden, patients 80 years or older who were randomly assigned to receive a medication reconciliation intervention by unit-based pharmacists had 16 percent fewer visits to the hospital and 47 percent fewer emergency department visits than controls [",
"      <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/18\">",
"       18",
"      </a>",
"      ]. Medication-related readmissions were reduced by 80 percent and the odds of all hospital visits was decreased by 16 percent (OR 0.84, 95% CI 0.72-0.99).",
"     </li>",
"     <li>",
"      A similar randomized in the United States involved a pharmacy-based intervention targeted to high-risk patients 80 years and older [",
"      <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/19\">",
"       19",
"      </a>",
"      ]. Readmission and ED postdischarge visit rates for the intervention group were reduced at 30 days post discharge, but not at 60 days compared to controls.",
"     </li>",
"     <li>",
"      At an academic medical center, patients deemed high risk for an adverse drug event after discharge were randomly assigned to receive no intervention or a pharmacy facilitated discharge, including medication reconciliation, medication education, adherence assessments, and a follow-up phone call at 72 hours and 30 days post-discharge [",
"      <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/20\">",
"       20",
"      </a>",
"      ]. Despite identifying and correcting medication discrepancies at discharge in one-third of patients in the intervention group, there was no difference in rates of readmission or emergency department visits compared to controls.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Medication reconciliation at points of care transitions was adopted as a National Patient Safety Goal for 2006 by The Joint Commission. Though recognized as an important concept in safety, medication reconciliation is hampered by several unresolved operational issues including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Who should perform medication reconciliation (eg, nurse, pharmacist, physician)?",
"     </li>",
"     <li>",
"      How can resources (personnel, systems) be most effectively allocated to perform medication reconciliation, and reimbursement attached to safety-oriented, time-consuming tasks such as medication reconciliation?",
"     </li>",
"     <li>",
"      How should one determine the \"gold standard\" list of medications for individual patients, to use as the basis for reconciliation?",
"     </li>",
"     <li>",
"      How can aftercare providers reliably be informed of medication changes in a timely and accurate fashion?",
"     </li>",
"     <li>",
"      How can patients and",
"      <span class=\"nowrap\">",
"       family/caregivers",
"      </span>",
"      be engaged in understanding the importance of medication reconciliation?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Difficulties with implementation by hospitals led to a subsequent decision to temporarily suspend this requirement for accreditation. In October 2010, a multi-organizational white paper suggested principles of effective medication reconciliation.&nbsp;These core principles were endorsed by multiple agencies including the American Medical Association, the American College of Physicians, the American Association of Critical-Care Nurses, as well as The Joint Commission [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/21\">",
"     21",
"    </a>",
"    ]. Thereafter, The Joint Commission released their updated medication reconciliation standard [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/22\">",
"     22",
"    </a>",
"    ], which is less prescriptive than the earlier version. The standard focuses on patient preparation for the transition, addressing the need for a written list and an explanation about the importance of medication management with the patient or caregiver.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Discharge summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary mode of communication between the hospital care team and aftercare providers is often the discharge summary, raising the importance of successful transmission of this document in a timely fashion. Unfortunately, the discharge summary reaches the primary care provider by the time of the first follow-up visit in only 12 to 34 percent of such visits, and even then often lacks key information [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Important elements in the discharge summary, as mandated by the Centers for Medicare and Medicaid Services, are [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The outcome of the hospitalization",
"     </li>",
"     <li>",
"      The disposition of the patient",
"     </li>",
"     <li>",
"      Provisions for follow-up care including appointments, statements of how care needs will be met, and plans for additional services (eg, hospice, home health assistance, skilled nursing)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This minimal content should be augmented by information critical to the aftercare providers. Utilizing a template for discharge summaries is helpful to ensure inclusion of relevant information [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/25\">",
"     25",
"    </a>",
"    ]. A suggested list of items that should appear in a discharge summary is shown in a table (",
"    <a class=\"graphic graphic_table graphicRef69756 \" href=\"UTD.htm?24/23/24955\">",
"     table 3",
"    </a>",
"    ). An essential component is identifying those laboratory or other tests for which final results remain pending at the time of discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several initiatives involving computer-based innovations to improve the discharge summary process [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/28\">",
"     28",
"    </a>",
"    ] or notification of pending tests at discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/29\">",
"     29",
"    </a>",
"    ] have been explored but issues involving cost and end-user adoption need further consideration. An initiative involving audit and feedback of discharge summaries was successful in improving discharge summary completeness [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/30\">",
"     30",
"    </a>",
"    ]. The Office of the National Coordinator for Health Information Technology (ONC) is supporting a pilot project to develop standardized data sets for transitions of care between acute and post-acute care sites and to measure the impact of those exchanges on healthcare service utilization [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Patient instructions",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the time of discharge, the patient should be provided with a document that includes language and literacy-appropriate instructions and patient education materials to help in successful transition from the hospital.",
"   </p>",
"   <p>",
"    These documents should be brief, focused on critical information to the patient, and primarily directed at what the patient needs to understand to manage his or her condition after discharge.",
"   </p>",
"   <p>",
"    One model for patient materials, developed by the National Patient Safety Foundation, is called Ask Me 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp;1. &nbsp;What is my main problem? (ie, why was I in the hospital?)",
"   </p>",
"   <p>",
"    &nbsp;2. &nbsp;What do I need to do? (ie, how do I manage at home, and what should I do if I run into problems?)",
"   </p>",
"   <p>",
"    &nbsp;3. &nbsp;Why is it important for me to do this?",
"   </p>",
"   <p>",
"    Discharge information, both written and verbal, should be reviewed with the",
"    <span class=\"nowrap\">",
"     patient/family",
"    </span>",
"    caregivers with an emphasis on assessing and ensuring comprehension. Teach back is a technique by which the provider asks the patient or caregiver to explain the recently taught concept in the patient's own words [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/33\">",
"     33",
"    </a>",
"    ]. This technique permits the provider to identify and correct any misunderstandings in real time, with the intent of preventing adverse events related to inadequate comprehension of discharge information. While the teach back method has been validated in teaching a patient a new skill (eg, administering insulin or changing a dressing), teach back has not been studied specifically as a mechanism for reducing readmissions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Discharge checklist",
"    </span>",
"    &nbsp;&mdash;&nbsp;Checklists provide an effective mechanism for ensuring that discharge communications (the discharge summary and direct communication with both aftercare providers and",
"    <span class=\"nowrap\">",
"     patients/families)",
"    </span>",
"    reliably incorporate all key elements. In 2005, a multi-institutional group created a discharge checklist containing a number of elements that are either required or optional during the preparation of the patient for discharge. This checklist has been endorsed by the Society of Hospital Medicine (",
"    <a class=\"graphic graphic_table graphicRef54279 \" href=\"UTD.htm?14/44/15053\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/34\">",
"     34",
"    </a>",
"    ]. Its effectiveness has not been studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     FACTORS CONTRIBUTING TO REHOSPITALIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many hospitalizations are not avoidable. Readmissions may represent progression in the natural history of the patient's underlying disease, a separate problem that is unrelated to the initial admission, or the consequence of patient inability to follow through with a discharge plan (eg, the patient does not fill prescriptions). Additionally, one study using Medicare data for over 200,000&nbsp;heart failure and pneumonia patients&nbsp;found that high initial admission rates for those conditions in patients with similar morbidity were correlated with high rates of readmission and that this factor contributed to more regional variation in readmission rates than other factors including case mix, discharge planning, hospital size, or number of primary care or specialist physicians [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/35\">",
"     35",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    With efforts to decrease length of stay for hospitalized patients over the past two decades, a reasonable concern has been raised that early discharge, if premature, could increase rates of rehospitalization. In an observational study from 129 Veterans Affairs acute care hospitals in the United States, reviewing over 4 million medical admissions from 1997 to 2010 for patients with one of five diagnoses (heart failure, COPD, acute myocardial infarction, community-acquired pneumonia, and GI bleed), a decrease in 30-day readmission rates for all diagnoses (from 16.5 to 13.8 percent) occurred in conjunction with a decrease in length of stay (from 5.44 to 3.98 days) over the 14 years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/36\">",
"     36",
"    </a>",
"    ]. Thus, at least within this hospital system, and given the limitations of an observational study, earlier discharge did not lead to an increase in rehospitalization.",
"   </p>",
"   <p>",
"    Some readmissions are likely preventable [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/37\">",
"     37",
"    </a>",
"    ], although the proportion of rehospitalizations that are preventable is uncertain. A systematic review of 34 studies found that the median proportion of readmissions deemed avoidable was 27 percent, but that variable and subjective criteria to define &ldquo;preventable&rdquo; readmissions led to a wide range of reported rates between studies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several factors that increase the likelihood of rehospitalization may be modifiable, especially those that relate to clinician or system level issues. Such factors include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Premature discharge or inadequate post-discharge support",
"     </li>",
"     <li>",
"      Insufficient follow-up",
"     </li>",
"     <li>",
"      Therapeutic errors",
"     </li>",
"     <li>",
"      Adverse drug events and other medication related issues",
"     </li>",
"     <li>",
"      Failed handoffs",
"     </li>",
"     <li>",
"      Complications following procedures",
"     </li>",
"     <li>",
"      Nosocomial infections, pressure ulcers, and patient falls.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Therapeutic error",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical errors are a major contributor to preventable rehospitalization. Issues related to medication use are a common form of error. Adverse events, most commonly medication-related, have been estimated to occur in approximately 20 percent of patients following discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Approximately two-thirds of such adverse events were determined to be either preventable or ameliorable.",
"   </p>",
"   <p>",
"    Examples of these types of errors include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients sent home without prescriptions for necessary medications",
"     </li>",
"     <li>",
"      Patients receiving duplicate prescriptions for medications they have at home labeled with a different name (eg, generic and proprietary names)",
"     </li>",
"     <li>",
"      Inadequate monitoring and follow-up for drug side effects",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, preventing therapeutic error post-discharge is challenging. In a randomized trial involving two tertiary care hospitals, an intervention involving pharmacist medication reconciliation at hospital discharge, pharmacist counseling, low-literacy aids, and post-discharge follow-up phone calls did not prevent clinically-important medication errors, which occurred in one-half of patients in both control and intervention groups [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/40\">",
"     40",
"    </a>",
"    ]. Almost a quarter of these errors were serious, while 13 percent led to rehospitalization or emergency department visits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Failed handoffs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poor information transfer from hospital-based providers to primary care providers occurs commonly. This may contribute to multiple adverse consequences, including the need for readmission, temporary or permanent disability, or death [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/23,38,39\">",
"     23,38,39",
"    </a>",
"    ]. Tests that are pending at discharge often fail to be communicated to providers responsible for their follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/26,27,41\">",
"     26,27,41",
"    </a>",
"    ]. Representative studies include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 41 percent of discharged patients had a test pending at discharge. Almost one in ten patients potentially required an intervention, but almost two-thirds of responsible aftercare providers were unaware that a test was outstanding [",
"      <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study, tests pending at the time of discharge were mentioned in discharge summaries only 25 percent of the time, and the list of pending studies was complete only 13 percent of the time [",
"      <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tests ordered on the day of discharge represent 7 percent of tests performed during hospitalization but account for 47 percent of tests that are never reviewed; processes are needed to assure review of pending tests [",
"      <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Almost one-third of tests recommended by the hospital-based team for follow-up were never obtained by the after care provider; such tests were recommended for about one quarter of discharged patients [",
"      <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Direct communication from hospital provider to aftercare provider is uncommon, and there are no clear or widely accepted standards about this communication. A meta-analysis revealed that only 12 to 34 percent of discharge summaries had reached aftercare providers by the time of the first post-hospitalization appointment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/23\">",
"     23",
"    </a>",
"    ]. Additionally, discharge documentation was often inaccurate and lacked important information such as noting additional workup indicated following discharge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Absent or delayed follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal time interval between hospital discharge and the first follow-up visit to a primary care or subspecialty provider is unknown. Many factors will contribute to this decision including the severity of the disease process being followed, the perceived ability of the patient to provide adequate self-care, and psychosocial and logistical factors.",
"   </p>",
"   <p>",
"    Several studies have evaluated the association between rates of readmission and scheduled outpatient follow-up post hospitalization. Most studies affirm that patients who are scheduled or seen for posthospital follow-up are less likely to be readmitted [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/39,44-46\">",
"     39,44-46",
"    </a>",
"    ]. Findings include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among Medicare beneficiaries requiring readmission within 30 days of discharge, only 50 percent had seen a clinician for a follow-up visit [",
"      <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study of Medicare patients hospitalized for heart failure in 225 hospitals found that rates of readmission within 30 days were highest for patients discharged from the quartile of hospitals with the lowest percentage of patients seen for early follow-up (within seven days of discharge) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a small prospective study (n=65), follow-up with a primary care physician (PCP) within 30 days of discharge from an inpatient medical service occurred for only 49 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/45\">",
"       45",
"      </a>",
"      ]. Hospital readmission was ten times more likely in those who did not have a follow-up visit, compared to patients who had a timely PCP visit (OR 9.9).",
"     </li>",
"     <li>",
"      In contrast, however, one retrospective study of nearly 5000 hospital discharges from the general medicine service at the Mayo Clinic hospitals found no difference in 30-day hospital admission, emergency department visits, or mortality comparing patients who had documentation of a scheduled follow-up appointment (median six days after discharge) compared with those who did not [",
"      <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/47\">",
"       47",
"      </a>",
"      ]. This study, however, did not document whether those patients had actually attended the follow-up appointments or whether attending the follow-up visit resulted in changes in outcomes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Higher-risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efforts to prevent readmissions can be targeted to patients known to be at a higher risk for readmission, including those at higher risk for adverse events post-discharge. Screening for increased risk may help healthcare providers and organizations target resources to patients most likely to be rehospitalized. However, there are several caveats to this approach:",
"   </p>",
"   <p>",
"    No screening tool will be perfectly accurate. Studies have found that clinical providers are not able to accurately predict which patients will require readmission [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/46\">",
"     46",
"    </a>",
"    ]. Efforts to develop prediction models for patients at high risk for rehospitalization have yielded only fair discriminative ability [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Additionally, in a systematic review of 26 models developed to predict rehospitalization, only one model focused on the prediction of preventable readmissions [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/50\">",
"     50",
"    </a>",
"    ], a concept that is itself fraught with issues regarding the definition of &ldquo;preventability&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Given the variability of resources, patient demographics, and case mix, it will be necessary to adjust risk prediction models for local factors.",
"     </li>",
"     <li>",
"      There will be patients with very advanced disease or complicated social situations for whom no intervention will prevent readmission. Often efforts to decrease hospitalization are most effectively directed towards those patients with intermediate levels of risk for whom interventions might be successful [",
"      <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A guiding principle for using risk assessment is understanding how to implement interventions that target the risks identified.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14129813\">",
"    <span class=\"h3\">",
"     Risk factors for readmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have suggested clinical and demographic parameters that may increase the risk of readmission.",
"   </p>",
"   <p>",
"    Clinical factors include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use of high risk medication (antibiotics, glucocorticoids, anticoagulants, narcotics, antiepileptic medications, antipsychotics, antidepressants, and hypoglycemic agents) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/39,52-56\">",
"       39,52-56",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Polypharmacy (five or more medications) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/57\">",
"       57",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      More than six chronic conditions [",
"      <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/58\">",
"       58",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Specific clinical conditions (eg, advanced COPD, diabetes, heart failure, stroke, cancer, weight loss, depression, and palliative care) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/56,59-67\">",
"       56,59-67",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Demographic and logistical factors include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prior hospitalization, typically including unplanned hospitalizations within the last 6 to 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/68-71\">",
"       68-71",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Black race [",
"      <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/56,72\">",
"       56,72",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Low health literacy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/73\">",
"       73",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Reduced social network indicators like being alone most of the day with limited or no family or friend contact by phone or in person [",
"      <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/71\">",
"       71",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One tool for identifying patients at risk of readmission, the LACE index [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/74\">",
"     74",
"    </a>",
"    ], has similar discriminating ability to other models, although may have some advantage in terms of simplicity. This model incorporates the patients length of stay (L), the acuity of the patients admission (A), the degree of comorbid illness (C) as measured by the Charlson Comorbidity Index, and the number of times the patients has been to the Emergency Department in the last six months (E).",
"   </p>",
"   <p>",
"    Another tool for identifying patients at higher risk for readmission is the",
"    <a class=\"external\" href=\"file://higherlogicdownload.s3.amazonaws.com/HOSPITALMEDICINE/e50d3bc4-44f8-4817-b826-c3f10a65ca30/UploadedImages/TARGET Letter.pdf\">",
"     8Ps Risk Assessment Tool",
"    </a>",
"    , proposed by the Society of Hospital Medicine [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/59\">",
"     59",
"    </a>",
"    ]. The 8Ps Risk Assessment Tool identifies risk factors for adverse events post hospital discharge. The risk factors are similar to those clinical, demographic, and logistical factors described above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14129862\">",
"    <span class=\"h3\">",
"     Discharge against medical advice",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are discharged against medical advice (AMA) are also higher-risk patients. A large retrospective cohort analysis performed at an urban academic medical center demonstrated that patients who were discharged against medical advice had a higher rate of readmission (OR 1.8, 95% CI 1.69-2.01) and also a twofold increased risk of death, compared to those discharged by their physician [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/75\">",
"     75",
"    </a>",
"    ]. Discharge against medical advice was more likely to occur for admissions related to substance abuse, sickle cell disease, or HIV infection.",
"   </p>",
"   <p>",
"    Patients who leave against medical advice should be informed regarding the disease-specific risks associated with premature discharge and the increased risk of death and readmission. Given the difficulty in engaging these patients with the medical community, efforts should be made to arrange appropriate post-hospitalization follow-up, in the hope of facilitating their access to medical care after hospitalization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DISCHARGE AND POST-DISCHARGE INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efforts to re-engineer the discharge process to assure a safe transition involve such issues as improved clinician communication, patient education, IT systems, involvement of community-based providers, and arrangements for prompt follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/76\">",
"     76",
"    </a>",
"    ]. Such interventions have the potential to substantially improve patient care and reduce healthcare expenditures.",
"   </p>",
"   <p>",
"    Researchers involved in the expanding field of Transitions of Care (TOC) are evaluating the effectiveness of various approaches to improving the discharge process. One classification scheme to categorize these interventions is to consider them as: predischarge interventions (patient education, discharge planning, medication reconciliation, scheduling a follow-up appointment); postdischarge interventions (follow-up phone call, communication with ambulatory provider, home visits); and bridging interventions (transition coaches, patient-centered discharge instructions), physician continuity between inpatient and outpatient settings [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/76\">",
"     76",
"    </a>",
"    ]. Several predischarge interventions (discharge planning, medication reconciliation, templated discharge summaries, and discharge checklists) are discussed above. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Elements of the discharge process'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A 2011 systematic review of interventions to reduce rehospitalization identified 43 relevant studies, 16 of which were randomized trials and the remainder observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/76\">",
"     76",
"    </a>",
"    ]. Most involved small numbers of patients (only two included more than 400 patients), and many studies had quality limitations, including incomplete data and the possibility of unrecorded rehospitalization at another institution, estimated to miss 20 percent of such events. Only 5 of the 16 randomized trials demonstrated significant improvement in rehospitalization rates, and four of the five successful studies involved several simultaneous interventions, including patient-centered discharge instructions and a postdischarge telephone call. A 2012 systematic review of interventions at the time of discharge found that many types of interventions (including medication reconciliation, structured electronic discharge summaries, discharge planning, and facilitated communication between hospital and community providers) impacted favorably on outcomes including rehospitalization rates, patient satisfaction, and continuity of care [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/77\">",
"     77",
"    </a>",
"    ]. Due to heterogeneity in interventions, patient populations, and outcomes, it was not possible to identify which specific interventions had direct impact on measured outcomes. Notably, 26 of the 36 interventions investigated involved transitional care managers. Consistent with previous studies, the successful interventions noted in this review overwhelmingly involved multifaceted interventions, suggesting that reducing adverse events after discharge requires a multipronged approach.",
"   </p>",
"   <p>",
"    Many multidisciplinary initiatives, known as disease management programs, have targeted patients with specific chronic diseases, to provide patient support, counseling, monitoring, and medication oversight through the continuum of care, including ambulatory, hospital, and hospital discharge settings. Disease management programs involving patients with heart failure are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37929?source=see_link\">",
"     \"Strategies to reduce hospitalizations in patients with heart failure\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Telephone call",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have looked at the impact of a telephone call from a member of the health care team following discharge on varying parameters of patient management. These calls have been initiated by various members of the care team, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The discharging clinician",
"     </li>",
"     <li>",
"      A clinical pharmacist",
"     </li>",
"     <li>",
"      A clinician from the patient's primary care clinic",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Such calls have been moderately effective at reducing emergency department visits [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/78\">",
"     78",
"    </a>",
"    ] and improving follow-up with ambulatory providers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/79\">",
"     79",
"    </a>",
"    ], but demonstrated a trend towards reduced hospital readmissions in only one study [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/78\">",
"     78",
"    </a>",
"    ]. A 2006 systematic review was unable to define a clear benefit from this type of intervention due to significant heterogeneity in the quality and design of this literature [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/80\">",
"     80",
"    </a>",
"    ]. Interestingly, the optimal origin of the post-discharge telephone follow-up (hospital based or ambulatory based) is also unknown. A systematic review of the literature examining the effect of a telephone follow-up initiated by the primary care provider showed no change in readmission rates but the intervention did improve rates of post-discharge follow-up with the primary care practice [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Home visits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Home visits made by a number of different types of providers have been shown to reduce need for rehospitalization. One trial illustrated that a single home visit by a nurse and pharmacist to patients discharged with a diagnosis of heart failure, with a goal of optimizing medication management, showed a trend towards almost a 50 percent reduced risk of unplanned readmission [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/82\">",
"     82",
"    </a>",
"    ]. Other studies looking at this question did not have as dramatic an effect on reduction in rehospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/83,84\">",
"     83,84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Telemonitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of telemonitoring devices have also been studied as a means for reducing readmissions. As an example, using an integrated telephonic stethoscope in conjunction with follow-up nursing calls in patients with heart failure reduced emergency department visits in one small study, and demonstrated a trend toward reduced readmissions and overall costs [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/85\">",
"     85",
"    </a>",
"    ]. Devices for remotely monitoring various physiologic variables, including blood pressure, heart rate, weight, and oxygen saturation have been repeatedly studied, mostly among heart failure patients, and have demonstrated variable effectiveness in reducing need for readmission [",
"    <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Multiple interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the complexity of transitions of care associated with hospital discharge, several groups have developed and evaluated programs incorporating multiple initiatives to address many elements in the discharge process. Examples of such programs include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized controlled trial at a large academic safety net hospital evaluated a multidisciplinary team effort that included the following intervention [",
"      <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/87\">",
"       87",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A nurse discharge advocate to assist with discharge planning and preparation",
"     </li>",
"     <li>",
"      A clinical pharmacist to call the patient two to four days following hospital discharge, to review the medication list, address any medication questions or concerns, reinforce the plan, and assess for adverse effects related to medications",
"     </li>",
"     <li>",
"      Follow-up appointments scheduled at times convenient to the patient",
"     </li>",
"     <li>",
"      Medication reconciliation",
"     </li>",
"     <li>",
"      A low literacy discharge instruction booklet for patients, also provided to the primary care clinician",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Post discharge, the rate of hospital utilization (emergency department visits or hospital readmissions) was 31 percent for the intervention group compared to 44 percent for the control group. Patients in the intervention group were also more likely to follow-up with their primary care provider.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Another study evaluated the Care Transitions Intervention (CTI) program in which older patients were paired with a nurse transition coach at the time of the discharge. The role of the Transition Coach was to facilitate patient self-management (or management by a family care giver) rather than provide direct care [",
"      <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/88\">",
"       88",
"      </a>",
"      ]. The coach encouraged the patient to maintain a personal health record, to obtain timely follow-up appointments, to provide self-care, and to understand what to do should problems arise. The transition coach met with the patient prior to discharge and at home two to three days after discharge, followed by three telephone calls over the first 28 days post discharge. This intervention reduced 30 and 90 day rehospitalization rates (8.3 versus 11.9 percent and 16.7 versus 22.5 percent, respectively) with a cost savings of approximately",
"      <span class=\"nowrap\">",
"       $500/case.",
"      </span>",
"     </li>",
"     <li>",
"      Components of the CTI program were implemented in the &ldquo;real-world&rdquo; setting of a sample of fee-for-service English-speaking Medicare patients being discharged home for specific cardiac or respiratory conditions from six hospitals in Rhode Island [",
"      <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/89\">",
"       89",
"      </a>",
"      ]. Readmission rates within 30 days were lower for patients who received coaching compared to data from Medicare claims of an &ldquo;external control group&rdquo; of discharged patients with similar diagnoses who were not offered the intervention (OR 0.61, 95% CI 0.42-0.88). Readmission rates for patients who either declined the program or were lost to follow-up before a home visit were no different than for the external control group. Overall, 55 percent of patients who were approached accepted participation and there was a 75 percent attrition rate for home visit participation.",
"     </li>",
"     <li>",
"      Another intervention assigned transitional care partners (advanced practice nurses) to 239 elderly heart failure patients, a subset of patients with very high rehospitalization risk [",
"      <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/90\">",
"       90",
"      </a>",
"      ]. The designated partner met with the patient daily during the index visit, made a home visit the day after discharge and at least weekly thereafter over the first three months, with one of the visits corresponding to the first follow-up visit to the patient's clinician. In a randomized trial, at one year, there were 104 readmissions among intervention patients, compared with 162 readmissions for control patients, resulting in a cost savings of $4845 per patient.",
"     </li>",
"     <li>",
"      A prospective study of a nurse-led transitional care program for patients with heart failure being discharged from one US hospital compared 30-day readmissions, length of stay, and 60 day direct costs with heart failure patients concurrently discharged from other hospitals within the same healthcare system [",
"      <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/91\">",
"       91",
"      </a>",
"      ]. The program was associated with a 48 percent decrease in 30 day readmissions but had little impact on direct costs to the healthcare system over 60 days, and under the existing Medicare reimbursement system had a negative impact on hospital revenue.",
"     </li>",
"     <li>",
"      A randomized trial in six geriatric inpatient units in France evaluated the effect of a multimodal intervention (comprehensive medication review; self-management education focusing on medications, depression, and nutrition; and detailed communication around transition-of-care) on rehospitalization [",
"      <a class=\"abstract\" href=\"UTD.htm?12/2/12330/abstract/92\">",
"       92",
"      </a>",
"      ]. Rates for rehospitalization and ED visits were lower at three months (a secondary outcome), but not at six months (the primary outcome), for the group assigned to the intervention. The intervention included implementation by a geriatrician dedicated to the project, and thus might not be readily reproducible outside of the research project.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     CLINICIAN RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several program initiatives are underway to investigate and facilitate interventions to promote improved hospital discharge processes. These programs and their websites include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The National Transitions of Care Coalition (",
"      <a class=\"external\" href=\"file://www.ntocc.org/\">",
"       www.ntocc.org",
"      </a>",
"      ) &mdash; This site offers tool and resources for both patients and providers to help improve the safety of healthcare transitions. Many of the tools are offered in languages other than English.",
"     </li>",
"     <li>",
"      The Institute for Healthcare Improvement (",
"      <a class=\"external\" href=\"file://www.ihi.org/\">",
"       www.ihi.org",
"      </a>",
"      ) &mdash; This site contains numerous resources about care transitions, as well as other quality-related components of healthcare in the United States.",
"     </li>",
"     <li>",
"      The Care Transitions Program (",
"      <a class=\"external\" href=\"file://www.caretransitions.org/\">",
"       www.caretransitions.org",
"      </a>",
"      ) &mdash; This site contains information about the Care Transitions Programs, and contains tools for implementing this program, discusses policy implications surrounding care transitions, and information about personal health records. Some features are translated into Spanish and Russian.",
"     </li>",
"     <li>",
"      Project BOOST (Society of Hospital Medicine) (",
"      <a class=\"external\" href=\"file://www.hospitalmedicine.org/BOOST\">",
"       www.hospitalmedicine.org/BOOST",
"      </a>",
"      ) &mdash; A step by step guide for implementing Project BOOST (Better Outcomes through Optimizing Safe Transitions). The site also offers extensive information about quality improvement practices.",
"     </li>",
"     <li>",
"      Project RED (Re-Engineered Discharge) (",
"      <a class=\"external\" href=\"file://www.ahrq.gov/professionals/systems/hospital/red/index.html\">",
"       www.ahrq.gov/professionals/systems/hospital/red/index.html",
"      </a>",
"      ) (",
"      <a class=\"external\" href=\"file://www.bu.edu/fammed/projectred/\">",
"       www.bu.edu/fammed/projectred/",
"      </a>",
"      ) &mdash; Information on the key concepts and primary tools that are the foundation for the National Quality Forum's National Patient Safety Goal on safe discharge. Their toolkit is also available (",
"      <a class=\"external\" href=\"file://www.ahrq.gov/professionals/systems/hospital/red/toolkit/index.html\">",
"       www.ahrq.gov/professionals/systems/hospital/red/toolkit/index.html",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The Care Transitions Quality Improvement Support Center (",
"      <a class=\"external\" href=\"file://www.cfmc.org/caretransitions/\">",
"       www.cfmc.org/caretransitions/",
"      </a>",
"      ) &mdash; This site is oriented toward Medicare Quality Improvement Organizations (QIOs) and also contains links for patients and providers to useful resources regarding care transitions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/16/34050?source=see_link\">",
"       \"Patient information: Going home from the hospital (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The decision whether or not a hospitalized patient is appropriate for discharge requires evaluation of multiple factors involving medical, as well as psychosocial, logistic, and economic considerations. Instruments for determining suitability for discharge that have been appropriately validated are not available. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Appropriateness for discharge'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The need for ongoing hospitalization is determined by the clinical condition and need for ongoing diagnostic or therapeutic interventions. Multiple logistic factors beyond these clinical considerations will determine if the patient is safe to be discharged home, or requires another setting. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Determining the post-discharge site of care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Discharge planning should involve the clinical staff and",
"      <span class=\"nowrap\">",
"       patient/family",
"      </span>",
"      caregivers to develop a patient-centered plan. Critical elements in successful discharge transitions include performing an accurate reconciliation of medications, establishing timely follow-up, and developing an appropriately detailed discharge summary that is communicated to aftercare providers in a timely fashion. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Elements of the discharge process'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Avoidable rehospitalizations may be related to therapeutic errors and failed handoffs. Identifying patients at increased risk for post-discharge adverse events and rehospitalization can help target interventions to minimize this risk. Identifying systems issues which contribute to failed discharge transitions may shed light on opportunities to improve the safety of the discharge process for all patients. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Factors contributing to rehospitalization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several systems initiatives have shown promise in minimizing rehospitalizations. These interventions include improved collaboration between the care team, patient, and aftercare provider prior to discharge; medication reconciliation; enhanced patient education and empowerment; home visits or telephone calls by clinical providers; remote monitoring; transitional care managers; and early post-discharge follow up. Patient instructions should take into account the patient's cognitive status, health literacy, and other barriers to self-care. Multiple concurrent interventions may be more effective than single components. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Discharge and post-discharge interventions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Healthcare Cost and Utilization Project net. Available at: file://hcupnet.ahrq.gov/ (Accessed on September 29, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/2\">",
"      Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med 2009; 360:1418.",
"     </a>",
"    </li>",
"    <li>",
"     Medicare &amp; Medicaid Statistical Supplement. Baltimore: Centers for Medicare &amp; Medicaid Services, 2007. Available at: www.cms.hhs.gov/MedicareMedicaidStatSupp/downloads/2007Table5.1b.pdf (Accessed on September 29, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/4\">",
"      van Walraven C, Bennett C, Jennings A, et al. Proportion of hospital readmissions deemed avoidable: a systematic review. CMAJ 2011; 183:E391.",
"     </a>",
"    </li>",
"    <li>",
"     www.whitehouse.gov/omb/assets/fy2010_new_era/jumpstarting_the_economy.pdf (Accessed on April 06, 2010).",
"    </li>",
"    <li>",
"     Centers for Medicare &amp; Medicaid Services. Readmissions Reduction Program. Available at: file://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Readmissions-Reduction-Program.html (Accessed on December 11, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/7\">",
"      Kuo YF, Goodwin JS. Association of hospitalist care with medical utilization after discharge: evidence of cost shift from a cohort study. Ann Intern Med 2011; 155:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/8\">",
"      Kane RL. Finding the right level of posthospital care: \"We didn't realize there was any other option for him\". JAMA 2011; 305:284.",
"     </a>",
"    </li>",
"    <li>",
"     Healthcare Costs and Utilization Project. file://www.hcup-us.ahrq.gov/reports/factsandfigures/2007/exhibit1_4.jsp (Accessed on September 29, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/10\">",
"      Siebens H. Applying the domain management model in treating patients with chronic diseases. Jt Comm J Qual Improv 2001; 27:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/11\">",
"      Kahn JM, Benson NM, Appleby D, et al. Long-term acute care hospital utilization after critical illness. JAMA 2010; 303:2253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/12\">",
"      Shepperd S, McClaran J, Phillips CO, et al. Discharge planning from hospital to home. Cochrane Database Syst Rev 2010; :CD000313.",
"     </a>",
"    </li>",
"    <li>",
"     The Joint Commission Comprehensive Accreditation Manual for Hospitals. Chicago. file://e-dition.jcrinc.com/Frame.aspx (Accessed on April 19, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/14\">",
"      Meyer MH, Jekowsky E, Crane FG. Applying platform design to improve the integration of patient services across the continuum of care. Managing Service Quality 2007; 17:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/15\">",
"      Jha AK, Orav EJ, Epstein AM. Public reporting of discharge planning and rates of readmissions. N Engl J Med 2009; 361:2637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/16\">",
"      Ziaeian B, Araujo KL, Van Ness PH, Horwitz LI. Medication reconciliation accuracy and patient understanding of intended medication changes on hospital discharge. J Gen Intern Med 2012; 27:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/17\">",
"      Mueller SK, Sponsler KC, Kripalani S, Schnipper JL. Hospital-based medication reconciliation practices: a systematic review. Arch Intern Med 2012; 172:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/18\">",
"      Gillespie U, Alassaad A, Henrohn D, et al. A comprehensive pharmacist intervention to reduce morbidity in patients 80 years or older: a randomized controlled trial. Arch Intern Med 2009; 169:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/19\">",
"      Koehler BE, Richter KM, Youngblood L, et al. Reduction of 30-day postdischarge hospital readmission or emergency department (ED) visit rates in high-risk elderly medical patients through delivery of a targeted care bundle. J Hosp Med 2009; 4:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/20\">",
"      Walker PC, Bernstein SJ, Jones JN, et al. Impact of a pharmacist-facilitated hospital discharge program: a quasi-experimental study. Arch Intern Med 2009; 169:2003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/21\">",
"      Greenwald JL, Halasyamani L, Greene J, et al. Making inpatient medication reconciliation patient centered, clinically relevant and implementable: a consensus statement on key principles and necessary first steps. J Hosp Med 2010; 5:477.",
"     </a>",
"    </li>",
"    <li>",
"     The Joint Commission. National Patient Safety Goal on Reconciling Medication Information. www.jointcommission.org/npsg_reconciling_medication/ (Accessed on February 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/23\">",
"      Kripalani S, LeFevre F, Phillips CO, et al. Deficits in communication and information transfer between hospital-based and primary care physicians: implications for patient safety and continuity of care. JAMA 2007; 297:831.",
"     </a>",
"    </li>",
"    <li>",
"     The CMS Hospital Conditions of Participation and Interpretive Guidelines, McDonald IG (Ed), HC Pro Inc, 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/25\">",
"      O'Leary KJ, Liebovitz DM, Feinglass J, et al. Creating a better discharge summary: improvement in quality and timeliness using an electronic discharge summary. J Hosp Med 2009; 4:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/26\">",
"      Roy CL, Poon EG, Karson AS, et al. Patient safety concerns arising from test results that return after hospital discharge. Ann Intern Med 2005; 143:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/27\">",
"      Walz SE, Smith M, Cox E, et al. Pending laboratory tests and the hospital discharge summary in patients discharged to sub-acute care. J Gen Intern Med 2011; 26:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/28\">",
"      Mourad M, Cucina R, Ramanathan R, Vidyarthi AR. Addressing the business of discharge: building a case for an electronic discharge summary. J Hosp Med 2011; 6:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/29\">",
"      Dalal AK, Poon EG, Karson AS, et al. Lessons learned from implementation of a computerized application for pending tests at hospital discharge. J Hosp Med 2011; 6:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/30\">",
"      Dinescu A, Fernandez H, Ross JS, Karani R. Audit and feedback: an intervention to improve discharge summary completion. J Hosp Med 2011; 6:28.",
"     </a>",
"    </li>",
"    <li>",
"     S&amp;I Framework. Longitudinal Coordination of Care. Available at: file://wiki.siframework.org/Longitudinal+Coordination+of+Care (Accessed on December 11, 2012).",
"    </li>",
"    <li>",
"     www.npsf.org/askme3 (Accessed on April 06, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/33\">",
"      Schillinger D, Piette J, Grumbach K, et al. Closing the loop: physician communication with diabetic patients who have low health literacy. Arch Intern Med 2003; 163:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/34\">",
"      Halasyamani L, Kripalani S, Coleman E, et al. Transition of care for hospitalized elderly patients--development of a discharge checklist for hospitalists. J Hosp Med 2006; 1:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/35\">",
"      Epstein AM, Jha AK, Orav EJ. The relationship between hospital admission rates and rehospitalizations. N Engl J Med 2011; 365:2287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/36\">",
"      Kaboli PJ, Go JT, Hockenberry J, et al. Associations between reduced hospital length of stay and 30-day readmission rate and mortality: 14-year experience in 129 Veterans Affairs hospitals. Ann Intern Med 2012; 157:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/37\">",
"      Benbassat J, Taragin M. Hospital readmissions as a measure of quality of health care: advantages and limitations. Arch Intern Med 2000; 160:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/38\">",
"      Forster AJ, Murff HJ, Peterson JF, et al. The incidence and severity of adverse events affecting patients after discharge from the hospital. Ann Intern Med 2003; 138:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/39\">",
"      Forster AJ, Clark HD, Menard A, et al. Adverse events among medical patients after discharge from hospital. CMAJ 2004; 170:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/40\">",
"      Kripalani S, Roumie CL, Dalal AK, et al. Effect of a pharmacist intervention on clinically important medication errors after hospital discharge: a randomized trial. Ann Intern Med 2012; 157:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/41\">",
"      Were MC, Li X, Kesterson J, et al. Adequacy of hospital discharge summaries in documenting tests with pending results and outpatient follow-up providers. J Gen Intern Med 2009; 24:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/42\">",
"      Ong MS, Magrabi F, Jones G, Coiera E. Last Orders: Follow-up of Tests Ordered on the Day of Hospital Discharge. Arch Intern Med 2012; 172:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/43\">",
"      Moore C, McGinn T, Halm E. Tying up loose ends: discharging patients with unresolved medical issues. Arch Intern Med 2007; 167:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/44\">",
"      Hernandez AF, Greiner MA, Fonarow GC, et al. Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. JAMA 2010; 303:1716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/45\">",
"      Misky GJ, Wald HL, Coleman EA. Post-hospitalization transitions: Examining the effects of timing of primary care provider follow-up. J Hosp Med 2010; 5:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/46\">",
"      Sharma G, Kuo YF, Freeman JL, et al. Outpatient follow-up visit and 30-day emergency department visit and readmission in patients hospitalized for chronic obstructive pulmonary disease. Arch Intern Med 2010; 170:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/47\">",
"      Grafft CA, McDonald FS, Ruud KL, et al. Effect of hospital follow-up appointment on clinical event outcomes and mortality. Arch Intern Med 2010; 170:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/48\">",
"      Hasan O, Meltzer DO, Shaykevich SA, et al. Hospital readmission in general medicine patients: a prediction model. J Gen Intern Med 2010; 25:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/49\">",
"      Kansagara D, Englander H, Salanitro A, et al. Risk prediction models for hospital readmission: a systematic review. JAMA 2011; 306:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/50\">",
"      Halfon P, Eggli Y, Pr&ecirc;tre-Rohrbach I, et al. Validation of the potentially avoidable hospital readmission rate as a routine indicator of the quality of hospital care. Med Care 2006; 44:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/51\">",
"      Lindquist LA, Baker DW. Understanding preventable hospital readmissions: masqueraders, markers, and true causal factors. J Hosp Med 2011; 6:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/52\">",
"      Forster AJ, Murff HJ, Peterson JF, et al. Adverse drug events occurring following hospital discharge. J Gen Intern Med 2005; 20:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/53\">",
"      Budnitz DS, Shehab N, Kegler SR, Richards CL. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med 2007; 147:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/54\">",
"      Budnitz DS, Pollock DA, Weidenbach KN, et al. National surveillance of emergency department visits for outpatient adverse drug events. JAMA 2006; 296:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/55\">",
"      van Walraven C, Forster AJ. Anticoagulation control in the peri-hospitalization period. J Gen Intern Med 2007; 22:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/56\">",
"      Allaudeen N, Vidyarthi A, Maselli J, Auerbach A. Redefining readmission risk factors for general medicine patients. J Hosp Med 2011; 6:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/57\">",
"      Campbell SE, Seymour DG, Primrose WR, ACMEPLUS Project. A systematic literature review of factors affecting outcome in older medical patients admitted to hospital. Age Ageing 2004; 33:110.",
"     </a>",
"    </li>",
"    <li>",
"     Medicare Hospital Quality Chartbook 2012 www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Downloads/MedicareHospitalQualityChartbook2012.pdf (Accessed on March 25, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/59\">",
"      Kim CS, Flanders SA. Transitions of care. Ann Intern Med 2013; 158:ITC3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/60\">",
"      B&uuml;la CJ, Wietlisbach V, Burnand B, Yersin B. Depressive symptoms as a predictor of 6-month outcomes and services utilization in elderly medical inpatients. Arch Intern Med 2001; 161:2609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/61\">",
"      Kartha A, Anthony D, Manasseh CS, et al. Depression is a risk factor for rehospitalization in medical inpatients. Prim Care Companion J Clin Psychiatry 2007; 9:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/62\">",
"      Strunin L, Stone M, Jack B. Understanding rehospitalization risk: can hospital discharge be modified to reduce recurrent hospitalization? J Hosp Med 2007; 2:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/63\">",
"      Ng TP, Niti M, Tan WC, et al. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med 2007; 167:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/64\">",
"      Phillips CO, Wright SM, Kern DE, et al. Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis. JAMA 2004; 291:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/65\">",
"      Gwadry-Sridhar FH, Flintoft V, Lee DS, et al. A systematic review and meta-analysis of studies comparing readmission rates and mortality rates in patients with heart failure. Arch Intern Med 2004; 164:2315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/66\">",
"      Coleman EA, Wagner EH, Grothaus LC, et al. Predicting hospitalization and functional decline in older health plan enrollees: are administrative data as accurate as self-report? J Am Geriatr Soc 1998; 46:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/67\">",
"      Mudge AM, Kasper K, Clair A, et al. Recurrent readmissions in medical patients: a prospective study. J Hosp Med 2011; 6:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/68\">",
"      Billings J, Dixon J, Mijanovich T, Wennberg D. Case finding for patients at risk of readmission to hospital: development of algorithm to identify high risk patients. BMJ 2006; 333:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/69\">",
"      Comette P, D'Hoore W, Malhomme B, et al. Differential risk factors for early and later hospital readmission of older patients. Aging Clin Exp Res 2005; 17:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/70\">",
"      Smith DM, Giobbie-Hurder A, Weinberger M, et al. Predicting non-elective hospital readmissions: a multi-site study. Department of Veterans Affairs Cooperative Study Group on Primary Care and Readmissions. J Clin Epidemiol 2000; 53:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/71\">",
"      Rodr&iacute;guez-Artalejo F, Guallar-Castill&oacute;n P, Herrera MC, et al. Social network as a predictor of hospital readmission and mortality among older patients with heart failure. J Card Fail 2006; 12:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/72\">",
"      Joynt KE, Orav EJ, Jha AK. Thirty-day readmission rates for Medicare beneficiaries by race and site of care. JAMA 2011; 305:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/73\">",
"      Baker DW, Gazmararian JA, Williams MV, et al. Functional health literacy and the risk of hospital admission among Medicare managed care enrollees. Am J Public Health 2002; 92:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/74\">",
"      van Walraven C, Dhalla IA, Bell C, et al. Derivation and validation of an index to predict early death or unplanned readmission after discharge from hospital to the community. CMAJ 2010; 182:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/75\">",
"      Southern WN, Nahvi S, Arnsten JH. Increased risk of mortality and readmission among patients discharged against medical advice. Am J Med 2012; 125:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/76\">",
"      Hansen LO, Young RS, Hinami K, et al. Interventions to reduce 30-day rehospitalization: a systematic review. Ann Intern Med 2011; 155:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/77\">",
"      Hesselink G, Schoonhoven L, Barach P, et al. Improving patient handovers from hospital to primary care: a systematic review. Ann Intern Med 2012; 157:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/78\">",
"      Dudas V, Bookwalter T, Kerr KM, Pantilat SZ. The impact of follow-up telephone calls to patients after hospitalization. Am J Med 2001; 111:26S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/79\">",
"      Balaban RB, Weissman JS, Samuel PA, Woolhandler S. Redefining and redesigning hospital discharge to enhance patient care: a randomized controlled study. J Gen Intern Med 2008; 23:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/80\">",
"      Mistiaen P, Poot E. Telephone follow-up, initiated by a hospital-based health professional, for postdischarge problems in patients discharged from hospital to home. Cochrane Database Syst Rev 2006; :CD004510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/81\">",
"      Crocker JB, Crocker JT, Greenwald JL. Telephone follow-up as a primary care intervention for postdischarge outcomes improvement: a systematic review. Am J Med 2012; 125:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/82\">",
"      Stewart S, Pearson S, Horowitz JD. Effects of a home-based intervention among patients with congestive heart failure discharged from acute hospital care. Arch Intern Med 1998; 158:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/83\">",
"      Rogers J, Perlic M, Madigan EA. The effect of frontloading visits on patient outcomes. Home Healthc Nurse 2007; 25:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/84\">",
"      Crossen-Sills J, Toomey I, Doherty M. Strategies to reduce unplanned hospitalizations of home healthcare patients: a STEP-BY-STEP APPROACH. Home Healthc Nurse 2006; 24:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/85\">",
"      Jerant AF, Azari R, Nesbitt TS. Reducing the cost of frequent hospital admissions for congestive heart failure: a randomized trial of a home telecare intervention. Med Care 2001; 39:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/86\">",
"      Chaudhry SI, Phillips CO, Stewart SS, et al. Telemonitoring for patients with chronic heart failure: a systematic review. J Card Fail 2007; 13:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/87\">",
"      Jack BW, Chetty VK, Anthony D, et al. A reengineered hospital discharge program to decrease rehospitalization: a randomized trial. Ann Intern Med 2009; 150:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/88\">",
"      Coleman EA, Parry C, Chalmers S, Min SJ. The care transitions intervention: results of a randomized controlled trial. Arch Intern Med 2006; 166:1822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/89\">",
"      Voss R, Gardner R, Baier R, et al. The care transitions intervention: translating from efficacy to effectiveness. Arch Intern Med 2011; 171:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/90\">",
"      Naylor MD, Brooten DA, Campbell RL, et al. Transitional care of older adults hospitalized with heart failure: a randomized, controlled trial. J Am Geriatr Soc 2004; 52:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/91\">",
"      Stauffer BD, Fullerton C, Fleming N, et al. Effectiveness and cost of a transitional care program for heart failure: a prospective study with concurrent controls. Arch Intern Med 2011; 171:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/2/12330/abstract/92\">",
"      Legrain S, Tubach F, Bonnet-Zamponi D, et al. A new multimodal geriatric discharge-planning intervention to prevent emergency visits and rehospitalizations of older adults: the optimization of medication in AGEd multicenter randomized controlled trial. J Am Geriatr Soc 2011; 59:2017.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2790 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-629A639819-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_2_12330=[""].join("\n");
var outline_f12_2_12330=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      APPROPRIATENESS FOR DISCHARGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Need for ongoing hospitalization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DETERMINING THE POST-DISCHARGE SITE OF CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Discharge home",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Discharge to another care facility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Types of care facilities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ELEMENTS OF THE DISCHARGE PROCESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Discharge planning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Medication reconciliation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Discharge summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Patient instructions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Discharge checklist",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      FACTORS CONTRIBUTING TO REHOSPITALIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Therapeutic error",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Failed handoffs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Absent or delayed follow-up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Higher-risk patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14129813\">",
"      - Risk factors for readmission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14129862\">",
"      - Discharge against medical advice",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DISCHARGE AND POST-DISCHARGE INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Telephone call",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Home visits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Telemonitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Multiple interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      CLINICIAN RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/2790\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2790|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/20/43340\" title=\"table 1\">",
"      Patient need at discharge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/10/30893\" title=\"table 2\">",
"      Types post-acute care facil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/23/24955\" title=\"table 3\">",
"      Discharge summary contents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/44/15053\" title=\"table 4\">",
"      Discharge checklist",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/16/34050?source=related_link\">",
"      Patient information: Going home from the hospital (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37929?source=related_link\">",
"      Strategies to reduce hospitalizations in patients with heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_2_12331="Cancer deaths in women 1996";
var content_f12_2_12331=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F82580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F82580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Estimated cancer deaths for United States women in 2012",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Site",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of deaths",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent of cancer deaths",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lung",
"       </td>",
"       <td>",
"        72,590",
"       </td>",
"       <td>",
"        26 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breast",
"       </td>",
"       <td>",
"        39,510",
"       </td>",
"       <td>",
"        14 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colon and rectum",
"       </td>",
"       <td>",
"        25,220",
"       </td>",
"       <td>",
"        9&nbsp;percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukemia and lymphomas",
"       </td>",
"       <td>",
"        19,180",
"       </td>",
"       <td>",
"        7 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ovary",
"       </td>",
"       <td>",
"        15,500",
"       </td>",
"       <td>",
"        6 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Siegel R, et al. CA-Cancer Journal for Clinicians 2012; 62:10.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_2_12331=[""].join("\n");
var outline_f12_2_12331=null;
var title_f12_2_12332="ESC treatment catechol poly VT";
var content_f12_2_12332=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    European Society of Cardiology recommendations for prevention of sudden cardiac death: catecholaminergic polymorphic ventricular tachycardia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Recommendation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Primary",
"prevention",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Beta-blockers",
"       </td>",
"       <td>",
"        Class IIa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Implantable cardioverter defibrillator (ICD)",
"       </td>",
"       <td>",
"        Class IIb",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Secondary prevention",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        ICD (plus beta-blockers)",
"       </td>",
"       <td>",
"        Class I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Beta-blockers",
"       </td>",
"       <td>",
"        Class IIa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\" rowspan=\"1\">",
"        Classification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class I:",
"        </strong>",
"        Conditions for which there is evidence and/or",
"general agreement that a given procedure or treatment is",
"useful and effective.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class II:",
"        </strong>",
"        Conditions for which there is conflicting",
"evidence and/or a divergence of opinion about the",
"usefulness/efficacy of a procedure or treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class IIa:",
"        </strong>",
"        Weight of evidence/opinion is in favor of",
"usefulness/efficacy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class",
"IIb:",
"        </strong>",
"        Usefulness/efficacy less well established by",
"evidence/opinion.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class",
"III:",
"        </strong>",
"        Conditions for which there is evidence and/or",
"general agreement that the procedure/treatment is not useful and in",
"some cases may be harmful.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Priori, SG, Aliot, E, Blomstrom-Lundqvist, C, et al, Eur Heart J 2001; 22:1374.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_2_12332=[""].join("\n");
var outline_f12_2_12332=null;
var title_f12_2_12333="Age-specific counseling to prevent smoking initiation";
var content_f12_2_12333=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Counseling about the health effects of smoking in different age groups",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Most compelling information",
"       </td>",
"       <td class=\"subtitle1\">",
"        Secondary information",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        <strong>",
"         Parent",
"        </strong>",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Effects of secondhand smoke on their children and other household members",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Personal health risks (emphasize those with personal relevance)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Higher rates of asthma, colds, pneumonia, and ear infections, even if parents do not smoke in the house",
"        </p>",
"        <p>",
"         Increases rates of heart disease in the long term",
"        </p>",
"        <p>",
"         Children are much more likely to become smokers if their parents smoke, even if parents tell children not to start",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Heart disease: chance of heart attack is 3 to 6 times higher in smokers",
"        </p>",
"        <p>",
"         Lung cancer: chance of getting lung cancer is up to 30 times higher in smokers",
"        </p>",
"        <p>",
"         Other cancers: smoking increases the risk for at least 10 types of cancer, including kidney, liver, lung, pancreas, stomach, and cervix",
"        </p>",
"        <p>",
"         Other lung disease: smoking increases asthma, bronchitis, pneumonia, chronic cough",
"        </p>",
"        <p>",
"         Other: smoking increases risk for infertility, premature birth, ulcers, osteoporosis, and diabetes",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         School age",
"        </strong>",
"        <br/>",
"        (5 to 11 years)",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Immediate effects of smoking",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Long-term or less concrete consequences",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Bad breath and smell",
"        </p>",
"        <p>",
"         Yellow teeth",
"        </p>",
"        <p>",
"         Harder to keep up in sports",
"        </p>",
"        <p>",
"         Even trying smoking just a few times can get your body hooked so that it is harder to stop",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Cigarettes are expensive. Smokers spend money on cigarettes that they could use for more fun things.",
"        </p>",
"        <p>",
"         Tobacco companys use ads to try to trick you into thinking that smoking is cool and safe",
"        </p>",
"        <p>",
"         Smoking has long-term effects on health, including several types of cancer, and heart attacks",
"        </p>",
"        <p>",
"         It is illegal to buy cigarettes when you are under-age",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"6\">",
"        <strong>",
"         Adolescent",
"        </strong>",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Immediate effects of smoking",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Long-term health consequences",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        <p>",
"         Cosmetic effects (smell, bad breath, yellow teeth, early wrinkles)",
"        </p>",
"        <p>",
"         Reduced endurance and athletic performance",
"        </p>",
"        <p>",
"         More hacking coughs, colds and pneumonias",
"        </p>",
"        <p>",
"         Smoking does not&nbsp;cause&nbsp;weight loss in teens",
"        </p>",
"        <p>",
"         You can get addicted to tobacco after smoking as few as 100 cigarettes",
"        </p>",
"        <p>",
"         Cigarette smoking is expensive. The cost of buying one pack a day for a year could buy a used car (as high as $4300 a year in some states).",
"        </p>",
"        <p>",
"         When you smoke you are being controlled by the tobacco companies' marketing; when you do not smoke you show smart independent thinking",
"        </p>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Selected long-term health risks listed under \"parents\" above",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Emphasize issues that are common rather than dire",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Emphasize issues that are relevant to patient's experience (ie, health problems in a parent or close relative)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alternative forms of tobacco (snuff, e-cigarettes) are no safer than cigarettes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Smoking exposes your friends and family to health risks from secondhand smoke",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This table summarizes the authors' approaches to advising patients about the health risks of smoking in different age groups.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drs. Marianna Sockrider and JB Rosen.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_2_12333=[""].join("\n");
var outline_f12_2_12333=null;
var title_f12_2_12334="Meningoencephalitis infxs causes";
var content_f12_2_12334=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Possible infectious etiologies of meningoencephalitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Viruses",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <strong>",
"             <span class=\"red\">",
"              Herpes simplex type 1",
"             </span>",
"            </strong>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <strong>",
"             <span class=\"red\">",
"              Herpes simplex type 2",
"             </span>",
"            </strong>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <strong>",
"             Enteroviruses",
"            </strong>",
"            (echovirus, parechovirus, coxsackievirus A and B, poliovirus, and the numbered enteroviruses)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <strong>",
"             <span class=\"red\">",
"              Varicella zoster virus",
"             </span>",
"            </strong>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <strong>",
"             Epstein-Barr virus",
"            </strong>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <strong>",
"             <span class=\"red\">",
"              Cytomegalovirus",
"             </span>",
"            </strong>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <strong>",
"             <span class=\"red\">",
"              Human herpesvirus 6",
"             </span>",
"            </strong>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <span class=\"red\">",
"             Human immunodeficiency virus",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <strong>",
"             Arboviruses",
"            </strong>",
"            (LaCrosse virus, West Nile virus,",
"            <span class=\"red\">",
"             St. Louis encephalitis virus",
"            </span>",
"            , Eastern and Western equine encephalitis virus, Japanese encephalitis virus)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rabies virus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Influenza virus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <span class=\"red\">",
"             Measles virus",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mumps virus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rubella virus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Murray Valley encephalitis virus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <span class=\"red\">",
"             Nipah virus",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hendra virus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tick-borne encephalitis virus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Powassan virus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Herpes B virus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hepatitis E virus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Creutzfeldt-Jakob disease",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Bacteria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <span class=\"red\">",
"             <em>",
"              Mycoplasma pneumoniae",
"             </em>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <span class=\"red\">",
"             <em>",
"              Listeria monocytogenes",
"             </em>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <span class=\"red\">",
"             <em>",
"              Mycobacterium tuberculosis",
"             </em>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <span class=\"red\">",
"             <em>",
"              Treponema pallidum",
"             </em>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <span class=\"red\">",
"             <em>",
"              Bartonella henselae",
"             </em>",
"             (cat scratch disease)",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <span class=\"red\">",
"             <em>",
"              Bartonella quintana",
"             </em>",
"             (\"trench fever\")",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <span class=\"red\">",
"             <em>",
"              Borrelia burgdorferi",
"             </em>",
"             (Lyme disease)",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <span class=\"red\">",
"             <em>",
"              Coxiella burnetii",
"             </em>",
"             (Q fever)",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <span class=\"red\">",
"             <em>",
"              Rickettsia rickettsii",
"             </em>",
"             (Rocky Mountain spotted fever)",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <span class=\"red\">",
"             <em>",
"              Ehrlichia chaffeensis",
"             </em>",
"             (human monocytotrophic ehrlichiosis)",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <span class=\"red\">",
"             <em>",
"              Anaplasma phagocytophilum",
"             </em>",
"             (human granulocytotrophic ehrlichiosis)",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <em>",
"             <span style=\"color: #ff0000;\">",
"              Tropheryma whipplei",
"             </span>",
"            </em>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Fungi",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <span class=\"red\">",
"             <em>",
"              Cryptococcus neoformans",
"             </em>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <span class=\"red\">",
"             <em>",
"              Coccidioides species",
"             </em>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <span class=\"red\">",
"             <em>",
"              Histoplasma capsulatum",
"             </em>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Parasites",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <span class=\"red\">",
"             <em>",
"              Toxoplasma gondii",
"             </em>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <span class=\"red\">",
"             <em>",
"              Plasmodium falciparum",
"             </em>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <span class=\"red\">",
"             <em>",
"              Naegleria fowleri",
"             </em>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <span class=\"red\">",
"             <em>",
"              Acanthamoeba spp",
"             </em>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <span class=\"red\">",
"             <em>",
"              Balamuthia mandrillaris",
"             </em>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <span class=\"red\">",
"             <em>",
"              Taenia solium",
"             </em>",
"             (cysticercosis)",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <span class=\"red\">",
"             <em>",
"              Baylisascaris procyonis",
"             </em>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <span class=\"red\">",
"             <em>",
"              Gnathostoma spinigerum",
"             </em>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <em>",
"             <span style=\"color: #ff0000;\">",
"              Trypanosoma brucei gambiense",
"             </span>",
"            </em>",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Pathogens depicted in",
"    <span style=\"color:#ff0000\">",
"     red",
"    </span>",
"    may require specific antimicrobial therapy. Pathogens depicted in",
"    <strong>",
"     bold",
"    </strong>",
"    text are the most commonly isolated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Hordur Hardarson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_2_12334=[""].join("\n");
var outline_f12_2_12334=null;
var title_f12_2_12335="Presternal PD catheter";
var content_f12_2_12335=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F58863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F58863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Presternal peritoneal dialysis catheter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 251px; height: 341px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of a presternal peritoneal dialysis catheter after implantation. The deep cuff with flange and bead is shown in the rectus muscle; the titanium connector (small arrow) is placed 2 to 3 inches above the deep cuff. The middle and superficial cuffs are in the parasternal area, and the exit site (large arrow) is 2 to 3 cm below the external cuff.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Twardowski, AJ, et al. Four-year experience with swan neck presternal peritoneal dialysis catheter. Am J Kidney Dis 1996; 27:99. Copyright &copy; 1996 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_2_12335=[""].join("\n");
var outline_f12_2_12335=null;
